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ABSTRACT 
All nucleated cells display a sampling of their protein contents in the form of short 
9-10 amino acid peptides bound to a product of the major histocompatibility complex 
(MHC) on the cell surface. This class of MHC-restricted antigens provides the broadest 
class of potential disease targets, as the peptides displayed are derived from the full 
antigenic repertoire of the cell, including intracellular, secreted, and cell-surface 
proteins. These peptides can be from endogenous “self” proteins, or they can result 
from viral infection or transformation to a cancerous state. Activation of the cell-
mediated immune response begins with the binding of “foreign” MHC-restricted antigens 
by T-cell receptors (TCRs) with an affinity above the threshold for activation by the T 
cells. Like antibodies, TCRs are generated with large diversity in order to have some 
TCRs that accomplish this antigen recognition, but unlike antibodies TCRs do not 
undergo somatic hypermutation and therefore have relatively low affinities (KD = 1-100 
µM). The generation of higher-affinity TCR variants provides a useful approach to 
improve targeting of cancerous cells, and to study the principles of TCR recognition and 
T cell triggering. 
TCRs are αβ heterodimers that interact with peptide-MHC (pepMHC) through six 
complementarity determining region (CDR) loops. The relative positions of these loops 
is conserved, such that the regions derived from the germline encoded regions of the 
TCR (i.e. CDR1 and CDR2) are positioned primarily over the MHC helices whereas the 
diverse regions derived from the junctions of somatically rearranged gene segments 
(i.e. CDR3) are positioned primarily over the peptide. Over the last 15 years, the Kranz 
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lab has developed a strategy to engineer stable, high affinity TCRs using yeast display 
of TCRs in a single-chain format (scTCR) that consists of the variable regions of the α 
and β chains connected by a flexible linker (Vα-linker-Vβ or Vβ-linker-Vα). The focus of 
this dissertation is the engineering of human high affinity scTCRs for the targeting of 
cancer antigens, and the use of high affinity scTCRs for understanding the principles 
MHC-restriction and T cell specificity. 
In Chapter 2, a human scTCR specific for the melanoma cancer antigen Melan-
A/MART-1 was engineered for improved stability and affinity by yeast display. The high 
affinity scTCR was expressed as a soluble protein in E. coli for MART-1/HLA-A2 binding 
studies and detection of the specific antigen on the surface of human antigen presenting 
cells (APCs). This TCR, called T1-S18.45, expresses the stable Vα2 region that is also 
expressed by two viral-specific TCRs, A6-X15 and 868-Z11, previously engineered by 
our lab. Using this panel of three high affinity scTCRs, engineered for high-affinity in 
CDR3 loops, mutational analysis was performed at residues in the CDR1α and CDR2α, 
testing a prominent hypothesis that holds that there are several evolutionary conserved 
residues in TCR variable regions that contact MHC.  
In Chapter 3, a human scTCR specific for Wilms’ Tumor Antigen-1 (WT-1) was 
engineered for improved stability and affinity by yeast display through a multi-step 
affinity maturation process. This scTCR was also expressed in E. coli as a soluble 
scTCR and used to detect WT-1/HLA-A2 on the surface of human antigen presenting 
cells. The WT-1 antigen is considered a promising therapeutic target for leukemia as 
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well as various solid tumors, and as a result the engineered receptor has been further 
pursued in adoptive cell therapy models. 
The conventional approach to engineering high affinity scTCRs to date has 
required the isolation of specific T cell clones and their clonotypic TCRs prior to in vitro 
engineering. In Chapter 4 a strategy using in vitro, directed evolution of a single TCR to 
change its peptide specificity is described. The approach, avoids the need to isolate T 
cell clones for each MHC-restricted antigen of interest. The human TCR A6, that 
recognizes the viral peptide Tax in complex with HLA-A2, was converted to TCR 
variants that recognized the cancer peptide MART-1/HLA-A2 through mutagenesis and 
selection. Mutational studies and molecular dynamics simulations identified CDR 
residues that were important in this specificity switch. In addition, TCR variants that 
exhibited broad cross-reactivity with different peptides were identified, providing 
opportunities to examine in an unprecedented way the basis of peptide specificity. 
These finding thus provided a new platform in which in vitro engineering strategies 
alone could be used to isolate designer TCRs with desired specificities. 
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CHAPTER ONE 
 
INTRODUCTION 
 
Overview of the Immune System 
The human immune system is highly evolved with the capability to control a 
variety of infectious diseases by distinguishing “non-self” molecules (derived from 
pathogens) from normal “self” tissues. Human immunity is a complex, multilayered 
system: As a first line of defense, the innate immune system works as a physical and 
chemical barrier to infection and has the ability to immediately target pathogens through 
the recognition of generic patterns found among broad groups of microorganisms. The 
second line of defense is the delayed but more comprehensive response of the adaptive 
immune system that leads to the specific targeting of pathogens through the generation 
and expansion of specific recognition molecules originating from a highly diverse pool. 
Additionally, adaptive immunity generates immunological “memory” of antigens it 
encounters through long-lived B and T cells that allow for a quick, effective response in 
the event of a future encounter. A summary of the innate and adaptive immune system 
is shown in Table 1.1. 
 
Innate immunity 
 The innate immune system serves as a first line of defense against invading 
pathogens. Unlike the adaptive immune system that takes days to react to invading 
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pathogens, the innate immune system is constitutively present and immediately poised 
to deploy its defenses through the use of anatomical barriers and humoral and cellular 
components. First, the epithelial layers of the skin and mucosal and glandular tissues 
provide a physical barrier to block pathogens from entering the body. Additionally, 
chemical barriers at these surfaces include acids that lower the pH (e.g. like in sweat 
and gastric secretions), anti-microbial proteins and peptides (e.g. lysozyme and 
phospholipases in tears and saliva), and the normal bacterial flora of the skin that can 
block the colonization of pathogenic microorganisms.  
 In the event that an invading pathogen is able to evade the anatomical barriers 
and infect human tissue, humoral innate defenses can lead to acute inflammation and 
the recruitment of phagocytic cells. These humoral defenses include the complement 
system and antimicrobial enzymes and peptides. The complement system includes a 
group of serum proteins that, when activated, can function to lyse pathogens or facilitate 
their clearance1. Antimicrobial enzymes, such as lysozyme, can act to destroy a variety 
of microorganisms often through the disruption of pathogen membranes. 
The cellular components of the innate immune system include neutrophils, 
macrophages, and natural killer (NK) cells. Neutrophils are the first cells to migrate to 
the site of an infection and act quickly to engulf invading bacteria via phagocytosis. They 
also act through the generation of reactive oxygen and nitrogen species and through the 
expression of antimicrobial peptides2. Macrophages are also responsible for 
phagocytosis of foreign pathogens and are able to generate reactive oxygen and 
nitrogen species. They are larger in size and persist longer in tissues than neutrophils, 
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continuing to engulf dead cells and cellular debris. Additionally, when activated, 
macrophages are responsible for the secretion of inflammation mediators including 
cytokines and complement proteins3. Finally, NK cells are responsible for destruction of 
transformed human cells (e.g. virally infected or cancerous) upon down-regulation of 
major histocompatibility complex (MHC) proteins4. 
The responses of innate immune cells such as neutrophils and macrophages are 
triggered primarily through receptors that recognize pathogen-associated molecular 
patterns (PAMPs). PAMPs are molecular motifs that are unique to microbes and viruses 
and are not found in normal cells. The Toll-like receptor (TLR) family of proteins is a 
class of membrane-bound receptors that have evolved to recognize PAMPs. Each TLR 
is responsible for the recognition of a different subset of ligands that collectively are able 
to identify a variety of bacteria, viruses, fungi, and protozoa. Activation of TLRs leads to 
changes in gene expression that ultimately lead to the production of inflammatory 
cytokines, interferons, antimicrobial enzymes and peptides, and chemotactic factors5,6. 
Importantly, activation of TLRs present on dendritic cells (DCs) is required for their 
maturation and ability to activate both CD4+ and CD8+ T cells in adaptive immunity7. 
Additionally, dendritic cells, and to some extent macrophages, serve as professional 
antigen presenting cells, bridging the innate and adaptive immune systems. 
 
Adaptive immunity 
 Whereas the innate system recognizes generic patterns common among viruses 
and microorganism, the adaptive system has the ability to specifically recognize and 
 4 
eliminate foreign antigens. The adaptive immune system developed in jawed 
vertebrates approximately 500 million years ago8. The main feature of the adaptive 
system is the somatic development of clonally diverse B and T lymphocytes (B and T 
cells) each expressing a unique antigen receptor, allowing potentially any pathogen to 
be recognized in an antigen-specific manner. Upon recognition of a foreign antigen, 
lymphocytes become activated, undergo clonal expansion, and develop into mature 
effector cells, such as B or T cells.  
 
B lymphocytes and antibodies 
 B cells express an antigen specific antibody on their membranes. Antibodies 
(also known as immunoglobulins) are glycoproteins consisting of two sets of identical 
polypeptide chains: heavy chains and light chains (Fig 1.1A). Each heavy chain is 
disulfide bonded to a light chain, and the two heavy chains are also covalently linked by 
additional disulfide bonds. At the amino terminal end of each heavy and light chain there 
is a single domain called the variable region that together form the antigen-binding sites 
responsible for antigen recognition.  
The antibody repertoire is highly diverse and estimated to be over 1010 in size9. 
The astonishing diversity of antibodies is accomplished through six mechanisms: (1) the 
presence of numerous V, D, and J gene segments, (2) somatic rearrangements of 
germline V-J segments in immunoglobulin light chain and V-D-J segments in 
immunoglobulin heavy chain, (3) junctional flexibility at the hypervariable region CDR3, 
(4) P- and N-nucleotide addition, (5) association of heavy and light chains, and (6) 
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somatic hypermutation10,11. Generation of a particular heavy and light chain pair to form 
an antibody occurs during B cell development. Each B cell expresses only a single type 
of antibody, but collectively all B cells in the body express a large repertoire of 
antibodies. 
 B cells develop in the bone marrow. Prior to encountering antigens for which their 
surface antibodies are specific, B cells are considered “naïve” or “resting.” If the B cell 
surface antibody is reactive with a “self” antigen in the bone marrow, it will be deleted or 
undergo receptor editing to produce a non-“self” reactive surface antibody (receptor). 
Once B cells migrate to the periphery, they can then bind antigens through their 
membrane bound antibodies (also called B cell receptors, or BCRs). If the antigen 
encountered in the periphery is a chronically expressed “self” antigen it had not 
encountered in the bone marrow, the B cell can become “anergic.” However, if an 
acutely expressed foreign antigen binds to the BCR, two primary events lead to 
activation of the B cell: (1) the interaction of the BCR and antigen induces a series of 
signal transduction pathways, and (2) the BCR with bound-antigen is internalized, 
degraded, and delivered to the surface as antigen-derived peptides of 15 to 24 amino 
acids in length bound to a major histocompatibility complex (MHC) class II molecule. 
CD4+ T helper (TH) cells then specifically recognize and bind to the surface-displayed 
peptide/MHC (pepMHC) molecules, secreting factors that further activate the B cell. 
Upon activation, a small subset of B cells will immediately produce a soluble 
pentameric version of the membrane-bound antibody (BCR), called IgM, which is 
capable of providing some protection to the infected host. Other activated B cells will 
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migrate to germinal centers of lymph nodes where they undergo further modifications. 
These include (1) somatic hypermutation, which generates mutations in the V region 
genes leading to affinity maturation of the antibody12, (2) class switching, which allows 
for different effector functions of the antibody through the use of different heavy chain 
constant regions after intrachromosomal deletion and recombination events13, and (3) 
differentiation of the B cell into either memory B cells or plasma cells14,15.  
Memory B cells, like naïve B cells, express membrane-bound antibodies, but 
have a much longer lifespan and can respond very quickly in event of another encounter 
with an antigen for which it is specific16. Notably, the generation and maintenance of 
memory B cell populations is the main goal of vaccinations and boosters17. On the other 
hand, plasma cells secrete high numbers of soluble affinity-matured, class-switched 
antibodies towards the latter end of the immune response18.  
Secreted antibodies of different isotypes or classes (i.e. IgM, IgG, IgA, and IgE) 
have specific functions and operate at select locations. Whereas IgM antibodies are low 
affinity requiring avidity effects for binding (i.e. pentamers have 10 antigen binding 
sites), IgG and IgA antibodies are typically higher affinity and are able to function as 
monomers and dimers, respectively. IgG antibodies are the predominant class of 
antibodies in the blood and extracellular fluid and function by the neutralization and 
opsonization of pathogens and activation of the classical pathway of the complement 
system (Fig 1.1a). As IgA antibodies are weaker opsonins and activators of the 
complement system than IgG, they function primarily as dimers on epithelial surfaces 
where they primarily neutralize pathogens. IgE molecules are typically bound to Fc 
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receptors on mast cells which, when bound to antigen (allergen), are stimulated to 
release various mediators leading to an allergic reaction19.  
The various effector functions of different antibody classes are enabled through 
their fragment crystallizable (Fc) region. The Fc portion of the antibody is comprised of 
the C-terminal domains of the heavy constant regions, whereas the antigen-binding 
fragment (Fab) is comprised of the N-terminal variable and first constant region domain 
of the heavy chain and the entire light chain (Fig 1.1a). The Fc regions of antibodies 
function through binding to Fc receptors (FcRs) on the surface of effector cells. Binding 
of an Fc to an FcR leads to various signaling and functional events, including the 
destruction of the antibody-bound pathogen or toxin through receptor-mediated 
endocytosis and/or via granzyme release20.  
Due to the ability of antibodies to specifically bind antigens with very high 
affinities, their long serum half-lives, and their ability to mediate immune effector 
functions, antibodies have been a primary focus of protein engineering strategies for 
therapeutics since the mid-1990s21. For example, in order to improve the binding 
properties of antibodies engineered single-chain variable fragments (scFv) of antibodies 
consisting of the variable region of each heavy and light chain connected by a short 
flexible peptide linker have been utilized to engineer antibodies for antigen specificity 
and affinity using phage and yeast display (discussed in a later section). The scFvs 
often retain specificity and affinity when converted to the full IgG framework22 (Fig 1.1a). 
Additionally, engineered Fc regions have been generated to improve or alter the effector 
functions of antibodies23,24. Despite the success of antibody-based therapeutics, 
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generation of antibodies with specificity for MHC-restricted antigens (i.e. antigenic 
peptide fragments displayed within a MHC-molecule on the surface of cells), although 
possible, has proven much more challenging. This could in part be due to the fact that 
antibodies did not naturally evolve to recognize this class of antigens, and thus 
obtaining antibodies with peptide antigen specificity (rather than MHC specificity alone) 
may be difficult. In the next section T lymphocytes, which recognize and bind to MHC-
restricted ligands through their membrane bound receptor, are described. 
 
T lymphocytes and T cell receptors 
 Like naïve B cells, T cells display an antigen-specific molecule on their surface 
that recognizes foreign antigens (called the T cell receptor, or TCR). However, unlike 
the BCRs of B cells which undergo somatic hypermutation and class switching allowing 
for their secretion as high-affinity soluble antibodies, TCRs remain cell-bound and are 
activated through binding to MHC-restricted antigenic peptides on the surface of antigen 
presenting cells (APCs)25. TCRs are αβ or γδ heterodimers consisting of variable and 
constant regions, similar to antibodies. The majority (>90%) of circulating TCRs in the 
body are comprised αβ TCRs (Fig 1.1b). The role of the less prevalent γδ receptor is 
less clear but they are thought to be involved in the inflammatory responses in the skin 
and epithelial tissues, are a primary source of interleukin-17 (IL-17) in acute infection, 
and do not require MHC presentation26. 
 Although TCRs do not undergo somatic hypermutation, αβ TCRs are still highly 
diverse with estimated repertoire of over 1014 in size27-29. Diversity is contributed through 
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five main mechanisms: (1) the presence of multiple V, D, and J gene segments, (2) 
somatic rearrangements of the V-J regions in the TCRα chain and V-D-J in the TCRβ 
chain, (3) junctional flexibility at the hypervariable region CDR3, (4) P- and N- nucleotide 
addition, and (5) the association of α and β chains (Fig 1.2a). A more in-depth 
description of the TCR structure and the molecular basis on how it engages its pepMHC 
ligand is described in the next section. 
T cells originate from hematopoietic stem cells in the bone marrow like B cells, 
but unlike B cells they migrate to the thymus (hence ‘T’ cells) to differentiate and to 
undergo tolerance that ensures they are not activated by “self” antigens. During thymic 
tolerance (also called central tolerance), developing T cells undergo two selection 
processes: (1) positive selection which allow survival of only those T cells whose TCRs 
bind at low affinity to self-peptide/MHC molecules, and (2) negative selection which 
deletes T cells whose TCRs react with too high an affinity with self-peptide/MHC 
molecules (Fig 1.2b). This process ensures that mature T cells will not become 
activated when presented with a “self” antigen but will have a high probability of being 
restricted by MHC30,31. 
Prior to tolerance induction, thymocytes become positive for expression of both 
CD4 and CD8 receptors (CD4+CD8+) in addition to the αβ TCR. The CD4 co-receptor, 
through its extracellular D1 domain, recognizes the β2 domain of MHC class II, whereas 
the CD8 co-receptor, through its extracellular α domain, recognizes the α3 domain of 
MHC class I (Fig 1.1b and Figure 1.2b). Interactions during positive selection between 
either CD4 or CD8 and its corresponding MHC class, together with the interaction of the 
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TCR and self-peptide/MHC ligands, determines whether the T cell becomes a CD4+ (or 
T helper, TH) or CD8+ (or cytotoxic, TC or CTL) T cell, respectively. Prior to migrating 
from the thymus, cells lose expression of the other co-receptor such that they are 
“single positive” (CD4+CD8- or CD4-CD8+)32. A subset of the CD4+ T cell population also 
expresses Foxp3, a transcriptional regulator, during central tolerance giving rise to 
another class of T cells, called regulatory T cells (or Tregs). Tregs are responsible for 
negative immunomodulation in the periphery in order to limit effector responses and 
further establish immunological tolerance33. 
Following central tolerance, naïve CD4+ and CD8+ T cells migrate out of the 
thymus and into circulation and upon stimulation with a foreign pepMHC antigen they 
become activated (or “primed”) leading to the differentiation of a series of potential 
effector cell types. Stimulation of CD4+ T cells can generate a series of TH cells (e.g. 
TH1, TH2, TH17, and TFH) whereas stimulation of CD8+ cells generates cytotoxic T cells 
(CTLs or Tc). In order for the this process to occur, three signals are required: (1) 
specific binding of the CD4+ and CD8+ T cell’s TCR to peptide-bound class II or I MHC, 
respectively, on the APC (2) costimulation by binding of CD28 on the T cell to a B7 
molecule on the APC34, and (3) the stimulation by various cytokines, such as IL-2, to 
regulate differentiation into various effector cells35. As with B cells, a “memory” 
population of T cells is also maintained in order to respond rapidly to future infections36.  
 A CD4+ T cell, upon receiving appropriate cytokine signals, will develop into a 
specific type of TH cell, such as TH1, TH2, TH17, and TFH37. Each of these different 
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subpopulations is characterized by a specific program of transcription factors, which 
result in subtype-associated cytokine profiles. 
 On the other hand, CD8+ T cells become cytotoxic T cells (CTLs) that lyse target 
infected cells or cancer cells upon recognition. CTLs are critical to defending the host 
against intercellular pathogens, such as viruses, since they are capable of destroying 
infected cells through the recognition of foreign protein degradation products presented 
in the context of a class I MHC on the surface of APCs (Fig 1.3). CD8+ T cell activation 
can be facilitated by stimulation of an effector CD4+ T cell that interacts with the same 
APC. However, they can also be activated directly by mature dendritic cells. Due to the 
high costimulatory capacity of dendritic cells in activating CTLs, dendritic cell vaccines 
have been pursued in immunotherapy strategies to activate naïve CD8+ T cells against 
tumors (described in detail later in the “Cancer Immunotherapy” section)38.  
 Signaling of T cells through the TCR that occurs upon pepMHC engagement 
initiates a cascade leading to Ca2+ efflux and Ras activation (Fig 1.3). In the proximal 
signaling complex, binding of TCR to pepMHC leads to phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) of associated CD3 molecules 
by CD4/8-associated p56LCK. The CD3 complex consists of three polypeptide dimers 
each containing ITAMs on their cytoplasmic tails: heterodimers γε and δε, and 
homodimer ζζ (occasionally a ζη heterodimer). ZAP-70 kinase is recruited upon 
phosphorylation of CDR3ζ chains and phosphorylates adaptor molecules, such as SLP-
76 and LAT, which recruit components of Ca2+-, PKC-, and RAS-mediated pathways 
leading to transcriptional regulation through global regulators, such as nuclear factor of 
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activated T cells (NFAT) and nuclear factor kappa B (NF-κB)35. Transcriptional changes 
lead to the CTL’s expression of potent cytotoxins, such as perforin, granzyme, and 
granulysin. Perforin forms pores in the infected cell’s plasma membrane causing lysis 
and allowing pro-apoptotic serine proteases, called granzymes, and granulysin to enter 
and induce apoptosis.  
 Due to the potent effector capacity of T cells and their ability to recognize 
intracellular antigen through surface-displayed MHC molecules through TCRs, 
immunotherapy strategies have focused on the engineering of T cells and their TCRs to 
better recognize tumors. Additionally, because the TCR evolved to recognize MHC-
restricted ligands, it provides a useful alternative to monoclonal antibodies (mAbs) as 
targeting molecules to deliver cytokines or drugs to cells displaying MHC-restricted viral, 
cancer, or autoimmune antigens. Our group has developed a single-chain TCR format 
called scTCR or scTv that is structurally analogous to a scFv (Fig 1.1d) for these 
purposes. The next section provides a detailed view of the molecular basis of CD8+ T 
cell recognition of peptide/class I MHC through the TCR. 
 
Molecular Basis of T Cell Recognition 
  As indicated above, in order for a T cell to make it through central tolerance, 
TCR binding affinity must follow the goldilocks principle: falling into a narrow range of 
possible affinities such that the TCR binds to pepMHC with sufficient affinity to be 
positively selected, but not too strongly as to be deleted during negative selection. As a 
result of this selection process and the fact that TCRs do not undergo somatic 
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hypermutation like their antibody counterparts, the natural TCR affinities for a foreign 
pepMHC are typically low, i.e. 1-100 µM39. In this section I summarize the molecular 
basis of TCR:pepMHC recognition and the current view of how the structural features of 
both MHC and TCR allow for the affinity and specificity requirements of TCR binding 
and activation.  
 
Structural view of the major histocompatibility complex (MHC) 
 There are two primary classes of MHC molecules: class I and class II. Class II 
MHC typically presents peptides to CD4+ TH cells and is located on the surface of 
professional APCs, such as B cells, dendritic cells, and macrophages. Class II MHC 
consists of two chains (α1β1) that form a peptide-binding groove composed of a seven-
stranded β sheet floor and two flanking α helices. Class II MHC-restricted peptides are 
typically 15-24 amino acids and extend past the open ends of the MHC molecule. In 
contrast, class I MHC molecules present peptides to CD8+ CTLs and are found on the 
surface of all nucleated cells. The class I MHC molecule consists of two polypeptide 
chains: the heavy chain (composed of three domains, α1α2α3) and the light chain (β2-
microglobulin or β2m)(Fig 1.4). The α1 and α2 domains form the peptide-binding grove 
of the MHC molecule, and the α3 domain non-covalently associates with β2m and 
anchors into the APC membrane. Despite composition by different chain lengths, the 
overall structural architecture of class I and II MHC are the same; however, the ends of 
the flanking α1 and α2 helices of class I MHC are closed and smaller (8-10 amino acid) 
peptides are bound and presented to CTLs40.  
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 The peptides presented in the context of the MHC class I molecule on the 
surface of APCs are derived from the products of proteolysis (Fig. 1.4b). Proteolysis 
products include those digested in the cytosol by the proteasome as well as those 
internalized from exogenous sources and digested by lysosomal degradation41. 
Peptides that are formed in the cytosol are typically translocated to the endoplasmic 
reticulum (ER) via an ATP-dependent transporter associated with antigen processing 
(TAP) and assembled with MHC class I heavy and light chains with aid from chaperone 
molecules, such as calnexin and tapasin. Although peptides derived from endocytic 
pathway are typically presented on class II MHC molecules, cross-presentation of 
exogenous antigens can occur such that endocytic degradation products are presented 
on class I MHC. Although the mechanism of cross-presentation is still unclear, it is 
thought it could occur through peptide exchange in the endosome or by the presence of 
endocytic peptides in the ER. In this regard, peptides presented in class I MHC 
represent the full protein repertoire of the cell, included intracellular, cell-surface, and 
secreted proteins including those that result from viral infection or transformation of 
human cells to a cancerous state. Additionally, it is notable that “self” peptide antigens 
presented on class I MHC molecules and polymorphisms in MHC itself often play a 
critical role in autoimmunity42. 
In humans, the human leukocyte antigen (HLA) complex is the name of the locus 
that encodes products of the major histocompatibility complex (MHC). In mice, the locus 
is called H-2. Class I HLA expression occurs at three loci, A, B, and C, and the resultant 
gene products are HLA-A, HLA-B, and HLA-C. In mice there are two loci, K (H-2K) and 
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D (H-2D), and sometimes L (H-2L). HLA-A2 is the most prevalent human MHC allele, up 
to 50% in some populations, and is expressed in many ethnic populations43. As a result, 
it is frequently used as a model MHC to study TCR:pepMHC interactions as well as a 
target for therapeutics.  
 
Structural view of the αβ T cell receptor (TCR) 
Studies of model TCRs, particularly the mouse TCR 2C (which binds alloantigen 
QL9/Ld, self-antigen dEV8/Kb, and synthetic antigen SIYR/Kb)44-46 and human TCR A6 
(which binds to cognate antigens Tax/HLA-A2 and Tel1p/HLA-A2) have provided a 
wealth of information on TCR structure and function47,48. T cell receptors (TCRs) are αβ 
heterodimers consisting of a membrane-proximal constant regions and distal variable 
regions (Fig. 1.1b and Fig. 1.4). The TCR variable regions of both the α and β chain 
form the antigen-binding site with six loops, called complementarity determining region 
(CDR) loops, that provide the binding energy with pepMHC40 (Fig 1.4b,c). Each chain (α 
and β) contains a CDR1, CDR2, and CDR3 loop: CDR1 and CDR2 loops are “germline 
derived” since they reside in the region encoded by each variable gene. As with 
antibodies, CDR3 loops are highly variable in sequence as they are encoded by the 
junctions of the somatically rearranged gene segments (Fig. 1.2a and Fig. 1.4b,c) 
 
TCR:pepMHC binding and activation 
 Since the mid-1990s when the first crystal structures of two TCR:pepMHC 
complexes were solved49,50, over two dozen additional structures have been reported. 
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These have collectively enabled extensive structural and biochemical characterization of 
the TCR:pepMHC interaction40. These structural studies have shown that overall 
docking orientation and CDR loop positioning is similar in TCR:pepMHC complexes 
(Fig. 1.4b). This invariant orientation positions the germline-derived CDR1 and CDR2 
loops of the TCR α and β chains primarily over the MHC α1 and α2 helices, and the 
highly variable CDR3 loops of both chains primarily over the peptide. Although residues 
of CDR3 loops are thought to be primarily involved with making contacts with peptide 
residues whereas CDR1 and CDR2 residues are thought to primarily make contacts 
with MHC helices, there are cases where direct peptide contacts are made with non-
CDR3 residues (particularly with CDR1α) and CDR3 residues make contacts with MHC 
helices51. Moreover, TCR specificity and engineering studies have suggested that up to 
all six loops are involved in specific recognition of the peptide, although they might not 
be involved directly in direct contacts. This phenomena has been attributed to two 
mechanisms: (1) “CDR editing,” in which the CDR3 loops of the TCR modulate 
interactions with germline derived CDR1 and CDR2 loops with pepMHC residues52, and 
(2) “peptide editing,” in which TCR:pepMHC interactions are influenced by changes of 
the binding surface of the MHC depending on the peptide bound53. 
 Although the molecular basis of the invariant TCR:pepMHC docking orientation is 
not fully understood, two prevailing models of TCR/MHC bias exist: (1) the germline 
codon bias model in which evolutionary pressure for TCR loop residues to yield a 
minimum basal affinity for MHC helices has shown a “preference” for productive 
contacts with MHC, eliminating TCRs which do not interact with MHC53,54, and (2) the 
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co-receptor model in which the TCR:pepMHC interaction is “imposed” by the geometries 
required for productive interactions of the TCR complex and CD4/CD8 co-receptor 
during positive selection55,56. Although compelling evidence for and against both models 
exists (including data presented in Chapter 2 of this dissertation57), it is likely that both 
play an important role in the specificity of MHC restriction51,58. 
 Where crystal structures provide insight on the likely endpoint of TCR:pepMHC, 
several models have been proposed for the binding mechanism, including a two-step 
binding mechanism and electrostatic steering40. In order to distinguish foreign antigens 
from “self” in the periphery, TCRs must rapidly “scan” a very large number of pepMHC 
complexes. The two-step binding mechanism model suggests that the initial encounter 
of the TCR with pepMHC involves cursory interactions of primarily CDR1 and CDR2 
TCR loops with the α1 and α2 helices of the MHC, followed by a more extensive 
sampling of the peptide by diverse CDR3 59. On the other hand, the electrostatic 
steering mechanism suggests that long range electrostatic steering events between 
charged TCR and MHC residues pre-orients the complex for potential interactions40. In 
any case, the structural changes of the TCR CDR loop positions that occur upon 
binding, as evidenced from crystal structures of bound and unbound TCRs, suggest that 
both highly dynamic and more subtle binding mechanisms are plausible and they 
involve mechanisms such as rigid-body association, induced fit binding, and 
conformational selection from a pre-existing equilibrium60. 
 Additionally, despite thorough characterization of kinetic and thermodynamic 
properties of TCR binding, the precise requirements for T cell activation remain 
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elusive39,61. Particularly, there has been considerable debate on what factor plays a 
decisive factor in whether or not a T cell is activated upon engagement of its TCR with 
pepMHC: affinity or off-rate. The importance of off-rates in T cell activation are evident 
by two models of T cell activation that suggest there is an “optimal dwell time” in 
TCR:pepMHC binding: (1) the kinetic proofreading model, in which TCR:pepMHC 
interactions must be sufficiently long enough to allow time for intracellular signaling 
events resulting in agonist activity62, and (2) the serial triggering model, by which the off-
rate must not be too long as to allow multiple TCRs to bind to and by activated by a 
single pepMHC molecule63. Although off-rates play an important roll in T cell activation, 
several studies indicate that on-rates are also important in determining agonist versus 
antagonist activity in T cell activation as well64-66. 
Furthermore, although TCRs are typically thought to be highly specific in terms of 
their immunological functions, it is clear from numerous studies that TCRs are inherently 
cross-reactive, allowing for the recognition of a range of self and foreign antigens67-69. 
This cross-reactivity has been attributed by a variety of mechanisms, including induced 
fit, differential docking, structural degeneracy, and antigen-dependent tuning of pepMHC 
flexibility70.  
Where the natural affinities of TCRs typically fall within the range of 1-100 µM, 
engineering TCRs for higher affinity, different specificities, and for altered binding 
properties is of considerable interest. In particular, engineering TCRs such that they no 
longer require co-receptor (i.e. CD4 or CD8) binding to the MHC complex for activation 
to occur could be beneficial, for example in recruiting the activity of CD4+ T cells against 
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a class I antigen. Previous work in our lab has shown that engineered receptors in the 
2C mouse TCR system with affinities (KD values) below a 1 µM threshold are able to 
activate T cells independent of the CD8 co-receptor71. The ability to activate a T cell in a 
co-receptor independent manner allows for TH cell responses upon binding of a class I 
pepMHC by the TCR (described later in the “Cancer Immunotherapy” section)72. 
 
Immunity and Cancer 
Despite the ability of the immune system to prevent a myriad of infectious 
diseases, the ability of cancer to evade such host defenses remains one of the primary 
challenges of modern medicine. Although cancer has declined by 20% over the last two 
decades due to advancing treatment, diagnostics, and preventative medicine, it remains 
one of the leading causes of death in the United States and other parts of the world, 
claiming one in four lives73. Because cancer arises from human cells and often not 
known pathogens, the “self/non-self” paradigm is not strictly applicable. In this section I 
discuss cancer markers and immunotherapy approaches currently under development 
as they pertain to TCR- and antibody-based targeting strategies. 
 
Cancer antigens 
 Despite challenges of the immune system’s ability to recognize and/or eliminate 
cancer, some patients can generate antibodies and T cells against their tumors. The 
tumor targets include proteins that are mutated, misfolded, aberrantly expressed, or 
improperly modified. As a result, the isolation of autoantibodies and cancer-reactive 
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tumor infiltrating lymphocytes (TIL) and the subsequent characterizations of the 
antigens they recognize has provided large number of therapeutic leads. These 
antigens, known as tumor-specific antigens (TSAs) and tumor-associated antigens 
(TAAs), can now be routinely identified through the use of high throughput proteomics 
strategies, such as serological or T cell analysis of recombinant cDNA expression 
libraries (SEREX), serological proteome analysis (SERPA), and analysis of protein-
based microarrays74. 
 As a result of these strategies, over 400 MHC-restricted cancer antigens have 
been identified and characterized (Fig. 1.5a)75. Furthermore, the National Cancer 
Institute (NCI) performed a pilot project for the “Acceleration of Translational Research” 
in 2009 that ranked many of these antigens according to a series of defined and 
weighted criteria (e.g. therapeutic function, immunogenicity, specificity, oncogenicity) as 
to their therapeutic potential76. Additionally, crystal structures of many of these 
complexes have been solved (Fig. 1.5b)77.  
MHC-restricted cancer antigens fall into four broad categories75: (1) antigens 
resulting from mutated proteins, (2) shared tumor-specific antigens, (3) overexpression 
antigens, and (4) differentiation antigens (Fig 1.5). Certain antigens, such as antigens 
resulting from mutated proteins, are highly specific to cancer, as they are not found in 
any normal healthy tissues. In terms of the development of therapeutics, these antigens 
(TSAs) represent the ideal targets, as the risk of adverse effects is minimal in other 
tissues78. The major disadvantage in terms of the development of therapeutics is that it 
requires that each treatment to be individualized, as oncogenic mutations typically vary 
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from patient to patient. Another class of TSAs includes the shared tumor-specific 
antigens, named as they are found on many different tumors. These include the 
cancer/testis antigens (e.g. MAGE-A family members) that are considered to be cancer 
specific as they are typically only expressed in the placenta or in germ line cells (which 
do not express MHC class I), although adverse effects in recent clinical trials have 
demonstrated that expression can occur in somatic cells79. Differentiation antigens are a 
type of tumor-associated antigens (TAAs) that are expressed in both cancer cells and in 
the cell lineage from where the malignancy developed (e.g. tyrosinase, gp100, MART-
1). Finally, some proteins are overexpressed in cancers such that the resultant peptides 
can serve as overexpression antigens (e.g. Her-2, EGFR). 
Because MHC restricted antigens are derived from the comprehensive protein 
repertoire (i.e. intracellular, cell-surface, and secreted proteins), it allows for virtually any 
protein to be targeted in cancer immunotherapeutic approaches through the recognition 
of a cell surface molecule (i.e. the pepMHC). To date, the success in engineering 
antibodies that specifically recognize pepMHC has been limited80-83. However, the use 
of TCRs to target this class of antigens in cancer immunotherapies offers unique 
advantages: (1) TCRs evolved to recognize MHC-restricted peptide antigens and as a 
result, the docking orientation and CDR loop footprint is largely invariant; this facilitates 
the engineering of TCR-based targeting molecules by allowing focused mutagenesis on 
residues most likely to contact the antigenic peptide. (2) TCRs, like antibodies, have the 
capacity to generate huge numbers of unique antigen-specific binding molecules. 
Although affinities are low as a result of central tolerance and the fact that they do not 
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undergo somatic hypermutation like their antibody counterparts, TCRs can now be 
engineered in vitro to very high affinities (nanomolar and picomolar range). (3) TCRs are 
composed of immunoglobulin (Ig) folds like antibodies and are amendable to similar 
engineering and therapeutic formats (e.g. Fc-receptor fusions).  
 The cancer antigens focused on in this dissertation are those that have met two 
general criteria: (1) restriction by HLA-A2, the most prevalent human MHC allele43, and 
(2) availability of TCRs isolated from reactive T cells that use the highly stable Vα2 
(TRAV-12) gene segment which is amendable to yeast display engineering (described 
in the ‘TCR Engineering’ section). Two antigens I engineered high affinity TCRs against 
were MART-1/Melan-A (Chapters 2 and 4) and Wilm’s Tumor Antigen (WT1; Chapter 
3)(Fig 1.5b).  
 MART-1 is a differentiation antigen that is expressed in over 80% of metastatic 
melanomas84 as well as in melanocytes in the eye, ear and skin85,86. In the 2009 NCI 
cancer antigen prioritization project, this antigen was ranked #14 of the top 75 antigens 
examined. MART-1 was one of the first MHC-restricted TAAs to be identified for the use 
as a therapeutic target of melanoma. Initial successful adoptive cell transfer (ACT) trials 
with melanoma TILs found that many of the T cell were reactive with MART-1/HLA-A287. 
As a result, several clinical trials involving the transfer of human T cells transduced with 
genes that encode a MART1-specific TCR were pursued. The first published study in 
2006 involved the transfer of an allogeneic T cells with a MART-1 specific TCR into 15 
patients in which one patient has a partial response88. Also in 2006, the seminal study 
describing the first successful clinical trial with gene-modified T cells was published by 
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researchers at the National Cancer Institute in which 4 of 31 melanoma patients showed 
sustained objective responses following ACT of autologous peripheral blood 
lymphocytes (PBLs) modified with a MART-1 specific TCR (named DMF4)89,90. Finally, a 
2009 NCI study by the same group utilizing genetically modified PBLs expressing an 
avidity-enhanced TCR against MART1 (named DMF5) shower partial responses in six 
of 20 patients, although on-target, off-tumor toxicity was demonstrated against normal 
melanocytes in the skin, eye, and ear91. Although adverse affects could be partially 
treated in this study through the use of local steroid administration, it suggested that the 
risk versus reward of the use of affinity or avidity enhanced TCRs, particularly against 
the MART-1 antigen, should be thoughtfully considered in future trials91 
 The other primary antigen discussed in this dissertation, WT1, is an 
overexpression antigen derived from a transcription factor involved in differentiation and 
cell proliferation as well as apoptosis92. Although initially classified as a tumor 
suppressor, it is clear that WT1 can also serve as an oncogene93. Overexpression of 
WT1 has been detected in six hematological malignancies (e.g. acute myeloid leukemia 
(AML), chronic myeloid leukemia (CML), multiple myeloma), and over 30 solid tumors 
(e.g. brain, breast, pancreatic)94. Despite low expression in normal tissues, thus far 
there have not been reports of toxicity in humans or mice with WT1-targeted 
immunotherapies94. As a result of these and other factors, WT1 topped the list of the 
2009 NCI cancer antigen prioritization project76. Throughout the last decade, numerous 
WT1 peptide vaccine trials have been used in early-phase clinical trials for both 
hematological malignancies and solid tumors, and in general they have been well 
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tolerated and safe although response rates have been low94. Additionally, two phase I/II 
clinical trials are currently underway utilizing T cells transduced with WT1-specific TCRs 
against various types of leukemia at both the University College in London and the Fred 
Hutchinson Cancer Research Center (FHCRC) at the University of Washington 
(http://www.clinicaltrials.gov, NCT01621724 and NCT01640301, respectively). Although 
no results have been reported on these two trials to date, a pilot study at FHCRC 
demonstrated that in a cohort of 4 patients introduction of donor WT1-specific CTLs 
pretreated with IL-21 prior to transfer led to substantial memory T cell development, no 
recurrence of cancer (since 30 months following infusion), and lack of symptoms of graft 
versus host disease (GVHD)95.  
 
Cancer immunotherapy 
 With the discovery and identification of TSAs and TAAs, and the development of 
a more comprehensive understanding on the interplay between tumors, the immune 
system, and the tumor microenvironment, immunotherapies against cancers have 
reached their golden age96. In fact, Science magazine named cancer immunotherapy 
involving T cells as the 2013 breakthrough of the year due to promising results in recent 
clinical trials with PD1-directed therapies and adoptive T cell therapies, shifting the 
paradigm on how cancer is treated97. Unlike traditional chemotherapies, immunotherapy 
focuses on targeting the immune system to eradicate cancer through the use of two 
main strategies: increasing immunosurveillance and decreasing immunosuppression. 
Cancer immunotherapies currently in use and under development include monoclonal 
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antibodies and antibody-like molecules, cell-based therapies, cancer vaccines, and 
other anti-cancer agents such as immune adjuvants (summarized in Table 1.2)98.  
 The use of monoclonal antibodies (mAbs) for the treatment of cancer has been 
one of the most successful therapeutic strategies for the treatment of both hematologic 
malignancies and solid tumors. To date, the FDA and EU have approved over 20 
therapeutic antibodies with many more still in various stages of clinical trials. Strategies 
using therapeutic mAbs have aimed to block TAA/TSAs, activate antibody effector 
functions, block immune checkpoints, inhibit signal transduction, and/or target drug 
molecules. Several therapeutic mAbs target receptors on the surface of tumor cells, 
such as HER-2 (e.g. trastuzumab), EGFR (e.g. cetuximab), and CD20 (e.g. rituximab), 
where others target molecules expressed by immune cells that are involved in immune 
signaling and regulation99. Of recent importance, mAbs that target receptors that 
negatively regulate T cell activation, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
and programmed cell death protein 1 (PD1), have been particularly successful in the 
clinic and in combination therapies. Ipilimumab, an FDA-approved anti-CTLA-4 antibody 
sold by Bristol-Myers-Squibb demonstrated a significant improvement to overall survival 
in a phase III clinical trial for patients of previously treated, advanced melanoma100, and 
has shown even more promise when used in combination with an anti-PD-1 antibody. 
Use of an anti-PD1 antibody, nivolumab, with ipilimumab lead to a 40% objective 
response rate and demonstrated a manageable safety profile101.  
 Monoclonal antibodies have also been used as bispecific molecules by linking a 
TAA/TSA-targeting scFv to a second scFv that binds an invariant region of the TCR 
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complex (i.e. CD3). Binding of these bispecific molecules results in the activation of T 
cells against the tumor cell expressing the TAA/TSA regardless of its TCR-mediated 
specificity102. Blinatumomab, a CD19/CD3-bispecific antibody that has been used 
clinically for the treatment B cell malignancies, has shown significant promise over the 
use of the CD19-specific antibody alone in ongoing trials with high objective response in 
ALL and non-Hodgkin’s Lymphoma (NHL)102. Other uses of antibodies include the 
development of antibody-drug conjugates103 and radio-immunoconjugates104. 
 Another immunotherapy strategy involves cancer vaccination, whereby dendritic 
cells or adjuvants are pre-loaded with TAA/TSAs through the use of peptide cocktails, 
DNA and RNA vectors encoding TAA/TSAs, or through gene therapy strategies105. In 
April 2010, the FDA approved the first cell-based cancer vaccine, Sipuleucel-T 
(commercially known as ProvengeTM and sold by the Seattle-based biotech company 
Dendreon), for use in patients with metastatic prostate cancer106. In this therapy, 
autologous peripheral blood mononuclear cells are isolated from the patient and treated 
with a recombinant prostatic acid phosphatase (PAP) cocktail to load and mature APCs 
ex vivo, and are then reintroduced into the patient. PAP has been shown to be 
expressed in ~95% of prostate cancers107. In a phase III clinical trial, Sipuleucel-T 
treatment led to an extension of median survival of 4.1 months over placebo108, 
although there has been significant criticism of the design of this trial, as tumor 
responses in patients have been limited since the drug hit the market109. 
 Another category of targeted immunotherapies includes adoptive cell therapies, 
which include the use of autologous TILs or genetically engineered T cells expressing a 
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TAA/TSA-specific TCR or chimeric antigen receptor (CAR)(Fig. 1.6 and Fig. 1.7). 
Adoptive cell therapies aim to increase the numbers of cancer-specific T cells and 
memory cells, and enhance the anti-tumor response through the release of cytokines 
and or cytotoxins110. Initial studies by Steven Rosenberg and colleagues at the NCI 
have demonstrated positive outcomes of harvesting TILs from tumors, expanding and 
activating them ex vivo, and reintroducing them into the patient111 (Fig. 1.6; navy 
arrows). However, in many cases cancers are able to down regulate immune activity 
making it a challenge to isolate adequate numbers of TILs using this approach. As a 
result, strategies to reprogram T cells to recognize cancer have been employed through 
genetic engineering approaches112. 
The two main strategies used to redirect the activity of T cells include introduction 
of TCR or CAR genes (Fig 1.6; purple arrows). In the case of TCRs, the α and β chain 
genes that form TCR heterodimers recognizing a TAA/TSA of interest can be introduced 
into a population of the patient’s polyclonal peripheral blood T cells to re-engineer their 
specificity (Fig. 1.6 and Fig. 1.7a). TCR genes introduced into T cells can be derived 
from several sources: (1) isolation from autologous T cell clones, (2) isolation from 
allogeneic T cell clones (that are not tolerized against the patients’ TAA/TSAs), or (3) 
isolation from transgenic mice that express human HLA genes112. In any case, the TCR 
genes isolated by these methods can be further engineered for enhanced affinity, 
avidity, or specificity using directed evolution and computational approaches (described 
in detail in the next section) or used without modification113. One recent success using 
this strategy at NCI involved the autologous transfer of T cells expressing an NY-ESO-1 
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cancer/testis specific-TCR with IL-2 where 4/6 patients with synovial cell sarcomas 
showed objective responses (one patient has a partial response), and 5/11 patients with 
NY-ESO-positive melanomas showed objective responses (with two demonstrating 
complete remissions)114.  
Despite this success, the use of T cells with genetically modified TCRs presents 
several challenges. One challenge in this approach involves mispairing of α and β 
chains, as the autologous T cell population already expresses its own specific 
receptors115,116. Mispairing of chains can be problematic if the native/transduced 
heterodimers produce TCRs that recognize “self” targets and lead to autoimmunity, 
although engineering strategies have been developed to favor pairing of the transduced 
chains110. As mentioned in brief in the previous section in regards to targeting of 
TAA/TSAs, another challenge of targeting TAA/TSAs with gene-modified T cells is 
potential off- and on-target toxicity. Off-target toxicity occurs when the transduced TCR 
recognizes an unintended pepMHC (such as by recognition of structurally similar 
peptides or through mispairing) causing destruction of healthy tissue whereas on-target 
toxicity occurs when the transduced T cells recognize the intended target in a non-
intended tissue. For example, two recent trials utilizing TCRs targeting the MAGE-A3 
cancer testis antigen led in one case to cardiac toxicities through recognition of an 
structurally related peptide derived from titin in the heart (i.e. off-target toxicity)117,118, 
and led in another case to neurological toxicities due to recognition of a similar epitope 
derived from the related antigen MAGE-A12 in the brain (i.e. off-target toxicity)79. As a 
result of this and other studies where toxicities have been demonstrated91, strategies to 
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assess antigen expression and cross-reactivity are at the forefront of adoptive cell 
transfer development110. In particular, the roles of TCR affinity and cross-reactivity of 
affinity- and avidity-engineered TCRs are currently being investigated in both CD8+ and 
CD4+ T cells as well as strategies to better evaluate the safety and efficacy of different 
TAA/TSA targets72. 
Another strategy for genetically engineering T cells with specificity involves the 
use of CARs (Fig 1.6 and Fig 1.7b). CARs act as artificial TCRs by combining the 
cytotoxicity and persistence properties of T cells with the specificity of mAbs. As with 
TCR-mediated adoptive cell therapies, CAR-mediated therapies involve isolation of T 
cells from a patient and genetic modification of the T cells ex vivo. However, rather than 
transduction of αβ TCR genes, CAR constructs typically utilize scFv genes fused to the 
signaling domains of a T cell molecule, leading to T cell activation by scFv (antibody) 
binding to a tumor cell surface antigen. First generation CARs described in the literature 
have been constructed by the fusion of an antibody-based binding fragment to ITAM-
containing signal transduction domains, such as CD3ζ or FcRγ. Subsequent generations 
of CARs have included costimulatory signaling domains (e.g. CD28, 4-1BB, OX40)119.  
To date, CARs have been successful in trials targeting B cell malignancies based 
on recognition of CD19120-126, which is only present on the surface of the B cell lineage. 
In a trial with a CD19-specific CAR with a 4-1BB cytoplasmic domain linked to CD3ζ, 
Carl June and colleagues at the University of Pennsylvania showed that two of three 
patients with advanced chronic lymphocytic leukemia (CLL) had complete sustained 
remissions and the third patient exhibited partial regression120,121. In a separate study at 
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NCI, 6 of 8 patients with progressive B cell malignancies had objective remissions 
following treatment with anti-CD19 CAR T cells, combined with IL-2122. The use of anti-
CD19 CARs has been extended to use in acute lymphoblastic leukemia (ALL)126 and a 
variety of other cancers with many clinical trials underway127. 
Despite success with CAR-mediated adoptive cell therapy trials, several 
challenges remain in its development to a routine medical practice. Where CARs avoid 
the risk of mispairing that could occur with TCR-mediated adoptive transfers, toxicity 
has been observed. For example, toxicities associated with anti-CD19 CAR strategies 
have included B cell aplasia, tumor lysis syndrome, and cytokine release syndrome127. 
Additionally, other on- and off- target toxicities are possible, especially as CAR-
strategies are applied to non-CD19-directed therapies. As a result, strategies to regulate 
CAR expression and/or T cell survival to mitigate these risks are currently being 
pursued119.  
 
Protein Engineering for Immunotherapy 
Because of the central role of the immune system in cancer, autoimmunity, and 
infectious disease, protein engineering strategies based on core immunological 
principles provide an opportunity to exploit the immune system for the treatment of 
many human diseases. The field of protein engineering emerged in the 1980s leading to 
the generation of the most rapidly expanding class of new drugs: protein-based 
therapeutics (also called “biologics”). A main focus of protein engineering strategies has 
been to modulate the affinity and specificity of proteins, such as mAbs, which can be 
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used in immunotherapy and diagnostic applications. Here I discuss the types of binding 
molecules currently being developed, the engineering strategies used to modulate 
binding properties (particularly directed evolution by yeast display), and finally the 
background of TCR engineering that lays the foundation for the work described in this 
dissertation. 
 
Antibody and TCR engineering formats 
 Since the advent of hybridoma technology in 1975128, monoclonal antibodies 
have become the primary framework for the development of specific binding molecules 
for the use in research, diagnostic, and therapeutic applications. Initial antibodies 
developed in the late 1980s as potential therapeutics were generated in mice, and as 
therapeutics they had significant drawbacks in terms of immunogenicity and minimal 
activation of Fc-mediated effector functions. As a result, chimeric mouse-human 
antibodies were developed in which the variable regions of murine antibodies were 
grafted on to the constant regions of a human antibody129. In the early 1990s, the 
advent of phage display130, an entirely in vitro technique by which the variable domains 
of antibodies could be evolved, allowed for the first fully human antibodies to be 
developed, reducing the immunogenicity for therapeutic applications. Since then, the 
use of a variety of antibody formats have been utilized, including scFv, Fab domains, 
and other multivalent fragments, for the specific binding of therapeutic targets (Fig. 
1.1a,c)131. 
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 Whereas antibodies have been successful in targeting numerous cell surface and 
soluble antigens, targeting of MHC-restricted antigens with antibodies has had limited 
success80-83. Because the TCR evolved to recognize the class of MHC-restricted 
antigens and like antibodies are naturally generated with substantial diversity, our 
group113 and others132 have proposed their use in both soluble and adoptive cell 
therapies. Although TCRs are naturally membrane bound, soluble single-chain TCR 
(scTCR or scTv) variants consisting of the extracellular TCR α and β variable domains 
connected by a linker can be generated and used to engineer TCRs in vitro in an 
analogous format to scFvs (e.g. Vα-linker-Vβ or Vβ-linker-Vα)(Fig 1.1d and Fig. 1.4c)133. 
In addition to TCRs, other binding scaffolds have been utilized in directed evolution 
approaches, such as designed ankyrin repeat proteins (DARPins)134 and fibronectin 
type III domain-based scaffolds (AdnectinsTM)135. In the next section I describe 
engineering approaches that have been used to alter the binding and specificity 
properties of TCRs, antibodies, and other binding proteins. 
   
Engineering approaches 
Protein engineering strategies that are used in order to modulate the binding 
affinity and specificity properties of proteins include directed evolution136, rational 
design137, computational design138, and combined approaches (e.g. “semi-rational 
design”)139. The most successful strategy used to engineer antibodies and TCRs 
involves directed evolution through the use of display technologies, such as yeast 
display, phage display, mammalian cell display, bacterial display, and in vitro display. 
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The general principle of these strategies involves the formation of a physical linkage of 
the protein or peptide being evolved to the gene that encodes it. Through genetic 
manipulation, large libraries of protein variants can be generated, from which variants 
with desired characteristics can be isolated, and the protein sequences can be 
determined.  
The first display technology, phage display, was developed in 1985140 and since 
then a variety of additional display techniques with additional benefits have been 
developed. Phage display involves the targeting of the protein of interest to the phage 
surface through fusion to a viral coat protein. Typically, the M13 filamentous phage coat 
protein pIII is fused to the C-terminus of the protein being evolved, mutational libraries 
are made in the protein of interest (up to 1010 in size), and the library is propagated in E. 
coli. Virus particles can be isolated from culture supernatants, then selected for protein 
mutants with desired properties through a process called “panning.” This process 
involves repeated iterations of selections where the binding partner of the protein of 
interest is immobilized to the surface of a microtiter plate allowing virions with productive 
mutations to bind while virions with non-productive mutations do not. Following a series 
of washes of modulated stringency, the virus particles with productive mutations are 
used to re-infect E. coli allowing for variants with improved properties to be isolated after 
several cycles141. Phage display has been used extensively for antibody engineering for 
both for affinity maturation of antibodies in vitro and for the isolation of de novo 
antibodies from synthetic libraries142. 
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Since the advent of phage display, several competing technologies have been 
developed to address some of its limitations. In vitro display systems, such as ribosome, 
mRNA, and covalent DNA display, eliminate the library size limitations of phage and 
cell-based display methods as there are no transformation steps, and it also allows for 
recursive mutations; however, it does not allow for the post-translational processing of 
expressed proteins or the quality control checkpoints of the eukaryotic ER of other 
systems that is advantageous in the evolution of immunoglobulin-domain containing 
proteins143. On the other hand, mammalian cell display allows for eukaryotic post 
translational processing including the complex mammalian glycosylation required for the 
full-length IgG frameworks, and it allows for tight control over selection parameters 
through the use of fluorescence activated cell sorting (FACs); however, it is rather 
limited as only small libraries can be generated (103 to 106)144.  
Although different display techniques offer different advantages and limitations 
for various applications, yeast display, first published in 1997 by Boder and Wittrup145, 
offers a good compromise for applications in antibody and TCR engineering. Yeast 
display involves the expression of the protein of interest on the yeast cell surface 
through a covalent linkage to the yeast cell surface (Fig 1.8). The protein of interest is 
typically cloned as a C-terminal fusion to the yeast mating protein AGA-2, which forms 
disulfide linkages to AGA-1 yeast mating protein on the cell surface upon being 
transported to the cell surface via the yeast secretory pathway. Typically, 10,000 to 
100,000 copies of the protein of interest are expressed on each yeast cell, allowing for 
avidity effects that enhance selections145,146. The advantages of yeast display include 
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the following: (1) eukaryotic post-translational processing including disulfide 
isomerization and glycosylation, (2) the quality control mechanisms of the yeast 
secretory pathway147-149, (3) precise control over selections based on affinities and off-
rates through the use of FACS150, (4) the ability to produce relatively large libraries (109-
1010)151,152, and (5) the ability to assess the evolved characteristics directly on the 
surface of yeast without the need to express large quantities of protein153-155. Although 
yeast display has been used for antibody engineering156 and other protein engineering 
applications157, our group has developed yeast display technology for the purpose of 
TCR engineering (summary of scTCRs engineered to date described in the next 
section)113. 
The general process for engineering scTCRs by yeast display involves the 
isolation of reactive T cells clone for the antigen of interest, cloning of the TCR genes, 
and generation of a single-chain construct from the full length α and β chains (Vα-linker-
Vβ or Vβ-linker-Vα)(Fig. 1.9). The single-chain construct is then cloned into the 
galactose-inducible pCT302 yeast display vector, which expresses the scTCR as a C-
terminal fusion protein to AGA-2 yeast mating protein. The vector also contains an N-
terminal HA epitope tag between AGA-2 and the scTCR gene that is used to probe for 
expression, and typically a c-myc epitope tag is added to the C-terminus of the scTCR 
for monitoring expression of the full-length fusion protein. Because scTCR fragments 
lack TCR constant regions that stabilize the TCR on the surface of the T cell, scTCR 
constructs typically require mutations to generate a stabilized form to express on the 
surface of yeast113.  
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In order to select for stabilized scTCR variants, mutations are introduced 
throughout the scTCR construct via error-prone mutagenesis and the variants are 
introduced into yeast cells. Following induction of scTCR expression, the yeast 
population is stained with a conformational-specific antibody that binds to epitopes on 
the Vβ and/or Vα chain, and the cells that express the most stable mutants are isolated 
by magnetic bead activated cell sorting (MACS) or FACS. Additionally, selections can 
be performed with antibodies against the c-myc epitope tag in order to eliminate scTCR 
library variants that result from truncations through introduction of pre-mature stop 
codons. Following various selection cycles, individual yeast clones expressing a single 
scTCR variant can be screened for desired properties directly on the yeast cell surface. 
The resultant stabilized scTCR mutant can then be used as a template for affinity 
maturation of the TCR by generation site-directed libraries in CDR loops (Fig 1.10).  
Affinity maturation libraries, generally in CDR3 loops but occasionally in CDR1 
and CDR2 loops, can be stained with soluble pepMHC reagents of various valencies 
and yeast displaying scTCR mutants with improved binding characteristics can be 
isolated in an iterative selection process with MACS and/or FACS as before. In general, 
initial selections identify mutants that bind to the pepMHC of interest and through each 
subsequent selection iteration, the stringency of selection is increased (e.g. through 
decreasing staining concentration of pepMHC, decreasing valency of staining reagents, 
or off-rate based selections). Following isolation and screening of individual variants on 
the surface of yeast, the scTCR gene can be introduced into a pET expression vector, 
expressed at high levels in E. coli, and refolded from inclusion bodies to produce a 
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soluble scTCR. Alternatively, the scTCR gene can be cloned into a variety of formats 
(e.g. full length TCR, CAR, bispecific) for assessment in therapeutic or diagnostic 
models. 
 
Engineering of T cell receptors 
For over 15 years, our group has developed strategies to engineer stable, high-
affinity TCRs using yeast display of TCRs in a single-chain format (scTCR or scTv) that 
consists of the variable regions of the α and β chains connected by a flexible linker (Vα-
linker-Vβ or Vβ-linker-Vα)113. Because normal TCR affinities are low (KD = 10-100 µM), 
engineering for improved affinity, stability, and specificity properties allows for their 
potential use in research, therpuetic, and diagnostic applications. In particular, 
engineering TCRs to affinities of less than 1 µM allows for use in applications that allow 
for T cell activation independent of CD8 co-receptor (e.g. activation of TCR-modified 
CD4+ cells upon recognition of class I pepMHC complexes)71 
Early work in the lab focused on the engineering and characterization of the 
mouse TCR 2C, which recognizes alloantigen QL9/Ld and synthetic antigen SIYR/Kb 
with wild type affinities in the µM range, for stability and high affinity against its various 
ligands. The resultant high affinity scTCRs (m6 and m33) recognized their respective 
ligands QL9/Ld and SIYR/Kb with binding constants (KD) of 10 nM and 30 nM, 
respectively158-160. Our lab also engineered 2C variants using a T cell display system, 
which allows for TCR selection in the native state161. In addition to engineering mouse 
TCRs which recognize class I pepMHC ligands, our group has also engineered the 3L2 
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TCR which recognizes the class II-restricted ligand Hb/I-EK via yeast display to an 
affinity of KD = 50 nM (from wild type KD = 16 µM)162.  
Despite successful yeast display engineering of mouse TCRs, until recently 
engineering human scTCRs by yeast display had proven more challenging. However, a 
2011 study by Aggen et al. determined certain conditions, such as the use of the highly 
stable human Vα2 region (IMGT, TRAV12 family) and the introduction of a serine 
substitution at the polymorphic residue 49 in Vα2, that enabled yeast display 
engineering of human scTCRs163. In this study, two human Vα2-containing TCRs that 
recognize the HTLV antigen Tax/HLA-A2 and the HIV antigen SL9/HLA-A2 (A6 and 
868, respectively) that were previously engineered for high affinity by phage 
display164,165, were engineered for stability and expressed as scTvs113. This platform has 
allowed for the engineering of several additional Vα2-containing human scTCRs 
described in this dissertation57.  
In addition to TCR engineering by yeast display, other groups have engineered 
TCRs of enhanced affinity and avidity using a variety of formats and directed evolution 
approaches113. For example, phage display has been used to engineer full-length TCRs 
with very high affinities (nanomolar to picomolar range) against various class I pepMHC 
complexes164-167. Additionally, computational approaches have been used to guide 
improvements in TCR affinity168-171. 
The applications of engineered high affinity TCRs include uses in both soluble 
and adoptive cell therapies described earlier, as well as diagnostic and research 
applications (Fig. 1.11). As soluble therapeutics, scTCRs can be used as biologic 
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agents for the delivery of drugs or cytokines to TAA/TSAs or to viral or autoimmune 
antigens. Additionally, scTCRs could be used as targeting modules in bispecific agents, 
directing T cell-mediated immune responses to infected or cancerous cells. For adoptive 
therapies, engineered TCRs can be used in the full-length format or as scTCRs as 
CARs in order to redirect the T cell response to diseased tissues. As diagnostics, high 
affinity scTCRs could be used to determine TAA/TSA expression of tumors. Finally, high 
affinity scTCRs provide an opportunity in basic science to study the principles of TCR 
triggering of the requirements of MHC restriction. 
 
Overview of Dissertation  
This dissertation focuses on the engineering and characterization of high affinity 
human scTCRs for potential therapeutic, diagnostic, and research applications, as well 
as for use in studies to understand basic principles of MHC restriction. The engineering 
aspects of this dissertation have focused on two goals: (1) yeast display engineering163 
for the affinity maturation of human TCRs isolated from T cell clones that recognize 
cancer antigens of interest (described in Chapters 2 and 3), and (2) the establishment of 
a platform by which high affinity TCRs with diverse specificities could be evolved entirely 
de novo from a single scTCR scaffold without the need to isolate a reactive TCR clone 
(described in Chapter 4). The resultant panel of engineered scTCRs also enabled a 
study of the molecular basis of MHC-restriction through the use of site-directed 
mutagenesis studies of various CDR loop residues (Chapter 2). The experiments 
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performed during the course of this project have addressed three main aims, the results 
of which are presented in Chapters 2-4 of this dissertation: 
 
Aim 1: Engineering of high affinity scTCRs against two defined cancer antigens 
To date I have engineered high affinity scTCRs against the MART-1/Melan-A57 
and WT1 antigens, recently ranked in a National Cancer Institute pilot project as the 14th 
and 1st priority cancer antigen therapeutic targets respectively76. Using yeast display, 
high affinity variants of MART-1 and WT1 scTCRs were isolated and showed binding 
affinities of 45 nM57 and 330 nM, respectively, for cognate peptide/HLA-A2 complexes, 
as measured by surface plasmon resonance (SPR). Both scTCRs could be expressed 
at high levels in E. coli, and the soluble protein could detect HLA-A2-positive APCs 
pulsed with the respective specific peptides. The engineering of the MART-1-specific 
scTCR is described in Chapter 2, and the engineering of the WT1-specific scTCR is 
described in Chapter 3. These receptors are currently being studied in adoptive T cell 
models by our group.  
 
Aim 2: Analysis of predicted key residues of TCR:pepMHC recognition 
In addition to their potential clinically, high affinity scTCRs provide a unique 
opportunity to study the energetic impact of several key residues in CDR1 and CDR2 
loops. Because the TCR binds to the pepMHC in an invariant diagonal docking 
orientation, it has been proposed that several evolutionary conserved residues in TCR 
variable regions evolved to contact the MHC. High affinity scTCRs enable the ability to 
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assess the contribution of these residues, as measuring even small decreases in 
binding affinity in their wild type counterparts would reduce binding such that 
measurements are often out of the detectable range achieved by conventional SPR 
techniques.  
In order to test the hypothesis that evolutionarily conserved residues dictate TCR 
recognition of MHC helices, I used the MART-1/HLA-A2-specific scTCR engineered in 
Aim 1 and two other high-affinity TCRs that all contain the same Vα region and 
recognize the same MHC allele (HLA-A2), with different peptides and Vβ regions. By 
performing site-directed mutagenesis, I measured the changes in binding energy of 
putative conserved residues in CDR1 and CDR2 of the three Vα2 regions. The results in 
the five residues examined showed the importance of one key germline codon residue, 
CDR2α Y51, whereas the other positions varied in their relative contributions to binding 
in the panel of TCRs. Additionally, selections of single-position, yeast display libraries in 
two of the key positions of the MART-1/HLA-A2-specific TCRs showed a strong 
preference for the wild-type germline residues although structurally similar amino acids 
were tolerated at the binding interface and mediated MHC-restriction. As a result, we 
propose that where the CDR1α residue Y51 could account for significant proportion of 
the binding energy associated with MHC restriction and perhaps even positive selection, 
there is plasticity in the requirements of other positions in the CDR1α and 
CDR2α depending on the Vβ usage and peptide recognized. These results are 
presented in Chapter 2. 
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Aim 3: Generation of a strategy, based on semi-rational design, to rapidly isolate 
scTCRs specific for a wide array of peptides loaded on HLA-A2 
Because recognition of pepMHC is mediated entirely by specific residues on 
CDR loops and the majority of TCRs adopt a similar Ig-fold and docking angle, I 
proposed that a stabilized scTCR could be used as a template for directing specificity 
and high affinity for a wide array of peptides displayed on HLA-A2. In this study I was 
able to accomplish the directed evolution of TCR variants with a change in binding 
specificity to a non-cognate pepMHC. Using the human TCR A6, whose cognate ligand 
is Tax/HLA-A2, as a template, computational approaches were used to guide the design 
of yeast displayed single-chain TCR libraries degenerate in CDR1α, CDR3α, and 
CDR3β loops. Selection with a non-cognate pepMHC, MART-1/HLA-A2, resulted in the 
isolation of mutants that bound specifically to MART-1 and no longer to the cognate 
ligand, Tax. 
Mutational studies of yeast-displayed mutants and comparative molecular 
dynamics (SMD) simulations of modeled TCRs suggest that a single position, TCRβ98, 
could account for the mechanism of the specificity switch in one MART1-specific variant, 
although reverting the residue at this position to the wild type A6 residue is not sufficient 
to regain Tax binding. Furthermore, a scaffold variant isolated from an alternative 
scaffold library for MART1/HLA-A2 specificity is unaffected by mutation at TCRβ98 and 
is thought to be able to accomplish MART1-specificity through a different mechanism. 
One of these variants has been further affinity matured via directed evolution to bind the 
selecting, non-cognate pepMHC at low nanomolar affinities. These results are shown in 
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Chapter 4. This scaffold-library approach is currently being further developed in the lab 
as a high throughput strategy to isolate designer TCRs with high affinity against virtually 
any desired target antigen.  
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Figures 
 
 
 
Figure 1.1 | Diagram of the native antibody (IgG) and TCR structure and single-chain engineering 
formats. (a) Schematic of an IgG antibody with relevant fragments indicated. The heavy chain (CH) 
constant and variable regions (VH) are colored in light blue and blue, respectively, and the light chain 
constant (CL) and variable regions (VL) are colored in pink and red, respectively, with the N and C terminal 
ends indicated. Interchain disulfide bonds are indicated by green lines, and the fragment crystallizable 
(Fc) and one of two antigen-binding fragments (Fabs) are labeled directly. The fragment variable (Fv) is 
also labeled directly, and the yellow stars indicate where antigen binding occurs. (b) Schematic of the 
TCR binding complex of an αβ TCR on the surface of a CD8+ T cell binding to a class I pepMHC on the 
surface of an antigen presenting cell (APC). With analogy to the antibody structure, the α chain constant 
region (Cα) is colored in pink and variable region (Vα) is colored in red, whereas the β chain constant 
region (Cβ) is colored in light blue and the variable region (Vβ) is colored in blue. The CD3 dimers (εγ, εδ, 
and ζζ) are indicated in orange, and the co-receptor CD8 (αβ heterodimer) is colored in purple. The 
variable regions of the TCR that make up the binding interface with pepMHC are indicated in a dotted 
box. The MHC molecule is shown as three heavy chain domains (α1, α2, and α3; light green) associated 
to the β2m light chain (green) with a bound peptide (yellow star). (c) Schematic of a single-chain Fv 
antibody format. Variable light (VL; red) and variable heavy (VH; blue) chains are connected by a flexible 
linker, and the yellow star indicates where antigen binding occurs. (d) Schematic of a single-chain TCR 
(scTCR or scTv). With analogy to the scFv, variable α (Vα; red) and variable β (Vβ; blue) chains are 
connected by a flexible linker. The yellow star enveloped by the α1 and α1 MHC helices (light green) 
indicates where MHC-restricted antigen binding occurs. 
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Figure 1.2 | T cell tolerance and somatic gene rearrangement of TCR genes. (a) Simplified 
schematic of gene rearrangement of TCR α and β genes by RAG recombinase. The TCRα gene is 
rearranged by the combination of V-J segments (top), where the TCRβ gene is rearranged by the 
combination of V-D-J segments (bottom). The final mRNA transcripts that encode the TCR protein 
product as a result of the rearranged segments are also shown (middle). The approximate diversities of 
the TCR gene segments at the α and β loci from the IMGT database [www.imgt.org] are listed in the 
accompanying table. (b) Positive and negative selection of thymocytes. First, T cell precursors undergo 
TCR gene rearrangement and migrate from the bone marrow to the thymus. Next, immature thymocytes 
(CD4+CD8+) undergo positive selection, where T cells expressing TCRs that bind to class I or II MHC 
survive and those that do not are deleted. Then, surviving thymocytes that bind too strongly to self-MHC 
or self-pepMHC molecules are deleted during negative selection. The resultant mature thymocytes (CD4+ 
or CD8+) migrate to peripheral tissues where they can encounter and be activated by foreign antigens.  
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Figure 1.3 | Schematic of CTL-mediated signaling. General steps are numbered: (1) Upon TCR 
recognition of pepMHC, the formation of the TCR signaling complex is initiated, including association of 
CD3 dimers (orange) and CD8 co-receptor (purple). (2) The CD8-associated p56LCK kinase 
phosphorylates ITAMs on CDR3ζ chains. (3) Phosphorylated ITAMs recruit the ZAP-70 kinase (green) to 
the signaling complex. (4) ZAP-70 phosphorylates adaptor molecules, such as SLP-76 and LAT. (5) 
Adaptor molecules recruit components of the Ca2+-, PKC-, and RAS/RAC-mediated pathways which 
ultimately lead in transcriptional changes leading to activation, differentiation, and expression of CTL 
signaling and effector molecule components.  
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Figure 1.4 | Structure of a TCR:pepMHC complex. (a) An example of a TCR:pepMHC complex 
(Mel5:MART-1/HLA-A2; PDB: 3HG1). The variable and constant regions of the α-chain are colored in red, 
and those of the β-chain in blue. HLA-A2 (α1, α2, α3, and β2m) is shown in gray and the peptide (MART-
1; ELAGIGILTV) is in black. (b) The TCR CDR footprint on pepMHC. CDR1 and CDR2 loops are 
positioned primarily over the MHC helices where CDR3 loops are positioned primarily over the peptide. A 
conserved diagonal docking orientation with the Vα region laying over the α2 MHC helix and the N-
terminal end of the peptide, and the Vβ region laying over the α1 MHC helix and C-terminal end of the 
peptide is observed in virtually all TCR:pepMHC structures to date. (c) The variable regions of the Mel 5 
TCR (from the Mel5:MART-1/HLA-A2 crystal structure; PDB: 3HG1) indicating the general format of a 
scTv. 
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Figure 1.5 | MHC-restricted cancer peptide antigens. (a) Table listing the number of cancer peptide 
antigens of the listed categories characterized to date. Source: Cancer peptide database 
[http://cancerimmunity.org/peptide/]75 (b) Overlay of peptides from crystal structures of cancer peptide 
antigens. The shared tumor-specific antigen NY-ESO-1 [PDB: 1S9W]172 is shown in magenta, 
differentiation antigen MART-1 [PDB: 1JF1]173 is shown in green, and overexpression antigen WT-1 [PDB: 
3HPJ]174 is shown in blue. HLA-A2 helices of the MART-1/HL-A2 structure [PDB: 1JF1]173 are shown in 
gray. 
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Figure 1.6 | Overview of adoptive cell therapy. Schematic showing the two general routes for adoptive 
cell therapy. (1) Tumor invading lymphocytes can be harvested from the patient, expanded and activated 
ex vivo, then reintroduced (navy arrows), or (2) peripheral blood lymphocytes can be isolated from the 
bloodstream, genetically modified to express TCRs (engineered or allogeneic) or CARs that recognize 
tumors, expanded and activated ex vivo, then introduced into the patient (purple arrows). 
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Figure 1.7 | Genetically engineered T cells for adoptive cell therapies. (a) TCR-mediated adoptive 
cell therapy involves the viral transduction of the full length α and β TCR genes into autologous T cells 
and utilization of the native signaling components to form the TCR signaling complex (i.e. CD8, CD3, 
etc.). (b) CAR-mediated adoptive cell therapy involves the transduction of an antibody-based binding 
fragment (usually a scFv) fused to the signaling domains of the T cell. An example construct includes a 
costimulatory signaling domain (e.g. CD28, 4-1BB; green) and an ITAM-containing CD3ζ domain (orange) 
fused to the scFv via the CD8 hinge transmembrane domain (purple). 
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Figure 1.8 | Yeast display engineering. Diagram showing the relevant cloning region of the pCT302 
yeast display vector for yeast display of a scTCR (bottom panel). The Vβ (blue) and Vα (red) are 
expressed as a single chain fusion protein connected by a flexible linker to the C-terminus of AGA-2 yeast 
mating protein. Flanking the N- and C-terminal end of the scTCR construct are fused HA and c-myc 
epitope tags to probe for expression. Libraries generated by mutagenesis of the indicated construct are 
introduced into yeast via homologous recombination. The resultant library consists of a population of 
yeast cells with each cell expressing 10,000-100,000 copies of a single scTCR variant on its cell surface 
(top panel). Yeast can be probed for expression utilizing fluorescent antibodies against the HA or c-myc 
epitope tags, for stability via antibodies that recognize conformational epitopes on the Vβ (blue) or 
Vα (red), or for affinity or off-rates via binding to a soluble fluorescent pepMHC ligand. 
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Figure 1.9 | General selection workflow for isolating a stable scTCR. Sample selection scheme for 
isolation of scTCR clones with improved stability through the use of antibodies specific for conformational 
epitopes or the c-myc epitope tag.  
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Figure 1.10 | General selection workflow for isolating a high affinity scTCR. Sample affinity 
maturation scheme for isolation of scTCR clones with improved binding to pepMHC through the use of 
fluorescently labeled or bead-conjugated pepMHC ligands.  
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Figure 1.11 | Summary of applications of engineered high-affinity TCRs. Examples of therapeutic, 
diagnostic, and research applications of engineered scTCRs. 
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Tables 
 
 
Features Innate Immunity Adaptive Immunity 
Components • Physical barriers (skin, 
mucosal membranes) 
• Chemical barriers (e.g. pH, 
lysozyme, phospholipases) 
• Humoral defenses (e.g. the 
complement system) 
• Cellular components (e.g. 
neutrophils, macrophages, 
NK cells) 
• Cellular components (B and T 
lymphocytes) 
• Antigen-specific receptors 
(Antibodies and TCRs) 
• Cell-mediated killing (CTLs) 
Response 
Time 
• Constitutively present 
• Responds in minutes to 
hours 
• Activated upon antigen 
encounter 
• Responds in days to weeks 
 
Specificity • Very limited 
• Recognition of general 
patterns (i.e. PAMPS) 
• Highly diverse and adaptive 
• Recognition of specific antigens 
Memory • No memory 
• Response to infection same 
in repeated exposures 
• Immunological memory 
• Response to same antigen is 
faster and more effective in 
subsequent exposures 
 
Table 1.1 | Comparison of innate and adaptive immunity. Summary of the main components of the 
innate and adaptive immune systems and their features. 
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Treatment Types Mechanisms of Action 
Targeted 
soluble 
therapies 
Monoclonal antibodies 
(mAbs) and antibody-
like molecules in various 
formats (e.g. scFv, 
bispecifics) 
• Targeting of drugs, toxins, or radioactive 
particles 
• Immune checkpoint blockade 
• TAA/TSA or growth factor neutralization 
• Inhibition of signal transduction 
• Activation of antibody-mediated effector 
functions (e.g. antibody-dependent cellular 
cytotoxicity (ADCC), complement) 
• Activation of the cell mediated immune 
response (bispecifics) 
Cancer 
vaccination 
Dendritic cells loaded 
with TAA/TSAs, peptide 
vaccines, gene therapy 
• TAA/TSA-specific activation and 
enhancement of immune response 
• Cancer prophylaxis 
Adoptive 
cell 
therapy 
Autologous or 
allogeneic transfer of 
TILs, TCR or CAR 
genetically engineered 
T cells 
• Generation of a TAA/TSA-specific 
lymphocyte population 
• Immune response enhancement 
• Establishment of immunological memory 
Non-
specific 
therapies 
Cytokines (e.g. IL-2, 
INF-α, GM-CSF), 
immunomodulatory 
chemotherapies 
• Tumor growth control 
• Promotion of apoptosis 
• Immunomodulation and activation of 
immune cells 
 
Table 1.2 | Summary of immunotherapy strategies. Examples of immunotherapy strategies currently 
being utilized for the treatment of cancer and their mechanisms of action.  
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CHAPTER TWO 
 
 
 
HUMAN HIGH-AFFINITY T CELL RECEPTORS AGAINST MELAN-A/MART-1: 
ENGINEERING BY YEAST DISPLAY AND ANALYSIS OF THE CONTRIBUTION OF 
T CELL VARIABLE REGION RESIDUES TO BINDING1 
 
 
 
Abstract 
 
One hypothesis accounting for major histocompatibility complex (MHC) restriction 
by T cell receptors (TCRs) holds that there are several evolutionary-conserved residues 
in TCR variable regions that contact MHC. While this “germline-codon” hypothesis is 
supported by various lines of evidence, it has been difficult to test. The difficulty stems in 
part from the fact that TCRs exhibit low affinities for peptide-MHC (pepMHC), thus 
limiting the range of binding energies that can be assigned to these key interactions 
using mutational analyses. To measure the magnitude of binding energies involved, 
here we used high-affinity TCRs engineered by mutagenesis of CDR3. The TCRs 
included a high-affinity, MART-1/HLA-A2-specific single-chain TCR and two other high-
affinity TCRs that all contain the same Vα region and recognize the same MHC allele 
(HLA-A2), with different peptides and Vβ regions. Mutational analysis of residues in 
CDR1 and CDR2 of the three Vα2 regions showed the importance of the key “germline 
                                            
1Smith S. N., Sommermeyer D., Piepenbrink K.H., Blevins S.J., Bernhard H., Uckert W., Baker B.M., 
Kranz D.M. Plasticity in the Contribution of T Cell Receptor Variable Region Residues to Binding of 
Peptide-HLA-A2 Complexes. 2013. J Mol Biol 425, 4496-4507. 
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codon” residue Y51. However, two other proposed key residues showed significant 
differences among the TCRs in their relative contributions to binding. With the use of 
single-position, yeast-display libraries in two of the key residues, MART-1/HLA-A2 
selections also revealed strong preferences for wild-type “germline codon” residues, but 
several alternative residues could also accommodate binding and hence, MHC-
restriction. Thus, although a single residue (Y51) could account for a proportion of the 
energy associated with positive selection (i.e. MHC-restriction), there is significant 
plasticity in requirements for particular side-chains in CDR1 and CDR2 and in their 
relative binding contributions among different TCRs. 
 
Introduction 
 T cell-mediated recognition of a foreign peptide bound to a product of the major 
histocompatibility complex (MHC) occurs through the αβ T-cell receptor (TCR), in a 
process that is referred to as MHC-restriction. TCRs contain six complementarity-
determining regions (CDRs), three (CDR1, CDR2, and CDR3) in each α and β chain. 
CDR1 and CDR2 loops are “germline derived” since they reside in the region encoded 
by each variable region gene, which do not undergo either somatic mutation or 
rearrangements. CDR3 loops are more variable in sequence as they are encoded by 
the junctions of somatically rearranged gene segments (VJ in the α locus and VDJ in 
the β locus), similar to antibodies. 
In virtually all of the structures of TCR:pepMHC complexes, the CDR1 and CDR2 
loops are found to dock over the helices of the MHC protein, whereas the CDR3 loops 
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are positioned over the peptide where they can contribute most importantly to the 
antigen specificity of the reaction1,2. Despite these generalizations, there are cases 
where CDR1 residues are near the peptide and CDR3 residues appear to contact the 
MHC protein3-6. 
While there is conserved, diagonal docking of TCRs over pepMHC ligands, the 
complexities associated with the diversity of TCRs, peptides, and MHC proteins have 
made it difficult to reveal conserved chemistries of the interactions that could account for 
the process of MHC restriction. More recent evidence, where the structures of TCRs 
with the same V regions and the same MHC-restricting elements have been compared, 
has led to the “germline codon” hypothesis. In this hypothesis, several key residues in 
CDR1 and/or CDR2 interact invariably with residues from the MHC protein, suggesting 
that these TCR residues evolved to establish the biochemical basis of MHC-restriction. 
Results of mutagenesis of these residues have been consistent with their contribution to 
binding7-11, or even in the process of positive selection12. However, these studies have 
been unable to reveal the energetic importance of the residues among different TCRs.  
A recent study suggested that there is no absolute requirement for specific residues 
within the germline Vα or Vβ loops, as it was possible to modify these very significantly 
and still achieve MHC-restriction and positive selection in the thymus13. Whether these 
modified TCRs retained the diagonal footprint characteristic of conventional TCRs 
remains to be seen. Another study showed that the CDR3 regions can significantly alter 
the germline-encoded interactions14. 
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Studies with the mouse 2C system showed that two of the predicted germline 
codon residues in CDR2β (Y46 and Y48) were unable to bind the SIY/Kb antigen when 
the residues were changed to alanines7,15. More recent work with a high-affinity mutant 
of the mouse 2C (named m33), generated in CDR3α, showed that the TCR docked in 
an identical way as the wild-type TCR, and that all of the CDR1 and CDR2 contacts 
were preserved16,17. In addition, both the 2C TCR and the m33 TCR had the same 
amino acid preferences at Y46, using an approach based on T-cell libraries18. To the 
best of our knowledge, there have not been studies with human TCR single-site mutants 
to understand the issue of CDR1 and CDR2 contributions to binding properties, in large 
part because wild-type affinities are already so low. This prompted us to more fully 
exploit the idea of using high-affinity TCRs to determine the requirements and binding 
energies associated with MHC restriction in a human system.  
Recently, we described the engineering of two human single-chain TCRs, 868 
and A6, with high-affinity for HLA-A2-restricted peptides HIV (SL9 or Gag) and Tax, 
respectively19. This study showed that the Vα2 (IMGT: TRAV12) region was stable 
compared to other V regions, and that a polymorphism in framework residue 49 of Vα2 
facilitated the display, engineering, and expression of soluble scTv (single-chain T cell 
variable) fragments in Escherichia coli. Using this as a platform for work with additional 
human TCRs, here we have engineered a third Vα2-containing scTv against the MART-
1/Melan-A peptide restricted by HLA-A2; MART-1 is a human differentiation antigen 
expressed in more than 80% of metastatic melanoma tumors20. Collectively, these three 
TCRs, with the same CDR1α and CDR2α, provided an opportunity to examine the 
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energetic impact of several key residues. In addition, there are several published crystal 
structures of Vα2-containing TCR:peptide-HLA-A2 (pepHLA-A2) complexes3-5,21, 
including the A6 TCR, providing a structural framework for the interpretation of the 
results.  
With the use of a combination of alanine-scanning mutagenesis, and library-
based selections with pepHLA-A2, our findings indicated (1) that two of the proposed 
CDR1 germline codon residues, R28 and Q31, contributed to binding in some cases, 
but not in others, consistent with recent structural studies suggesting that CDR3 editing 
can influence CDR1 contacts14; (2) that one of the germline codon residues, Y51, 
exhibited similar and significant contributions to binding in all three cases 
(approximately 1.5-2 kcal/mol in free energy, ∆G); the free energy contributions of this 
residue, together with that contributed by one of the CDR1 residues, would be sufficient 
to produce an equilibrium binding constant (KD value ~ 1 mM; ∆G ~ 4 kcal/mol) 
associated with co-receptor-dependent positive selection; and (3) that, using a library 
approach, the tyrosine at position 51 was preferred for pepHLA-A2 binding, relative to 
almost all other amino acids, although several conserved side chains (Phe and Trp) 
could be substituted. Thus, there is plasticity in the binding requirements of the 
germline-encoded residues, but the evidence suggest that there has been evolutionary 
pressure to maintain certain key residues. 
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Materials & Methods 
Antibodies, pepHLA-A2, and flow cytometry 
 Antibodies used to detect yeast surface expression included the following: anti-
HA epitope tag (Clone HA.11; Covance), anti-Vβ16 antibody (Clone TAMAYA1.2; 
Beckman-Coulter), anti-Vβ14 antibody (Clone CAS1.1.3; Beckman-Coulter), anti-Vα2 
monoclonal antibody generated in our laboratory (data not shown), goat-anti-mouse IgG 
F(ab’)2 AlexaFluor 647 secondary antibody (Invitrogen), and streptavidin-phycoerythrin 
(SA-PE, BD Pharmingen). Peptides that bind to HLA-A2 [Tax11 – 19: LLFGYPVYV, SL977 
– 85 (HIV-Gag): SLYNTVATL, MART-126–35 A27L: ELAGIGILTV, MART-127-35: AAGIGILTV, 
and MART-127-35 A28L: ALGIGILTV] were synthesized by standard F-moc [N-(9-
fluorenyl)methoxycarbonyl] chemistry at the Macromolecular Core Facility at Penn State 
University College of Medicine (Hershey, PA, USA). For FACS and flow cytometry 
analysis, recombinant soluble dimeric HLA-A2-Ig fusion protein (BD DimerX) was used. 
Additionally, a monomeric HLA-A2-biotin reagent generated by the exchange of a UV-
cleavable peptide for another HLA-A2-restricted peptide in the presence of UV light was 
utilized to determine fold changes of binding in alanine mutants on the surface of yeast 
cells22,23.  
 
Cloning and expression of scTv in yeast display vectors 
TCR variable region fragments (scTv) were expressed in yeast display plasmid 
pCT302 (Vβ-L-Vα)24, which contains a galactose-inducible AGA2 fusion allowing for 
growth in Trp media. 
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Induction of the scTv gene involves growth of the transformed EBY100 yeast 
cells to stationary phase in selection media followed by transfer to galactose-containing 
media. The R1 and T1 single-chain genes for TCRs were synthesized by Genscript 
(Piscataway, NJ, USA) with an F49S mutation in the Vα2-domain of the construct19.  
The MART-1-specific TCR genes were isolated from CTLs obtained by the 
MART-1/HLA-A2 multimer-guided cloning as previously described25. The R1 and T1 
scTvs consisted of the variable contains attached by the linker region 
GSADDAKKDAAKKDGKS19,26,27. The scTvs were introduced into the NheI and XhoI 
restrictions sites of pCT302. The R1 scTv C105Fα mutation was introduced by site-
directed mutagenesis using a Quikchange kit (Stratagene, La Jolla, CA, USA). 
 
Generation, display, and selection of mutated scTv yeast display libraries 
Error-prone PCR was used to generate random mutations, as previously 
described28. CDR3 libraries were generated using splicing by overlap extension (SOE) 
PCR spanning 5 adjacent codons at a time (2 libraries in each CDR3 loop)29. Pre-SOE 
PCR products were generated for each of the four libraries utilizing the following primer 
pairs and the T1-S18 scTv as a template: β1, 5'- GGC AGC CCC ATA AAC ACA CAG 
TAT -3' (Splice 4L) and 5'- TGA AGA GGC GCA AAA ATA CAC ACC AGA ATC TTC 
CAG TTC GGC CGG TTG AAT TTT CAG GG -3', and 5'- GGA AGA TTC TGG TGT 
GTA TTT TTG CGC CTC TTC ANN SNN SNN SNN SNN SGT TGA ACA GTA TTT 
TGG TCC AGG TAC CCG TC -3' and 5'- TAA TAC GAC TCA CTA TAG GG -3' (T7); 
β2, Splice 4L and 5'- TGA AGA GGC GCA AAA ATA CAC ACC AGA ATC TTC CAG 
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TTC GGC CGG TTG AAT TTT CAG GG -3', and 5'- GGA AGA TTC TGG TGT GTA TTT 
TTG CGC CTC TTC ACA TGC GGG TCT GNN SNN SNN SNN SNN STT TGG TCC 
AGG TAC CCG TCT GAC C -3' and T7; α1, Splice 4L and 5'- CAC CGC GCA CAG ATA 
AGT GGC TGA ATC AGA TGG TCG AGA ATC TCT AAT CAG CAG TGA AAC ATA 
CTG AGA -3', and 5'- CCA TCT GAT TCA GCC ACT TAT CTG TGC GCG GTG NNS 
NNS NNS NNS NNS CTG ATG TTT GGC GAT GGT ACC CAG CTG GTT GTG -3' and 
T7; α2, Splice 4L and 5'- CAC CGC GCA CAG ATA AGT GGC TGA ATC AGA TGG 
TCG AGA ATC TCT AAT CAG CAG TGA AAC ATA CTG AGA -3', and 5'- CCA TCT 
GAT TCA GCC ACT TAT CTG TGC GCG GTG AAT GAT NNS NNS NNS NNS NNS 
TTT GGC GAT GGT ACC CAG CTG GTT GTG -3' and T7. SOE PCR was performed 
with each corresponding Pre-SOE along with both T7 and Splice 4L for each library (i.e. 
β1, β2, α1, and α2).  
Yeast libraries were made by homologous recombination in EBY100 yeast by 
electroporation of error-prone or SOE PCR products along with NheI and XhoI digested 
pCT30229. The library was induced in galactose-containing media (SG-CAA) for 48 
hours, washed with 1 ml of 1% PBS (phosphate buffered saline)/BSA (bovine serum 
albumin), and stained with the following: anti-HA epitope tag (1:50), anti-Vα2 antibody 
(1:50), anti-Vβ16 antibody (1:50) along with goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 
secondary antibody (1:100), and corresponding pepHLA-A2 DimerX (100 nM) followed 
by goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100). Cells were 
washed (1 mL, 1% PBS/BSA), and the most fluorescent cells were selected using a 
FACS Aria (BD Bioscience) high-speed sorter. Selection was performed on the error-
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prone library for anti-Vβ16 antibody staining (1:50). In order to test thermal stability of 
isolated clones, we incubated yeast at elevated temperature for 30 minutes prior to the 
staining protocol. Each individual CDR library was sorted for positive Vβ16-staining, 
pooled in equal cell numbers, and expanded. The CDR3 library was then selected with 
MART-1/HLA-A2 dimer (10-100 nM). 
 
Expression in E. coli, refolding, and biotinylation of soluble scTv fragments 
T1 wild-type, T1-S18, and T1-S18.45 scTvs were introduced into the pET28a 
expression vector with a N-terminal 6-His tag using NcoI and EcoRI restriction sites 
(forward primer: 5’ TAT ACC ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC 
AGC GGC CTG GTG CCG CGC GGC AGC GAA GCT GGT GTT ACT CAA TTC 3’, 
Reverse primer: 5’ T TTA GAA TTC TTA AAT ATT CGG TTT CAC AAC CAG 3’). 
Plasmids were transformed into the BL21 cell line, expanded, and induced for 
expression. Following induction, cells were passed through a microfluidizer 
(Microfluidics Corporation, Newton, MA, USA), inclusion bodies were isolated, and 
protein was purified as previously described30. Soluble scTvs were refolded and purified 
with Ni-NTA agarose resin (Qiagen, Valencia, CA, USA) followed by gel filtration 
(Superdex 200, GE Healthcare). Folded scTvs were biotinylated using N-
hydroxysuccinimide (NHS) biotin ester (EZ-Link Sulfo-NHS-LC-Biotin Kit, Pierce/Thermo 
Scientific). Biotinylation was verified by gel-shift with streptavidin by SDS–PAGE (data 
not shown). 
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Binding of scTv proteins measured by SPR  
The binding of purified refolded scTv proteins to cognate pepHLA-A2 was 
monitored with surface plasmon resonance (SPR) using a Biacore 3000 instrument. 
PepHLA-A2 complexes were generated by refolding from bacterially expressed heavy 
chain and β2m inclusion bodies as previously described31. Due to the high affinities of 
the scTv proteins, a kinetic titration assay was utilized, in which increasing 
concentrations of analyte were sequentially injected over the surface without the 
requirement for disruptive regeneration injections32. Experiments were performed with 
Τ1 wild-type (not detectable), T1-S18, and T1-S18.45 scTvs amine coupled to a 
standard CM5 sensor chip. PepMHC analyte was sequentially injected at various 
concentrations. The amount of immobilized scTv was kept below 500 RU and the flow 
rate was set to the maximum of 100 ml/min to minimize mass transport effects. Data 
were analyzed using Biaevaluation 4.1 as described previously32. Solution conditions 
were 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM ethylenediaminetetraacetic acid, 
and 0.005% surfactant P-20, 25°C. 
 
Binding of scTv fragments to peptide-pulsed antigen-presenting cells 
HLA-A2+ human cell line, T2 was incubated at 37 °C for 2-3 hours with 1 μM 
MART-1 (ELAGIGILTV) or null SL9 (SLYNTVATL) peptide. Cells were then washed 
twice with 1% PBS/BSA, and incubated on ice for 1 hour with biotinylated scTv at 
various concentrations. Cells were washed twice with 1% PBS/BSA, followed by 
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incubation with SA-PE for 30-45 min on ice. Cells were washed twice and analyzed 
using an Accuri C6 Flow Cytometer. Experiments were performed with n=4. 
 
Alanine-scanning mutagenesis of scTvs 
Five site-directed alanine mutants (CDR1α D27A, R28A and Q31A, and CDR2α 
Y51A and S52A) were introduced into previously described high-affinity scTvs, A6-X15 
and 868-Z1119, and T1-S18.45 by site-directed mutagenesis using a Quikchange kit 
(Stratagene, La Jolla, CA, USA). TCR-variable residue numbering has been kept 
consistent with sequence alignments with previously published high-affinity scTvs (Fig. 
2.2 and Fig. 2.5)19. Yeast cells displaying the single-site mutants were titrated with 
cognate-peptide-exchanged HLA-A2 monomers in triplicate at 8 nM, 40 nM, 200 nM, 1 
μM, and 5 μM and analyzed by flow cytometry22,23. Values were normalized using 
nonlinear regression analysis. Changes in binding affinity were approximated by 
determining the scTv concentrations at one-half maximal wild-type binding (5 μM). 
Independent experiments were performed with pepHLA-A2 dimers (BD DimerX) with 
similar results (data not shown).  
 
Yeast display library generation, selection, and 454 sequencing of scTv libraries 
Two libraries were generated in the high-affinity T1-S18.45 scTv construct at 
CDR1α residue Q31 and CDR2α residue Y51 using SOE PCR as described above. 
Each library was stained with 45 nM MART-1 (ELAGIGITV)/HLA-A2 and sorted via 
 80 
FACS. Top staining (8-10%) clones were isolated, and amino acid sequences were 
determined by 454 sequencing (Roche/454 GS FLX+ Sequencer). 
 
Results 
Engineering a stabilized human scTv against MART-1/HLA-A2 
The Vα2-positive MART-1-reactive T cell clones, INRi-T1 (referred to as T1; uses 
Vβ16) and INRi (referred to as R1; uses Vβ14), were isolated from melanoma-reactive 
T-cell lines. In order to engineer receptors with improved binding affinities, we cloned 
the V regions as a single-chain TCR fragments (scTvs) in the orientation Vβ-linker-Vα 
into a yeast-display vector. The scTvs were expressed on the surface of yeast via an N-
terminal Aga2 fusion followed by a hemagglutinin (HA) epitope tag for detection of the 
displayed protein. Additionally, an F49S mutation was introduced into the Vα2-domain 
of the construct to confer thermal stability to the scTv, as described previously19.  
Induced yeast cells containing the T1 scTv fusion (template)(Fig. 2.1a) were 
positive with an anti-HA epitope antibody (Fig. 2.1b). In order to detect individual Vα and 
Vβ domains, we used anti-Vα2 and anti-Vβ16 monoclonal antibodies for staining. 
Positive staining was seen with the anti-Vα2 antibody and weak staining was observed 
with the anti-Vβ16 antibody.Temperature stability assays have suggested that the Vβ16 
antibody recognizes a conformational epitope whereas the Vα2 antibody recognizes a 
linear epitope (Fig. 2.4 and data not shown). This suggested that most of the T1 scTv 
fragments were not properly folded on the surface of yeast. 
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Induced yeast cells expressing the R1 scTv fusion on the surface were also 
positive for staining with an anti-HA epitope antibody; however, they did not show any 
detectable staining with the Vβ14 antibody (data not shown). Sequence alignments of 
the R1 TCR with the variable chain sequences of other Vα2-containing scTvs suggested 
that absence of the canonical J region “FGXG” motif (where X is any amino acid) at 
positions 105 to 108 of the TCRα, could potentially account for the poor stability of the 
R1 scTv on the yeast cell surface (Fig. 2.2a). As a result, the cysteine at position 105 of 
the TCRα was mutated to phenylalanine and stained at several concentrations of Vβ14 
antibody; however, staining did not improve and only the T1 clone was pursued any 
further (Fig. 2.2b). 
To generate a more stable T1 scTv that would be expressed on the surface of 
yeast, we performed random mutagenesis and selected for clones with improved 
surface expression by binding to the anti-Vβ16 antibody (Fig. 2.3). Previous work with 
mouse TCRs 2C and 3L.2 and human TCRs A6 and 868 have shown that selection of 
scTvs with enhanced yeast surface expression and temperature stability also correlate 
with increased soluble expression19,27,33. Following two rounds of sorting, several 
mutants that had improved binding to the anti-Vβ16 antibody were isolated. Clones 
were screened for resistance to thermal denaturation using the Vβ16 as a probe (data 
not shown). One scTv mutant, called T1-S18, was highly temperature stable showing 
positive staining with the Vβ16 antibody when incubated at temperatures up to 80°C 
(Fig. 2.4). As a result, T1-S18 was selected for use as a template for affinity engineering 
(Fig. 2.1b, middle panels). The T1-S18 scTv was sequenced and shown to contain four 
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mutations: two in the Vα (S40P and Q80R), one in the Vβ (V80I), and one in the linker 
(K8E)(Fig. 2.5). Mutational analysis studies revealed that all four mutations (including 
that in the linker) contributed to the thermal stability of the T1-S18 clone (data not 
shown). 
 
Engineering of a high-affinity, surface-displayed T1 scTv fragment via site-directed 
mutagenesis 
 Degenerate libraries were made in the CDR3 loops in order to select for mutants 
for increased affinity to peptide MART-1/HLA-A2-Ig dimers. CDR3 libraries of the T1-
S18 template were sorted with two variants of the MART-1 peptide: the nonamer 
spanning residues 27–35 (AAGIGILTV)(Fig. 2.6a) and the decamer spanning residues 
26–35 that contained a modified anchor residue at position 2 (ELAGIGILTV)(Fig. 2.6b). 
Some MART-1-specific TCRs have been shown to cross-react with nonamer, decamer, 
and anchor-modified decamer peptides34-37. After four rounds of selection by FACS 
(fluorescent activated cell sorting) with both 9mer and 10mer MART-1/HLA-A2-Ig 
dimers, various clones were isolated and examined for binding. Clone T1-S18.45, 
isolated with MART-1 (ELAGIGILTV)/HLA-A2, showed significant binding, whereas the 
template T1-S18 and wild-type T1 did not (Fig. 2.1b). Clone T1-S18.45 also showed the 
greatest binding improvement to the 9mer variant of the MART-1 peptide (AAGIGILTV) 
on the surface of yeast, despite isolation with the anchor-modified 10mer peptide (Fig. 
2.7). Sequencing revealed that T1-S18.45 contained five adjacent mutations in CDR3α, 
from wild-type NDNAR to SSSDF (Fig. 2.5).  
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Expression and binding studies of soluble T1 single-chain TCRs 
 The T1, T1-S18, and T1-S18.45 scTv genes (Vβ-linker-Vα) were cloned into an 
E. coli expression vector, induced to express recombinant scTvs, and refolded from 
inclusion bodies. Refolded preparations were purified by Ni-affinity and size-exclusion 
chromatography, yielding scTv proteins of the expected monomeric molecular mass of 
30 kDa (Fig. 2.8a). Surface plasmon resonance (SPR) was performed with immobilized 
scTv fragments to determine kinetics and binding affinities for the various MART-1 
peptide variants. Kinetic titrations were performed in order to avoid regeneration steps. 
SPR data analysis revealed nanomolar affinities of T1-S18.45 for all three MART-1 
peptide variants examined (Fig. 2.8b and 2.8c). The stabilized T1-S18 variant bound 
with micromolar affinities, yielding affinity improvements of the T1-S18.45 scTv of 700-, 
900- and 4,500-fold for the ELAGIGILTV, ALGIGILTV, and AAGIGILTV peptide 
complexes, respectively (Fig. 2.8c). The wild-type scTv T1 did not exhibit detectable 
binding, perhaps because it lacked adequate stability for immobilization and analysis. 
The micromolar affinities of the T1-S18, non-affinity-matured TCR are in the same range 
as typically seen for most pepMHC antigens. 
 To study whether the high-affinity, soluble scTv T1-S18.45 protein could detect 
pepHLA-A2 complexes on the surface of antigen-presenting cells (APCs), we 
biotinylated the protein utilizing a biotin-succinimidyl cross-linking agent38. MART-1 
(ELAGIGILTV) or null SL9 (SLYNTVATL) peptides were incubated with the TAP-
deficient, HLA-A2+ human antigen-presenting cell line T2. Following peptide pulsing, we 
stained T2 cells with various concentrations of T1-S18.45-biotin followed by SA-PE, and 
 84 
analyzed them by flow cytometry (Fig. 2.9). Specific staining for MART-1 was observed, 
yielding an estimated EC50 affinity measurement of 120 nM, similar to that observed by 
SPR.  
 
Alanine-scanning mutagenesis of Vα2-containing high-affinity scTv fragments 
The availability of three Vα2+ TCRs with high-affinity (A6-X15, 868-Z11 and T1-
S18.45; called A6, 868, and T1 here, respectively), each for a different pepHLA-A2 
ligand, allowed us to compare the exact binding contribution of proposed key CDR1 and 
CDR2 residues among different TCRs. To examine the binding energetics of these 
pepMHC interactions, we generated alanine mutants at five positions in a panel of high-
affinity Vα2-containing scTv proteins: CDR1α residues D27, R28, and Q31, and CDR2α 
residues Y51 and S52. These residues have shown conservation based on TCR 
sequence alignments39, and the R28, Q31, Y51, and S52 side chains appear to be 
involved in contacts with the HLA-A2 helices in structures of three Vα2-containing TCRs 
(A6, Mel5, and DMF5; PDB files 1AO7, 3HG1, and 3QDG)(Fig. 2.10)3-5. Position D27 in 
CDR1α was the target of mutation for computationally-guided affinity increases in two 
Vα2-containing TCRs, A6 and DMF540,41, and thus was also included in our analysis.  
The yeast display system allows direct titrations of the fusion protein in order to 
examine affinities above a threshold KD of about 1 µM, thereby avoiding the need to 
purify each protein or mutant42. Accordingly, each alanine mutant was titrated with 
various concentrations of cognate pepHLA-A2 and analyzed by flow cytometry (Fig. 
2.11a,b,c). To compare mutants, we calculated the magnitude of changes in binding 
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affinity from the concentrations of ligand that resulted in half-maximal binding of alanine 
mutant compared to “wild-type” high-affinity scTv (Fig. 2.11d). For all three scTv 
fragments, the tyrosine at position 51 was the only residue that uniformly contributed 
significant binding (10 to ≥15-fold reductions in binding affinity of the alanine mutants) to 
the pepHLA-A2 interaction, regardless of the Vβ or the peptide. Other positions showed 
minimal effects for all three TCRs (R28A and S52A), an effect on only one TCR (D27A 
in the A6 TCR), or an effect on two TCRs (Q31A in the A6 and 868 TCRs). Thus, these 
positions showed plasticity in their contribution to the binding energy. 
In order to determine if the effect of the Y51A mutation observed in the high-
affinity T1, A6, and 868 scTv fragments would hold true for the wild-type TCRs, we 
cloned variants of each scTv that contained the wild-type CDR loops, with or without the 
corresponding Y51A mutation, and expressed them in E. coli (note that the affinities of 
wild-type scTv fragments are too low to detect binding in the yeast display format). The 
868 scTv fragment and its Y51A mutant were unstable and could not be used to make 
reliable SPR measurements. However, we were able to measure steady-state 
equilibrium binding parameters for wild-type T1 and A6 single-chain TCRs and their 
Y51A mutants (stabilized versions of these scTv, without the affinity mutations). These 
binding measurements yielded a ΔΔG value of over -2 kcal/mol for Y51A of the T1 
scTCR (i.e., a KD of 22 µM for the wild-type, whereas binding by the Y51A mutant could 
not be detected; hence, we estimated a KD value of greater than 1 mM for the Y51A 
mutant). A ΔΔG value of -0.8 kcal/mol for Y51A of the A6 scTCR was measured (KD 
values of 2.2 µM and 10 µM for wild-type and Y51A, respectively). Additionally, a recent 
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study by Piepenbrink et al. showed that the Y51A mutation in the wild-type, full-length 
A6 TCR yielded a ΔΔG value of -0.6 kcal/mol mol, similar to that of the Vα2-containing 
DMF5 TCR43. Thus, we conclude that tyrosine 51 in the CDR2 of Vα2 contributes to 
binding energy among different TCRs in both the affinity-matured TCRs and the wild-
type affinity TCRs. 
 
PepHLA-A2 selections from single-residue libraries of the MART-1 TCR 
 If during evolution the key CDR1 and CDR2 residues have been selected for 
MHC-binding, then pepMHC sorting of a yeast display library of all amino acids at these 
positions should yield enrichment for the evolutionary-driven residues. In order to 
determine the allowable residues at key positions of MHC restrictions, we generated 
degenerate libraries (NNS codons) at Vα positions 31 and 51 positions in the T1-S18.45 
scTv yeast display vector. Each library underwent one round of selection with 45 nM 
MART-1/HLA-A2, and the top 8-10% binding clones were isolated by sorting. DNA from 
the enriched population of yeast was then subjected to 454 high-throughput sequencing 
to determine the amino acid frequency selected at each position (Fig. 2.12). At position 
31, the wild-type glutamine was the highest frequency isolate, followed by alanine, 
cysteine, and valine (Fig. 2.12a). At position 51, tyrosine (wild-type), phenylalanine, and 
tryptophan were the highest frequency isolates (Fig. 2.12b). Thus, each positional 
library demonstrated a preference for the wild-type, energetically important residue, 
consistent with an evolutionary pressure to maintain these residues. However, several 
other amino acids were also capable of supporting pepMHC binding. 
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Discussion 
 Crystal structures of different TCR:pepMHC complexes have shown a conserved 
docking mode of TCR on the pepMHC such that the CDR1 and CDR2 loops are 
approximately positioned over the MHC helices and the CDR3 positioned over the 
peptide1,2,39. Evidence for the co-evolution of these molecules has been shown by the 
presence of conserved residues and interactions in specific positions in CDR1 and 
CDR2 loops39. In the current study, we focused on the energetic contribution of putative 
conserved TCR residues that shape immune recognition.  
During development in the thymus, T cells are required to bind to MHC within a 
narrow affinity range in order to pass both positive and negative selection. Mutagenesis 
studies have shown that single residue differences in CDR1 and CDR2 loops are able to 
shift T cells out of this affinity such that negative selection or death by neglect can 
occur12,39. Although the TCR’s intrinsic reactivity towards MHC could be partially 
masked by the negative selection process, structural and sequence data have 
suggested putative conserved residues that may play an important role in the binding 
energetics of the TCR:pepMHC interface. 
Higher-affinity, single-chain TCRs provide an approach to rapidly assess alanine 
mutants using yeast display and flow cytometry without the need to express large 
quantities of protein as has been done in previous studies7-11,44,45. Use of the higher-
affinity scTvs allows for detection of up to 100-fold decreases in affinity that would not 
otherwise be measurable within the normal range for TCR:pepMHC (1-100 μM)2. Thus 
far, mutations that confer higher affinity on the variants of TCRs have most often been 
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engineered in the CDR3 loops, in order to retain peptide specificity19,27,46-51. CDR1 loops 
often contact the MHC helices, and CDR2 loops tend to almost exclusively contact the 
MHC helices; thus, wild-type residues in these loops provide a good framework to 
access the binding energetics of “germline-encoded” contacts on HLA-A2 by alanine-
scanning mutagenesis. Furthermore, the structures of several high-affinity mouse TCRs 
in CDR3 residues have shown virtually identical CDR1 and CDR2 contacts with MHC as 
the wild-type TCR16,17. Thus, we believe that the high-affinity TCRs provide a useful 
surrogate for these wild-type, germline-encoded residues in CDR1 and CDR2. 
Our data showed that the putative conserved CDR2α residue Y51 contributed 
substantially to binding in all three of the high-affinity scTv fragments examined. 
Although tyrosine at this position is not abundant (in 12-16% of Vα regions), it interacts 
with the same region of MHC class I (near residue Q155) and class II (near βA73) in 
various structures39. Structural analysis of three Vα2-containing TCRs, A65, Mel54, and 
DMF53, suggest that the binding energy associated with mutation of Y51 to alanine 
could be due to the loss of contacts with HLA-A2 α2 helix positions E154, Q155, and/or 
A158 (Fig. 2.10). In all three high-affinity scTv fragments examined, mutation to alanine 
led to a 10- to ≥15-fold decrease in binding affinity (≥1.4 kcal/mol in free energy).  
While measurement of these interactions took advantage of the ability to use 
yeast display to rapidly analyze binding by the higher-affinity variants, we were able to 
confirm the energetic role of the tyrosine at position 51 in wild-type scTv variants in 
which all CDR affinity mutations were reverted to the wild-type residues. These results 
are consistent with the similar docking and chemistries associated with wild-type TCR 
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and affinity-matured TCRs in the 2C system, showing only the CDR3 loop with 
mutations in a different position16,17. Although qualitatively we show that Y51 contributed 
to binding in both high-affinity and wild-type TCRs, structural studies will be required to 
determine if there are changes in the docking of each of the loops and their residues. In 
this regard, a recent comparison of the A6 TCR:Tax/HLA-A2 complex with the high-
affinity mutant A6-c134 TCR:Tax/HLA-A2 complex showed that the docking orientations 
were virtually identical21. While there were subtle changes in the positions of the CDR3 
and CDR2β loops, the positions of the CDR1α and CDR2α, and in particular the position 
of the side chain of Y51, were very similar (Fig. 2.13). In their report, the authors 
proposed that most of the increase in binding affinity of the A6-c134 TCR was achieved 
through a greater number of interactions between the CDR3 loops and the peptide. 
As positive selection is associated with weak affinities and free energies in the 
range of ~4 kcal/mol52, the contributions by this conserved tyrosine could reflect a 
substantial portion of this “minimal” affinity to ensure representation in the T cell 
repertoire. Early studies in the 2C system showed that affinities as low as 300 µM were 
able to yield agonist activity53. Additionally we have shown that a single peptide point 
substitution, F5R, in the peptide of the 2C TCR:QL9/Ld interaction reduced the affinity of 
the 2C TCR from 1.6 µM to 300 µM, yet the interaction was sufficient for agonist 
activity54. Based on this, it is reasonable to assume that an affinity of 1 mM (~4 kcal mol-
1) or even lower (higher KD value) is likely to be in the range for positive selection. 
Although binding analysis showed a consistent role of CDR2α residue Y51, more 
plasticity was observed in the contribution of CDR1α residues. For example, the D27A 
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mutation led to a >15-fold decrease in binding of Tax/HLA-A2 by the A6-X15 TCR but 
this same mutation did not have a significant impact on binding by the other TCRs. The 
effect of the D27A mutation in the A6 TCR could be indirect, perhaps influencing the 
adjacent R28 through electrostatic interactions and affecting the stability of the entire 
loop. Similarly, the Q31A mutation caused a >15-fold change in both A6-X15 and T1-
S18.45 TCRs, but the 868-Z11 TCR was not significantly affected. It has been proposed 
that CDR3 loops are able to modulate interactions of the MHC with germline-derived 
CDR1 and CDR2 loops in a process termed "CDR editing14." This may account for the 
variation in binding contribution of residues in CDR1α. Analysis of contacts in crystal 
structure of Vα-containing TCRs DMF4, DMF5, A6, and Mel5 suggests a role of CDR1α 
in making peptide contacts in addition to MHC contacts3,4, which may also explain 
differences in the energetic contribution with different peptide ligands (Fig. 2.10). 
In order to further understand the requirements for binding, we generated single-
codon, yeast display libraries at the two most energetically important CDR1 and CDR2 
residues of the high-affinity T1-S18.45 TCR. The preferential selection of aromatic 
amino acids at position 51 (i.e., wild-type Tyr, Phe, and Trp) further supports the 
conservation at this position and may reflect a general requirement for bulky amino 
acids that can adapt to varying MHC structures or chemistry55. However, position 31 
showed a more diverse collection of allowable amino acids, from the chemical 
perspective, at this position (i.e. wild-type Gln, Cys, Ala, and Val). Nevertheless, the 
preferences for the wild-type residues in each case are consistent with their evolutionary 
pressures to retain these in the context of the Vα2:HLA-A2 interaction. This is not to 
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say, however, that other CDR loops or residues would not suffice to provide the very low 
energy of interaction required for MHC-restriction through positive selection13. Clearly, 
the maintenance of the docking angle and general positions of each CDR loop in all 
wild-type TCRs and their high-affinity TCR counterparts suggests that the MHC 
interactions with CDR1 and CDR2 could collectively be capable of restraining the 
orientation of the complex, even in the absence of co-receptor (since the high-affinity 
TCRs described here were selected in the absence of CD8).  
In a recent study comparing the crystal structures of G4 and E4 TCRs with their 
cognate ligand mutTPI-DR1, Deng et al. showed that CDR2α made identical contacts 
with the MHC helices in both structures but there was more plasticity or “wobble” in 
CDR1α loops, a finding that they attribute to the influence of the CDR314. Our study 
provides a corresponding binding energy analysis that is consistent with these structural 
findings. Furthermore, we suggest that the energetically-conserved CDR2α residue 
(Y51) provides sufficient binding energy to contribute significantly to the very low affinity 
interactions required for positive selection. Although our study does not examine the 
importance of TCRβ chain residues or the impact of the co-receptor, crystal structures 
of the A6 TCR have suggested that the TCRα chain may dominate in the interaction 
with Tax/A25,56-58. The structures of the other two Vα2-positive TCRs described here are 
not known; thus, it remains to be seen if their Vβ CDR1 and CDR2 play a more 
significant role than the A6 TCR.  
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Figures 
 
 
Figure 2.1 | Yeast display and isolation of INR1-T1 (T1) single-chain TCR variable fragments 
(scTv). (a) Schematic of scTv fusions for the human TCR, T1, which recognizes MART-1 peptides in 
presented in the context of HLA-A2. (b) The T1 TCR was cloned as a scTv and expressed on the surface 
of yeast (left panels). Yeast surface levels of scTV fusions were monitored for expression of an N-terminal 
tag [hemagglutinin (HA), black line] with anti-HA antibody and goat anti-mouse IgG alexa 647 secondary 
antibody or secondary only as a control (gray). The negative peak is due to yeast that have lost plasmid, 
and serves as an internal control for each induced yeast sample. Cells were incubated with anti-Vβ16 and 
anti-Vα2 antibodies followed by goat anti-mouse IgG alexa 647 secondary antibody, or secondary only as 
a control (gray). Cells were incubated with MART-1 peptide (ELAGIGILTV)/HLA-A2 dimer at 100 nM. A 
random mutagenesis library was generated using the T1 scTv as a template and sorted with anti-Vβ16 
antibody and goat anti-mouse IgG alexa 647 secondary antibody. Clone T1-S18 was isolated after two 
rounds of sorting (middle panels). Site-directed libraries were made in CDR3 loop regions of the stabilized 
T1-S18 clone. The high-affinity clone, T1-S18.45, was isolated following four rounds of sorting with 
MART-1 peptide (ELAGIGILTV)/HLA-A2 dimer (right panels, black line). Histograms are representative of 
three or more experiments. 
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Figure 2.2 | Yeast display of MART-1-reactive TCRs INRi-T1 (T1) and INRi (R1). (a) Sequence 
alignments of the scTvs generated from the INRi-T1 (T1) and INRi (R1) T cell clones. The Vα S49 residue 
that was engineered into the template for thermal stability is shown in magenta. The “FGXG” motif is 
indicated in the alignment in boxes in cyan. The C105 of R1 is indicated in yellow. TCR-variable residue 
numbering has been kept consistent with sequence alignments with previously published high-affinity 
scTvs19. (b) Yeast displaying the R1 C105F mutant scTv was stained with a 1:10 and a 1:50 dilution of 
anti-Vβ14 antibody followed by APC-conjugated goat anti-mouse secondary antibody. No positive staining 
is detectable relative to the control (gray). 
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Figure 2.3 | Flow cytometry histograms of the selections of the T1 error-prone library with an 
antibody against TCR Vβ . The T1 error-prone library was sorted sequentially with anti-Vβ16 antibody for 
two FACS selections. Aliquots of yeast cells after each sort were incubated with a 1:50 dilution of antibody 
followed by APC-conjugated goat anti-mouse secondary antibody. 
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Figure 2.4 | Thermal denaturation of the T1-S18 scTv mutant. Yeast displaying the T1-S18 scTv were 
incubated at the indicated elevated temperatures prior to staining with a 1:50 dilution of anti-Vβ16 
antibody followed by APC-conjugated goat anti-mouse secondary antibody. 
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Figure 2.5 | Sequence line-ups of T1 template scTv, stabilized T1-S18, and high-affinity T1-S18.45. 
Conserved immunoglobulin fold residues are in cyan. Green residues indicate stabilizing mutations and 
yellow indicate high-affinity mutations. The Vα S49 residue that was engineered into the template for 
thermal stability is shown in magenta. TCR-variable residue numbering has been kept consistent with 
sequence alignments with previously published high-affinity scTvs19. 
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Figure 2.6 | Flow cytometry histograms of the selections of the T1-S18 CDR3 libraries. The 
combined T1-S18 CDR3 libraries were sorted sequentially with MART-1 (nonamer; AAGIGILTV)/HLA-A2 
(a) or MART-1 (decamer; ELAGIGILTV)/HLA-A2 (b) for a total of 4 sorts. Aliquots of yeast cells after each 
sort were then incubated with 100 nM selecting MART-1 pepHLA-A2-Ig dimer followed by APC-
conjugated goat anti-mouse secondary antibody. 
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Figure 2.7 | T1-S18.45 scTv stained with 9mer and 10mer MART-1 peptide variants. Aliquots of the 
yeast-displayed T1-S18.45 clone stained at the indicated concentrations with MART-1 (nonamer; 
AAGIGILTV)/HLA-A2-Ig dimer (a) or MART-1 (decamer; ELAGIGILTV)/HLA-A2-Ig dimer (b) followed by 
APC-conjugated goat anti-mouse secondary antibody. 
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Figure 2.8 | Purity and SPR of soluble MART-1-specific, single-chain TCR T1 and its engineered 
variants. T1 template, T1-S18, and T1-S18.45 were expressed in the E. coli pET28 expression system, 
refolded from inclusion bodies, and purified by Ni-column and size-exclusion chromatography. (a) SDS-
PAGE of purified scTvs and molecular mass markers (M). (b) SPR trace of MART-1 (ELAGIGILTV)/HLA-
A2 binding immobilized T1-S18.45. Fitted parameters (KD, kon, koff) are shown in the inset. (c) Table 
showing the binding affinities of the T1-derived scTvs for variants of the MART-1 peptide.  
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Figure 2.9 | Binding of peptide-loaded antigen presenting cells by soluble T1-S18.45 scTv. (a) 
Titration of biotinylated T1-S18.45 scTv on antigen-presenting cell line T2 (HLA-A2+) pre-loaded with 
MART-1 peptide (1 μM) or null peptide, SL9 (1 μM). Cells were stained with 3.9 nM (tan), 7.8 nM (gray), 
15.2 nM (red), 31.1 nM (purple), 62.5 nM (green), 250 nM (blue), or 1 μM (black) biotinylated T1-S18.45 
scTv, followed by SA-PE. Data shown are representative of four experiments. (b) Mean fluorescence 
intensity (MFI) values of histograms in (a) are plotted versus scTv-biotin concentration.  
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Figure 2.10 | Crystal structures of Vα2-containing TCRs showing MHC contact positions in CDR1α  
and CDR2α  loops. CDR1α residues D27, R28, and Q31 (a, c, and e), and CDR2α residues Y51 and 
S52 (b, d, and f) assessed in the alanine-scanning study are highlighted in the structures of the A6 (a and 
b)5, Mel5 (c and d)4, and DMF5 (e and f)3 TCRs, which all contain the Vα2 region. PDB files 1AO7, 
3HG1, and 3QDG were used, respectively, in PyMol. TCR residue positions are indicated in black. MHC 
residues are italicized in gray. TCR-variable residue numbering has been kept consistent with sequence 
alignments with previously published high-affinity scTvs, not the numbering in PDB files19. 
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Figure 2.11 | Alanine-scanning mutagenesis of Vα2-containing single-chain TCRs. Binding titrations 
of yeast-displayed mutants of Vα2-containing single-chain TCR fragments (scTv): (a) A6-X15 specific for 
Tax/HLA-A2, (b) 868-Z11 specific for SL9/HLA-A2, and (c) T1-S18.45 specific for MART-1/HLA-A2. 
Alanine mutants were stained in triplicate with 8 nM, 40 nM, 200 nM, 1 μM, and 5 μM cognate pepHLA-
A2 monomers followed by PE-conjugated streptavidin. Normalized percent max mean fluorescence 
intensity (MFI) is plotted against cognate pepHLA-A2 monomer concentration. Error bars represent 
standard deviations of triplicate experiments. (d) Fold changes in binding were determined by the scTv 
concentrations at one-half maximum wild-type binding from titrations in a-c. Error bars represent standard 
deviations of triplicate experiments. 
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Figure 2.12 | In vitro selected mutants of yeast display libraries of the MART-1-specific TCR, T1-
S18.45. Yeast display libraries at position 31 in CDR1α (a) and position 51 in CDR2α (b) were generated, 
stained with 45 nM MART-1/HLA-A2, and selected by FACS. The top staining (8-10%) clones were 
isolated, and amino acid distribution was determined by 454 sequencing. Amino acid residues that were 
positively and negative selected are indicated on the y-axis as a function of the logarithm of amino acid 
frequency post-selection divided by the frequency pre-selection. A total of 11,736 and 13,600 clones from 
the unselected position 31 library and selected position 31 library were sequenced, respectively; a total of 
6,806, and 24,532 from the unselected position 51 library and selected position 51 library were 
sequenced, respectively. 
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Figure 2.13 | Overlay of the structures of the A6:Tax/HLA-A2 complex and the high-affinity TCR 
A6-c134:Tax/HLA-A2 complexes. The wild-type A6:Tax/HLA-A2 complex crystal structure (PDB: 
1AO7)5 is shown in gray with the CDR1α and CDR2α loops indicated in red. The CDR1α and CDR2α of 
the high-affinity mutant A6-c134:Tax/HLA-A2 (PDB: 4FTV)21 are overlayed with the wild-type loops in 
green. CDR1α residues D27, R28, and Q31 and CDR2α residues Y51 and Q31 that were assessed in 
our alanine-scanning study are indicated. TCR-variable residue numbering has been kept consistent with 
sequence alignments with previously published high-affinity scTvs, not the numbering in PDB files19. 
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 CHAPTER THREE 
 
 
 
ENGINEERING HUMAN HIGH-AFFINITY T CELL RECEPTORS AGAINST WILMS’ 
TUMOR ANTIGEN BY YEAST DISPLAY1 
 
 
Abstract 
Wilms’ Tumor Antigen (WT1) is a transcription factor that is overexpressed in 
many hematological and solid tumors. A peptide from WT1 and its variants are being 
developed for use in peptide- and dendritic cell-based cancer vaccines, and several 
ongoing clinical trials are using WT1-specific T cell receptors (TCRs) in adoptive T cell 
transfer for the treatment of leukemia. Higher-affinity TCRs may improve the efficacy of 
T cell targeting to the WT1 antigen as they could better recruit CD4+ helper T cells to the 
tumor. In this study, I describe the multi-step engineering of WT1-specific TCR variants 
for improved binding affinities for the WT1/HLA-A2 antigen by yeast display and directed 
evolution of single-chain variable fragments (scTvs or scTCRs). The high-affinity variant 
called WT1-D13.1.1 (KD = 330 nM) isolated following multiple rounds of mutagenesis 
and selection could be expressed at high levels in E. coli and used to detect WT1/HLA-
A2 complexes on the surface of antigen presenting cells (APCs). The WT1-D13.1.1 
TCR is also currently being examined in CD4+ and CD8+ adoptive T cell models. 
 
 
                                            
1Author’s contribution statement: The WT1-P20 and WT1-P22 TCR genes were obtained from the 
laboratory of Phil Greenberg at the University of Washington. Dan Harris (Kranz lab) performed follow-up 
studies utilizing the high-affinity WT1 TCR described here in adoptive cell therapy models. These studies 
are briefly mentioned in the final paragraphs of the discussion. 
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Introduction 
Activation of the cell-mediated immune response begins with the recognition of a 
foreign antigen presented in the context of a self-MHC molecule on the surface of 
antigen presenting cells (APCs). Despite the ability of some cancer cells to evade the 
immune response, it has been demonstrated that in many cases the human immune 
system is capable of developing antigen-specific molecules, T cell receptors (TCRs) and 
antibodies, against tumors. Based on the isolation of T cells that recognize these 
tumors, numerous tumor-associated antigens (TAAs) have been identified and 
classified1,2. In 2009 the National Cancer Institute (NCI) ranked 75 of these antigens 
according to a list of weighted criteria (e.g. therapeutic function, immunogenicity, 
specificity, oncogenicity) in a pilot project for the “Acceleration of Translational 
Research3.” The top antigen listed in this project was Wilms’ Tumor Antigen (WT1). 
In the 1990s, WT1 was initially classified as a tumor suppressor gene as it was 
the causative gene in autosomal-recessive pediatric kidney malignancy called Wilms’ 
tumor (WT)4-8. However, subsequent studies found that the WT1 transcription factor was 
often implicated in leukemia and in many solid tumors, and as a result, it was also 
classified as an oncogene4,9. In healthy individuals, WT1 expression is typically 
restricted to the urogenital system during embryogenesis10 and has been shown to be 
essential for kidney development in WT1 knockout mice11. Expression in adults is 
limited to discreet tissues at very low levels, and as a result it has been considered a 
promising target for immunotherapies12. In particular, its expression in leukemia cells 
surpasses its highest normal expression in adult tissues 10- to 1,000-fold13,14. 
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Additionally, WT1-specific CD8+ T cells have been shown to distinguish tumor cells 
overexpressing the antigen from normal cells and to specifically mediate killing of 
leukemia cells but not healthy CD34+ cells15. To my knowledge, there have not been 
any reports of autoimmunity in humans or mice using WT1-targeted 
immunotherapies12,16,17.  
Several additional factors have suggested that WT1 is an ideal target for cancer 
vaccine and targeted cell-based immunotherapies. First, its overexpression is ubiquitous 
in hematological malignancies and solid tumors. To date, WT1 overexpression has been 
shown in over 36 types of tumors with a growing list of potential cancer types that could 
benefit from WT1-targeted therapuetics12. Second, loss of expression of WT1 in cancer 
cells leads to reduced proliferation or cell death, suggesting that the risk of tumor 
escape through the evolution of antigen-loss variants is relatively small18,19. Finally, WT1 
appears to be highly immunogenic, inducing robust T-cell-20-25 and antibody-26-28 
mediated adaptive immune responses. As a result, WT1 has been the focus of over 20 
peptide- and dendritic cell-based clinical trials aiming to boost the adaptive immune 
response against a variety of hematological and solid tumors12. 
WT1 vaccinations have focused largely on the HLA-A2-restricted nonomeric 
epitope spanning residues 126-135 of WT1 (WT1126-134: RMFPNAPYL) (Fig. 3.1) or 
modified variants that contain substitutions that are typically involved in improving HLA-
A2 binding and thus MHC presentation29. Despite the high safety profiles in WT1-
vaccine trials published to date, the clinical response rates have been modest, with 
overall objective response rates of 46% in solid tumors and 64% in hematological tumor 
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and detection of immunological responses in 35% and 68% of the patients evaluated, 
respectively12. Hypotheses accounting for the lack of clinical benefit in a significant 
portion of patients treated included poor immunogenicity of vaccines, the compromised 
state of patients’ immune systems, immunosuppression by Tregs and inadequate T cell 
repertoires to generate WT1-specific TCRs12. Because WT1 is a self-antigen it is likely 
that reactive T cell clones would be deleted during negative selection in the thymus, 
leading to minimal immunogenicity in response to WT1/MHC antigen presentation30. 
In order to address these limitations, strategies involving adoptive transfer of T 
cells expressing WT1-specific TCRs are currently under development. Accordingly, 
there is a need to isolate or engineer TCRs that direct specific recognition and activation 
of T cell to tumors that express WT131. Wild-type TCRs that have been isolated from 
human tumor infiltrating lymphocytes (TILs) to date have been of relatively low binding 
affinities (KD = 1-300 µM)32. To compensate for low affinities, T cells have evolved co-
receptors on their surfaces (CD4 and CD8) that synergistically bind to MHC molecules 
(class II and class I, respectively) along with TCRs in order to mediate potent activity in 
an antigen-specific manner. Notably, TCRs with high affinities (less than a KD value of 
about 1µM) are able to mediate T cell responses in a co-receptor-independent manner 
such that recognition of class I MHC by TCR-modified CD4+ T cells can mediate potent 
activation and tumor control due to greater functional avidity33,34. It has been shown that 
TCRs of higher-affinity or avidity may have significant advantages in conferring 
persistence in vivo and the acquisition of memory T cell phenotypes: a requirement for 
potent anti-tumor responses16,31,35. 
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In vitro directed evolution has been used to generate TCRs with higher affinity for 
a specific pepMHC, including yeast display36-38, phage display39, and T cell display40. In 
all three approaches, the general process involves engineering wild-type TCRs that 
have low affinity for their cognate pepMHC for increased affinity by selection of libraries 
of site-directed mutants in the TCR loops that contact the pepMHC interface41. These 
TCR loops, called complementarity determining region (CDR) loops, contact the 
pepMHC in a common diagonal docking orientation that has been observed in virtually 
all crystal structures of TCR:pepMHC structures to date, such that germline-encoded 
CDR2 regions are positioned primarily over the MHC helices and the highly diverse 
CDR3 regions encoded by the junction of somatically rearranged gene segments lie 
primarily over the peptide42,43. CDR1 regions are also encoded by the germline V 
region, but are capable of forming specific contacts with peptide in addition to forming 
contacts with MHC helices44-48.  
Because of this conserved docking orientation, affinity maturation libraries have 
generally been targeted to CDR3 loops, as this might favor the highest level of peptide 
specificity possible38,49-53. However, mutagenesis libraries in CDR1 and CDR2 loops 
have also yielded high-affinity TCRs that maintain peptide specificity39,54-56. It has been 
proposed that this occurs through “CDR editing,” in which the residues in the diverse 
CDR3 loops modulate the interactions of V region TCR residues with pepMHC 
residues57, or via “peptide editing,” in which TCR:pepMHC interactions are influenced by 
changes of the binding surface of the MHC depending on the peptide bound43.  
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Over the last 15 years, the Kranz group has developed a strategy for engineering 
high-affinity αβ TCRs in a format analogous to single-chain antibody variable fragments 
(scFv). Hence, the TCR variable regions that make up the antigen binding domains of 
each chain are expressed as a single-chain, connected by a flexible linker (Vα-linker-Vβ 
or Vβ-linker-Vα); this form has been called single-chain TCR (scTCR) or single-chain 
TCR variable fragment (scTv). Recently, we showed that one of the human Vα regions, 
called Vα2 (IMGT: TRAV12 family), is exceptionally stable in the single-chain format 
and highly amendable to engineering by yeast display58.  
In the current study, I describe the engineering of Vα2-containing WT1-specific 
TCR variants by yeast display using multiple rounds of mutagenesis and selection. First, 
the template scTv was stabilized through introduction of random mutations selected for 
improved display on the surface of yeast58,59. Using stabilized scTv templates, affinity 
maturation libraries were generated in CDR3 and CDR1α loops and these were 
selected for improved binding to WT1/HLA-A2. A scTv variant with modestly enhanced 
binding affinity was isolated from the CDR1α library, and this was used as a template 
for the generation of additional CDR3 libraries. From the CDR3 yeast display libraries, a 
high-affinity WT1-specific scTv was further isolated.  
The highest affinity Vα2-containing WT1-specific scTv was used to confirm the 
amino acid preference and binding at CDR2α position Y51 using site-directed 
mutagenesis and a single-codon library approach, which I previously showed to be 
highly restricted in a panel of three other Vα2-containing scTv fragments (Chapter 2)38. 
The high-affinity scTv could be expressed in E. coli and refolded from inclusion bodies 
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to produce soluble scTv with a binding constant (KD) of 330 nM as determined by 
surface plasmon resonance (SPR). The soluble, biotinylated scTv could also detect 
WT1/HLA-A2 complexes on the surface of APCs loaded with exogenous WT1 peptide. 
The high-affinity TCR has also been examined by our lab in various adoptive T cell 
approaches in mouse models. 
 
Materials & Methods 
Antibodies, pepHLA-A2, and flow cytometry reagents 
Antibodies used to detect yeast surface expression included the following: anti-
HA epitope tag (Clone HA.11; Covance), anti-c-myc epitope tag (A21281; Molecular 
Probes), anti-hVβ3 FITC antibody (Clone CH92; Beckman-Coulter), anti-hVβ3.1 FITC 
antibody (Clone 8F10; Thermo Scientific), anti-Vα2 monoclonal antibody generated in 
our laboratory (data not shown), goat-anti-mouse IgM APC (Life Technologies), goat-
anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (Invitrogen), goat anti-
chicken IgG (H+L) AlexaFluor 647 secondary antibody (Molecular Probes), and 
Streptavidin-phycoerythrin (SA-PE, BD Pharmingen). 
Peptides that bind to HLA-A2 [WT1126-134: RMFPNAPYL, MART126–35 A27L: 
ELAGIGILTV, Tax11 – 19: LLFGYPVYV] were synthesized by standard F-moc (N-(9-
fluorenyl)methoxycarbonyl) chemistry at the Macromolecular Core Facility at Penn State 
University College of Medicine (Hershey, PA, USA). For FACS and flow cytometry 
analysis, recombinant soluble dimeric HLA-A2-Ig fusion protein (BD™ DimerX) was 
used. Additionally, a monomeric HLA-A2-biotin reagent generated by the exchange of a 
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UV-cleavable peptide for another HLA-A2-restricted peptide in the presence of UV light 
was utilized for flow cytometry60,61. 
 
Cloning and expression of scTv in yeast display vectors 
TCR variable region fragments (scTv) were expressed in yeast display plasmid 
pCT302 (Vβ-L-Vα)62, which contains a galactose-inducable AGA2 fusion allowing for 
growth in Trp media. Induction of the scTv gene involves growth of the transformed 
EBY100 yeast cells to stationary phase in selection media followed by transfer to 
galactose-containing media. The wild-type WT1-P20 and WT1-P22 scTv genes 
contained the highly stable Vα2 gene segment and a serine at position 49α that was 
previously shown to provide added stability in other scTvs58. The template genes were 
synthesized by Genscript (Piscataway, NJ, USA) with codon optimization for yeast. 
The WT1 specific TCR genes were isolated from CTL clones and obtained from 
our collaborator, Phil Greenberg, at the University of Washington. The genes were 
synthesized by Genscript, cloned as a single-chain format (Vβ-linker-Vα) and introduced 
into the yeast display vector for expression on the surface of yeast. The scTvs consisted 
of the variable contains attached by the linker region GSADDAKKDAAKKDGKS58,63,64. 
The scTv was introduced into the NheI and XhoI restrictions sites of pCT302. 
 
Generation, display, and selection of mutated scTv yeast display libraries 
Error-prone PCR was used to generate random mutations libraries using WT1-
P20 or WT1-P22 as a template, as previously described65. The resultant libraries 
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contained about 9.6 X 106 and 2.3 X 107 independent clones, respectively, as 
determined by plating limiting dilution aliquots of yeast after electroporation. CDR1α and 
CDR3 libraries were generated using splicing by overlap extension (SOE) PCR 
spanning 4-5 adjacent codons at a time66. The resulting WT1-wt/D13/D15 CDR1α 
library yielded 3.1 X 106, and the resultant pooled WT1-D13.1 CDR3 libraries yielded 3.5 
X 106 independent clones, as judged by plating limiting dilution aliquots of yeast after 
electroporation. 
For the WT1-wt/D13/D15 CDR1α library, pre-SOE PCR products were generated 
utilizing the following primer pairs on three templates (WT-P22, WT1-D13, and WT1-
D15): 5' - GGC AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) and 5’ - ACG ATC 
GCT ATA GGT GCA GTT CAA TGA TGC AAT AGC ACC TTC CGG GAC ACT TAA 
TGG GCC GCT - 3’, and 5’ – ATT GCA TCA TTG AAC TGC ACC TAT AGC GAT CGT 
NNS NNS NNS NNS TTC TTT TGG TAT AGA CAG TAC AGT GGC AAA TCC CCG – 
3’ and 5'- TAA TAC GAC TCA CTA TAG GG -3' (T7). SOE PCR was performed with 
each corresponding pre-SOE along with both T7 and Splice 4L. 
For the WT1-D13.1 CDR3 libraries (as well as the initial WT1-D13/D15 CDR3 
libraries mentioned that did not yield improved variants), pre-SOE PCR products were 
generated for each of the four libraries utilizing the following primer pairs: β1: 5' - GGC 
AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) and 5’ – TGC ACA CAG GTA CAT 
GGA AGT TTG ATT GGT ACT AGC GCT TTC CAG AAT CAA ACT GAA ACG TTC 
TTT – 3’, and 5’ – AGT ACC AAT CAA ACT TCC ATG TAC CTG TGT GCA NNS NNS 
NNS NNS NNS GAA CAG TTT TTC GGC CCA GGT ACA AGA TTA ACG GTG – 3’ and 
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5'- TAA TAC GAC TCA CTA TAG GG -3' (T7); β2: Splice 4L and 5’ – TGC ACA CAG 
GTA CAT GGA AGT TTG ATT GGT ACT AGC GCT TTC CAG AAT CAA ACT GAA 
ACG TTC TTT – 3’, and 5’ – AGT ACC AAT CAA ACT TCC ATG TAC CTG TGT GCA 
AGC AGT TCC ATC NNS NNS NNS NNS NNS GGC CCA GGT ACA AGA TTA ACG 
GTG – 3’ and T7; α1: Splice 4L and 5’ – GGC GCA CAG GTA AGT GGC GCT ATC 
TGA CGG TTG GCT ATC ACG GAT TAA CAG AGA GAC ATA CTG GGA – 3’, and 5’ – 
CAA CCG TCA GAT AGC GCC ACT TAC CTG TGC GCC NNS NNS NNS NNS NNS 
AAT ATG CTG ACC TTC GGT GGC GGT ACT CGC TTA ATG – 3’ and T7; α2: Splice 
4L and 5’ – GGC GCA CAG GTA AGT GGC GCT ATC TGA CGG TTG GCT ATC ACG 
GAT TAA CAG AGA GAC ATA CTG GGA – 3’ , and 5’ – CAA CCG TCA GAT AGC 
GCC ACT TAC CTG TGC GCC GCG AAT AAC GCG NNS NNS NNS NNS NNS TTC 
GGT GGC GGT ACT CGC TTA ATG – 3’ and T7 . 
Yeast libraries were made by homologous recombination in EBY100 yeast by 
electroporation of error-prone or SOE PCR products along with NheI and XhoI digested 
pCT30266. The libraries were induced in galactose-containing media (SG-CAA) for 48 
hours, washed with 1 mL 1% PBS/BSA, and stained with antibodies or pepMHC 
reagents at the concentrations indicated in Tables 3.1, 3.2, and 3.3. Cells were washed 
(1 ml, 1% PBS/BSA), and the most fluorescent cells were selected using a FACS Aria 
(BD Bioscience) high-speed sorter. 
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Isolation and staining of high-affinity clones 
Following selections, library clones were isolated by plating limiting dilutions. 
Colonies were expanded and induced in galactose-containing media (SG-CAA) for 48 
hours, washed with 1 mL 1% PBS/BSA, and stained with various concentrations of 
peptide/HLA-A2 (pepHLA-A2) DimerX, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 
secondary antibody, or various concentrations of UV-exchanged pepHLA-A2, SA-PE. 
Cells were washed (1 ml, 1% PBS/BSA) and analyzed on an Accuri C6 flow cytometer. 
Plasmids were recovered using Zymoprep™ Yeast Plasmid Miniprep II (Zymo 
Research) and introduced back into E. coli via heat shock transformation into 
Subcloning Efficiency™ DH5α™ Competent Cells (Invitrogen). E. coli cells were 
expanded and plasmids were isolated using QIAprep Spin Miniprep Kit (Qiagen). 
Sanger sequencing was used to determine the sequences of individual scTv clones by 
sequencing relevant regions of the pCT302 plasmid. 
 
Site-directed mutagenesis of the WT1-D13.1.1 scTv to generate the WT1-D13.0.1 and 
WT1-D13.1.1 Y51A scTvs 
In order to revert the CDR1α loop of the WT1-D13.1.1 scTv to the wild-type 
(WT1-P22) sequence, three adjacent site-directed mutants were made in positions 29-
31 of the CDR1α using a QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies): D29Vα, L30Sα, and G31Qα. Yeast cells displaying the resultant mutant, 
called WT1-D13.0.1, were titrated with WT1/HLA-A2-Ig dimers from 160 pM to 500 nM 
and analyzed by flow cytometry.  
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Additionally, the QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies) was used to mutagenize the WT1-D13.1.1 tyrosine at position 51α to 
alanine. Yeast cells displaying the resultant mutant, called WT1-D13.1.1 Y51Aα, were 
titrated with WT1/HLA-A2-Ig dimers at concentrations ranging from 0.1 to 100 nM and 
analyzed by flow cytometry. 
 
Yeast display library generation, selection, and 454 sequencing  
A degenerate (based on NNS codon composition) library was made at CDR2α 
residue Y51α of the WT1-D13.1.1 scTv using SOE PCR as described above. The library 
was stained with 100 nM WT1/HLA-A2-Ig dimer and sorted by FACS one time. The top 
staining (8-10%) clones were isolated, plasmids were recovered and amino acid 
sequences were determined by 454 sequencing (Roche/454 GS FLX+ Sequencer) as 
previously described38.  
 
Expression in E. coli, refolding, and biotinylation of soluble scTv fragments 
The WT1-D13.1.1 scTv was introduced into the pET28a expression vector with a 
C-terminal AviTag (Avidity) using NcoI and EcoRI restriction sites (forward primer: 5’ - 
TAT ACC ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC AGC GGC CTG 
GTG CCG CGC GGC AGC GAT GTT AAA GTG ACA CAA TCT - 3’, and reverse 
primer: 5’ - T TTA GAA TTC TTA TTC GTG CCA TTC GAT TTT CTG AGC CTC GAA 
GAT GTC GTT CAG ACC GCC ACC GAT GTG AGG CTT AAC CAT TAA - 3’. Plasmids 
were transformed into the BL21-DE3 expression cell line (NEB), expanded, and induced 
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for expression. Following induction, cells were passed through a microfluidizer 
(Microfluidics Corporation, Newton, MA, USA), inclusion bodies were isolated and 
protein was purified as previously described67. Soluble scTvs were refolded and purified 
with Ni-NTA agarose resin (Qiagen, Valencia, CA) followed by gel filtration (Superdex 
200, GE Healthcare). Folded scTvs were biotinylated in vitro (Avidity, BirA enzyme). 
Biotinylation was verified by a gel-shift assay with streptavidin by SDS-PAGE (data not 
shown). 
 
Binding of WT1-D13.1.1 scTv measured by surface plasmon resonance  
The binding of purified refolded WT1-D13.1.1 to WT1/HLA-A2 was monitored by 
surface plasmon resonance (SPR) using a Biacore 3000 instrument. Kinetic and 
equilibrium binding data were determined by immobilizing biotinylated pepMHC 
monomers on a neutravidin-coated CM5 sensor chip to 400-800 response units. A null 
pepMHC molecule was immobilized to the reference cell. Purified soluble scTvs were 
diluted to various concentrations in Biacore buffer (10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA, 0.005% Tween-20, pH 7.4) and flowed over the reference and experimental flow 
cells at 30 ml/min at 25°C. Binding of the scTv to the null complex was subtracted from 
the scTv binding to the experimental complex to correct for bulk shift and any non-
specific binding. Additionally, data obtained from injections with no analyte were 
subtracted from each concentration. Curve fitting and determination of on-rates and off-
rates were performed using BIAEvaluation 4.1.1 software. Equilibrium KD values were 
determined by calculating half-max values from non-linear regression analysis of plots 
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of the maximum response units (RU) for each scTv concentration. Values from repeated 
experiments were averaged and reported with standard deviations (n = 3). 
 
Binding of WT1-D13.1.1 scTv to peptide-pulsed APCs 
HLA-A2+ human cell line, T2 was incubated at 37°C for 2-3 hours with 1 μM WT1 
(RMFPNAPYL), MART-1 (ELAGIGILTV), or Tax (LLFGYPVYV) peptide. Cells were 
washed with 1% PBS/BSA, and incubated on ice for 1 hour with biotinylated scTv at 
various concentrations. Cells were washed again with 1% PBS/BSA, followed by 
incubation with SA-PE (1:100) for 30-45 min on ice. Cells were washed twice more and 
analyzed using an Accuri C6 Flow Cytometer.  
 
Results 
Engineering a stabilized scTv against WT1/HLA-A2 
The WT1-P20 and WT1-P22 TCR clones were isolated and cloned from WT1-
reactive T cell lines by Phil Greenberg and colleagues at the University of Washington. 
Both WT1-P20 and WT1-P22 used the highly stable Vα2 segment58 and the Vβ3 
segment. In order to engineer WT1 TCRs for improved stability and affinity against the 
WT1/HLA-A2 cancer antigen using yeast display, the variable regions of these TCR 
genes were cloned as single-chain TCR fragments (scTvs or scTCRs) in the Vβ-linker-
Vα orientation as a C-terminal fusion to AGA-2 yeast mating protein in the pCT302 
yeast display plasmid (Fig 3.2). The linker used for both constructs was 
GSADDAKKDAAKKDGKS58,63,64,68. Additionally, an N-terminal HA epitope tag and C-
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terminal c-myc epitope tag were included in the construct flanking the TCR variable 
genes in order to probe for expression and possible truncations that could occur due to 
the introduction of premature stop codons during the selection process, respectively. It 
was previously shown by my group that the presence of a serine at position 49 in the 
Vα2 segment conferred additional stability to yeast-displayed TCR58; Both the WT1-P20 
and WT1-P22 wild-type scTvs contained this amino acid in their wild-type sequences.  
Yeast expressing the WT1-P20 (data not shown) and WT-P22 (Fig. 3.3; first 
column) were induced to express their respective scTv fragments. Both were positive 
when analyzed by flow cytometry following staining with anti-HA and anti-c-myc 
antibodies, indicating that the yeast expressed the full-length constructs. In order to 
probe for expression of individual TCR variable domains, monoclonal antibodies that 
recognize the Vα and Vβ domains were used. These included anti-hVβ3.1 FITC IgG 
(Thermo Scientific) and anti-hVβ3 FITC IgM (Beckman Coulter), and an anti-Vα2 
monoclonal antibody generated in our lab. Temperature stability assays suggested that 
the two monoclonal antibodies against the Vβ3 domain recognized conformation 
epitopes (i.e. the denatured TCR was not bound). This justified the use of these 
antibodies as probes for folding and stability of the yeast displayed Vβ3 domain (data 
not shown). On the other hand, the Vα2 monoclonal antibody, which was generated in 
our lab, likely recognizes a linear epitope and thus would not provide a useful probe for 
properly folded Vα on the surface of yeast38.  
Whereas both WT1-P20 (data not shown) and WT1-P22 (Fig 3.3) yeast clones 
showed staining with the anti-Vα2 antibody, staining was not observed with the anti-Vβ3 
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antibodies. This result suggested that the scTv construct was not folded properly on the 
yeast cell surface. Because scTv fragments lack TCR constant regions that stabilize the 
TCR on the surface of the T cell, scTv constructs typically require mutations to generate 
a stabilized form that can be expressed on the surface of yeast38,58,64,65,68,69. 
To generate a stabilized variant of the scTv fragments of WT1-P20 or WT1-P22 
that would be amendable to engineering on the yeast cell surface, error-prone 
mutagenesis was used to create random libraries using each TCR as a template, and 
libraries were selected in tandem with the two Vβ3 antibodies (Table 3.1). Previous 
studies by our group with mouse TCRs 2C and 3L2 and human TCRs A6, 868, and T1 
have shown that selection of scTv variants with enhanced expression and temperature 
stability on the surface of yeast correlate with increased soluble expression38,58,64,69. The 
WT1-P20 and WT1-P22 error-prone mutagenesis libraries were subjected to three 
rounds of selection with the two anti-Vβ3 antibodies (conditions shown in Table 3.1).  
Staining of the yeast populations following selections showed the emergence of 
positive populations (Fig 3.4). Because only a modest increase in positive staining was 
observed following three selections of the WT1-P20 library (Fig. 3.4a), only the WT1-
P22 library, which showed a stronger positive population (Fig. 3.5b), was pursued 
further. After three selections of the WT1-P22 library with the anti-Vβ3 antibodies, 
individual yeast clones were isolated and assessed for improved stability as measured 
by increased surface levels with anti-Vβ3 antibodies (data not shown). Two clones, 
called WT1-D13 (Fig 3.3; second column) and WT1-D15 (not shown), showed improved 
binding with very similar staining profiles (Fig. 3.3b; second column). As a result, both 
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were used as templates for affinity maturation of the WT1-P22 scTv. The WT1-D13 and 
WT1-D15 scTv plasmids were isolated and sequenced (Fig. 3.5), and both contained 
four stabilizing mutations. Two of the mutations were common to both scTvs (D51Gβ 
and S32Pα), and the other two varied (S79Cα and N92Sα for WT1-D13; and I103Tβ 
and I50Vα for WT1-D15). Notably, these mutations are located in both CDR loops and 
framework regions. Stabilizing mutations in other engineered scTvs have occurred at 
the interface of the α and β V domains, at the exposed regions of the variable regions 
that are normally buried by the constant regions, or in CDR loops38,58,64,65,68,69. 
 
Engineering an affinity-enhanced scTv against WT1/HLA-A2 
Although affinity maturation libraries were initially constructed in the CDR3 
regions of the stabilized WT1-D13 and WT1-D15 scTv clones, no clones with improved 
binding were isolated following three selections with WT1/HLA-A2-Ig dimers (data not 
shown). As a result a CDR1α affinity maturation library spanning four adjacent residues 
at positions 29-32 was made utilizing the wild-type (WT1-P22) and stabilized WT1-D13 
and WT1-D15 clones as templates by splicing by overlap extension (SOE) PCR (Fig. 
3.5)66.  
The WT1-wt/D13/D15 CDR1α library was FACS sorted according to Table 3.2 for 
binding to WT1/HLA-A2-Ig dimers (BD DimerX). Following five rounds of selection by 
FACS with WT1/HLA-A2-Ig dimers, a weakly positive population began to emerge (Fig. 
3.6a). Sequencing of ten individual clones following the fifth sort revealed that all had 
the identical sequence, which was called WT1-D13.1. WT1-D13.1 contained CDR1α 
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sequence at positions 29-32 that were DLGS, thus containing three mutations from the 
wild-type P22 sequence (i.e. V29Dα, S30Lα, and Q31Gα) and reverting the WT1-D13 
stabilizing mutation S32Pα back to the wild-type serine (i.e. P32Sα) (Fig. 3.5). 
Additionally, an F48Sβ mutation was introduced near the CDR2β, likely as a result of a 
PCR-based error. The WT1-D13.1 clone showed only a modest improvement in binding 
to WT1/HLA-A2 (Fig. 3.3; third column). 
 
Engineering a higher-affinity scTv against WT1/HLA-A2 
In order to further improve the affinity of the WT1 scTv, CDR3 libraries were 
generated using the WT1-D13.1 clone isolated from the WT1-wt/D13/D15 
CDR1α library as a template. The WT1-D13.1 CDR3 libraries were generated by 
splicing by overlap extension (SOE) PCR at five degenerate codons in each CDR: two 
libraries in the CDR3β loop [β1: positions 95-104 and β2: positions 103-107] and two in 
the CDR3α loop [α1: positions 91-100 and α2: positions 100-105]. Each WT1-D13.1 
CDR3 library was introduced into the yeast display vector by combining the linearized 
pCT302 vector, WT1-D13.1 CDR3 PCR product (i.e. CDR3α1, CDR3α2, CDR3β1, or 
CDRβb2 library), and competent EBY100 yeast cells. The four resultant libraries were 
pooled, and the combined libraries were FACS selected for binding to WT1/HLA-A2-Ig 
dimers as described in Table 3.3.  
After three rounds of selection by FACS with WT1/HLA-A2-Ig dimers, a positive 
population began to emerge (Fig. 3.6b). Following the third sort, ten individual clones 
were stained individually, and one, called WT1-D13.1.1 showed increased binding to 
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WT1/HLA-A2 (Fig. 3.3; fourth column). Sequencing revealed that WT1-D13.1.1 was 
derived from the CDR3β1 library and contained four CDR3β mutations that varied from 
the WT1-D13.1 template: S95Tβ, S97Nβ, I103Yβ, and N104Lβ (Fig 3.5). 
 
Binding analysis of WT1-D13.1 and WT1-D13.1.1 on the surface of yeast 
In order to assess the binding of the WT1-D13.1 and WT1-D13.1.1 clones 
isolated from selections of affinity maturation libraries, yeast populations displaying the 
WT1-D13.1 and WT1-D13.1.1 scTvs on their surfaces were titrated with two pepMHC 
reagents. Because the WT1-D13.1 scTv was lower affinity, it was titrated with 
WT1/HLA-A2-Ig dimers only (160 pM to 500 nM), in order to enhance signal through 
avidity effects (Fig. 3.7a). Yeast cells were then washed and analyzed by flow 
cytometry. A plot of the MFI versus WT1/HLA-A2-Ig dimer concentration suggested that 
the WT1-D13.1 scTv exhibited an EC50 value of greater than 1 µM (Fig. 3.7b). The 
higher affinity WT1-D13.1.1 scTv was titrated with both WT1/HLA-A2-Ig dimers and UV-
exchanged WT1/HLA-A2 monomers expressed and purified from E. coli. The WT1/HLA-
A2 dimers were assayed at 160 pM to 500 nM (Fig. 3.8a), and the monomers were 
assayed at 6.4 nM to 4 μM (Fig. 3.8b). Mean fluorescence intensity (MFI) were plotted 
for each histogram versus the concentration of the WT1/HLA-A2 complex. Values were 
normalized using nonlinear regression analysis and EC50 values of 25 nM and 240 nM 
were determined for dimer and monomer, respectively (Fig 3.8c,d). Typically, pepMHC 
dimers show half-maximum values at concentrations considerably lower than that of 
monomers due to avidity effects on the yeast cell surface. 
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Mutational analysis of the selected WT1-D13.1.1 CDR1α loop 
In order to determine if the four mutations derived from selection of the WT1-
D13.1 CDR3 library were dependent on the WT1-D13.1 CDR1α mutation framework, 
site-directed mutagenesis was used to revert the WT1-D13.1.1 CDR1α to wild-type (i.e. 
positions 29-31 DLG to VSQ). The resultant scTv variant, called WT1-D13.0.1 was 
displayed on the surface of yeast and titrated with the WT1/HLA-A2-Ig dimer at 
concentrations ranging from 32 pM to 500 nM and compared to the WT1-D13.1.1 (Fig. 
3.9). Where the WT1-D13.1.1 scTv bound even to concentrations as low as 32 pM, the 
WT1-D13.0.1 did not bind even at the highest concentration of WT1/HLA-A2-Ig dimer 
(500nM), indicating that the CDR1α mutations were required to increase the binding 
affinity of the CDR3 mutations.  
 
Evaluation of the role of CDR2α residue Y51 of the WT1-D13.1.1 scTv 
 In Chapter 2, I described experiments with a panel of three Vα2-contining scTv 
fragments (A6-X15, 868-Z11, and T1-S18.45) that showed: (1) the germline codon 
residue Y51 had similar and significant contributions in binding to cognate pepMHC in 
all three scTvs (approximately 1.5-2 kcal/mol in free energy), and (2) the tyrosine was 
preferred at position 51 for cognate pepMHC binding using a single-codon library 
aprroach that mimics positive selection, although structurally similar amino acids (e.g. 
phenylalanine and tryptophan) were allowable38. In order to determine if this position 
was also important for WT1/HLA-A2-binding of WT1-D13.1.1, a site-directed alanine 
mutant was made at position 51 (i.e. Y51Aα) and titrated on the surface of yeast with 
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0.1-100 nM WT1/HLA-A2-Ig (Fig. 3.10a). Whereas the wild-type WT1-D13.1.1 staining 
with WT/HLA-A2-Ig dimer showed staining at concentrations as low as 160 pM (Fig. 
3.8a), no significant binding was seen at the highest concentration tested of WT1/HLA-
A2-Ig dimer (100 nM) in the WT1-D13.1.1 Y51A mutant (Fig. 3.10a), suggesting that 
position Y51 also played a critical role in binding in the WT1-D13.1.1 TCR. 
 A single-codon library (NNS) was generated in CDR2α position 51 and selected 
once with 100 nM WT1/HLA-A2-Ig dimer, as performed with the T1-S18.45 scTv in 
Chapter 2. Following collection of the top 8-10% binding clones by FACS, plasmids 
isolated from the enriched population of yeast were subjected to 454 high-throughput 
sequencing to determine the amino acid frequency selected at the degenerate position 
(Fig. 3.10b). As was seen with the T1-S18.45 scTv library, selections showed an 
enrichment of the wild-type tyrosine, as well as structurally similar amino acids, 
phenylalanine and tryptophan. Histidine was also preferred at position 51 in the WT1-
D13.1.1 scTv library, perhaps due to the aromatic imidazole ring. 
 
Expression and binding studies of the high-affinity WT1-D13.1.1 scTv 
The WT1-D13.1.1 scTv gene was cloned into a pET expression vector and 
expressed in E. coli. scTv proteins were refolded from inclusion bodies and purified by 
Ni-affinity and size exclusion chromatography. Although capable of being expressed at 
high levels, the folded protein appeared less stable at room temperature compared to 
several other higher-affinity scTvs expressed by my group previously38,58. The purified 
scTv protein was used in surface plasmon resonance (SPR) experiments to determine 
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binding affinities. Soluble pepMHC monomers were immobilized to the surface of a 
neutravidin-coated CMF5 sensor chip (with a null pepMHC in the reference cell). The 
equilibrium binding constant (KD) determined from the average of independent SPR 
experiments was 330 ± 32 nM, whereas the affinity determined from the kinetic 
constants was 240 ± 290 nM. 
To show that the WT1-D13.1.1 scTv could recognize WT1/HLA-A2 on the 
surface of APCs, soluble WT1-D13.1.1 scTv was cloned with a C-terminal peptide 
substrate for BirA, and the purified protein was biotinylated in vitro58,70. To assess 
binding, the human cell line T2 (HLA-A2+) was incubated with 1 µM Tax, MART-1, or 
WT1 peptides and washed. Biotinylated WT1-D13.1.1 scTv was titrated on T2 cells pre-
loaded without peptide (Fig. 3.11a), or with the null peptide Tax (4 nM to 1 µM) (Fig. 
3.11b), null peptide MART-1 (4 nM to 1 µM) (Fig. 3.11c), or cognate peptide WT1 (4 nM 
to 1µM) (Fig. 3.11d). The cells were washed, incubated with SA-PE and analyzed by 
flow cytometry. Only cells loaded with WT1 peptide were bound by the soluble WT1-
D13.1.1 TCR (Fig. 3.11d). Non-linear regression of the plot of MFI versus scTv 
concentration of the WT1 titration showed that the soluble scTv exhibited an EC50 value 
of 260 nM (Fig. 3.11e), consistent with SPR data. 
 
Discussion 
 A study using T cells transduced with an affinity-enhanced TCR in an adoptive 
therapy model showed that T cells exhibited increased persistence and anti-tumor 
efficacy31. Recently, our group71 and others72 have shown that CD4+ T cells expressing 
 132 
engineered nanomolar affinity TCRs mediated more potent activity than their wild-type 
counterparts in the murine 2C model system. It has thus been proposed that high-
affinity TCRs might be particularly effective in targeting the WT1/HLA-A2 cancer 
antigen, especially in light of recent clinical trials and mouse studies16,17,31.  
Recently Chapuis and coworkers in the Greenberg laboratory demonstrated the 
clinical efficiency of WT1-reactive CTLs in a limited adoptive T cell therapy trial in 
human patients with high-risk, post-bone marrow transplant leukemias16. In this pilot 
study, 11 leukemia patients were given donor-derived WT1-reactive CTLs; in 4 of the 11 
patients the WT1-reactive CTLs were pretreated with IL-21 to prolong persistence prior 
to infusion. In the 7 patients that receive CTLs without IL-21, leukemia was temporarily 
suppressed, although transferred CTLs did not persist past 14 days. In contrast, the 4 
patients that received IL-21-pretreated CTLs survived without leukemia relapse for >30 
months without additionally treatment or without exhibiting symptoms of graft-versus-
host disease (GVHD). Additionally, the transferred T cells continued to persist and 
demonstrated phenotypes characteristic of a memory T cell population16. Two phase I/II 
clinical trials using T cells transduced with WT1-specific TCRs against various types of 
leukemia are in progress at both the University College in London and the Fred 
Hutchinson Cancer Research Center (FHCRC) at the University of Washington 
(http://www.clinicaltrials.gov, NCT01621724 and NCT01640301, respectively). 
In the current study, I engineered high-affinity variants of a WT1-reactive TCR, 
called WT1-P22, which retained specificity for WT1/HLA-A2. Unlike previous efforts in 
my lab in engineering both human and murine TCRs with enhanced affinities37,38,58,64, 
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the engineering of the WT1-D13.1.1 high-affinity scTv involved a multi-step engineering 
process in which different regions were mutagenized and the resultant variants were 
used as templates for further engineering. First, the WT1 TCRs were expressed as 
scTvs on the surface of yeast, and stabilized through the introduction and selection of 
random mutations. Although stabilization of TCRs as scTvs on the surface of yeast have 
typically shown the selection of mutations at the interface of variable regions or at the 
ablated interface between variable and constant regions38,58,64,65,68,69, several mutations 
in both the WT1-D13 and WT1-D15 clones showed mutations in CDR loops (Fig. 3.5). 
With the exception of the CDR2β D51G other stabilizing mutations in CDR loops were 
not selected or maintained in affinity matured variants, perhaps due to altering the 
binding specificity in the regions. Notably, during the first affinity maturation round (i.e. 
CDR1α libraries) the resultant WT1-D13.1 clone had an additional PCR-based mutation 
just prior to CDR2β (i.e. F48S) that could have served to further stabilized the TCR. It 
was noted in purification of the high-affinity WT1-D13.1.1 scTv that E. coli expressed 
and refolded scTv fragments were relatively unstable at room temperature compared to 
other scTvs I have generated in my laboratory (data not shown)38,58, perhaps due to the 
limited number of stabilizing mutations at regions where they are typically found in the 
high-affinity variant.  
Binding affinity estimates were determined from yeast-displayed WT1-D13.1.1 
(EC50 = 25 nM and EC50 = 240 nM for dimeric and monomeric pepMHC, respectively) 
and soluble preparations of the protein (equilibrium KD = 330 nM by SPR and EC50 = 
260 nM in T2 binding assays). Often, SPR values show higher affinities as there are no 
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wash steps as there are in flow cytometry assays of scTvs on the yeast cell surface38,58, 
although the estimates for both forms of WT1-D13.1.1 were similar. 
Following the isolation WT1-D13 and WT1-D15 clones, I generated affinity 
maturation libraries in CDR3 and CDR1α regions using the wild-type and stabilized scTv 
as templates. Although no scTv variants were isolated from the combined CDR3 
libraries, the CDR1α library yielded a single variant, called WT1-D13.1, with improved 
binding to WT1/HLA-A2. Because WT1-D13.1 only showed modest improvement in 
binding to WT1/HLA-A2, further mutagenesis was performed in the same regions as in 
the initial WT1-D13/D15 CDR3 libraries. The resultant high-affinity scTv variant, WT1-
D13.1.1, selected mutations in the CDR3β positions 95-104 of WT1-D13.1, whereas 
mutagenesis of this same region utilizing the WT1-D13/D15 libraries did not yield scTvs 
with improved binding.  
To further explore if the CDR1α mutations were required for the binding 
enhancement seen from affinity maturation of WT-D13.1 to WT1-D13.1.1, I reverted the 
selected CDR1α loop back to the wild-type residues. This resulted in a complete loss in 
detectable binding suggesting that the CDR3 residues selected in the second round of 
affinity maturation (i.e. to generate WT1-D13.1.1 from WT1-D13.1) acted cooperatively 
with the mutated CDR1α loop of WT1-D13.1. This could possibly account for why I did 
not isolate improved variants from the initial WT1-D13/D15 CDR3 libraries (i.e. perhaps 
no CDR3 mutants present in the library were capable of producing productive contacts 
with WT1/HLA-A2 in the context of the wild-type CDR1α loop). These results suggest 
that multi-step selection schemes, focusing on one loop at a time, may prove a 
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productive strategy in redesigning the TCR:pepMHC interface by making a series of 
modest improvements in a step-wise fashion which in combination form a higher affinity 
TCR. However, in terms of mutagenizing TCR loop positions that come in close 
proximity to MHC helices, preventative measures should be taken to ensure that non-
specific contacts through strong interaction with MHC in a peptide-nonspecific manner 
are not selected, perhaps through the use of robust negative selection strategies73 with 
panels of non-cognate pepMHCs that mimic the negative selection process of central 
tolerance30. In this regard, it will be interesting to revert the CDR2β mutations (F48S and 
D51G) that were isolated as “stabilizing” variants in WT1-D13.1.1 in order to make sure 
that these do not increase the affinity for WT1/HLA-A2. As these were isolated for 
improved surface display with the anti-Vβ antibody, one would not expect them to 
increase affinity for pepMHC substantially. 
Along the same lines, it has been proposed that affinity mutations in CDR1 and 
CDR2 loops might increase affinity by binding to MHC residues due to their relative 
positioning, and therefore mediate non-specific T cell responses due to stronger 
interactions with non-cognate pepMHC31,41. In one of two recent adoptive cell therapy 
trials utilizing T cells engineered to target the MAGE-A3 cancer testis antigen with 
severe adverse effects74-76, a CDR2-engineered TCR resulted in an off-target cardiac 
toxicity through recognition of an unrelated peptide derived from titin in the heart74,75. It 
has been proposed that TCRs with affinity-enhancing mutations in CDR3 regions only 
would be less likely to cross-react since the germline-encoded TCR regions are similar 
to the parental TCR that has been subjected to selection in the thymus31,41. I suggest 
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that restricting the CDR1α library design to the four positions that are nearest to the 
peptide in crystal structures of Vα2-containing TCRs44,46,47,77,78 may likewise provide a 
safety margin, as CDR1 regions have also been shown to make direct contacts to 
peptide residues in specific TCRs44-48 and selected residues could potentially mediate 
similar contacts. Although no structures are available for the WT1-D13.1 and WT1-
D13.1.1 scTvs, the CDR1α is positioned over the N-terminus of the peptide in virtually 
all TCRs42,43. Accordingly, I predict that the acidic aspartate residue selected at position 
29 of the CDR1α in WT1-D13.1 and WT1-D13.1.1 could potentially interact with the N-
terminal arginine at position 1 of the WT1 peptide to mediate a direct, peptide-specific 
interaction (Fig. 3.1).  
The use of some affinity- or avidity-enhanced TCRs could lead to unacceptable 
risk for use in adoptive T cell therapies due to a higher cross-reactivity potential due to 
affinity-enhancing mutations. However, additional factors play an important role in 
determining the safety of engineered TCRs. In particular the specificity of the antigen 
being targeted plays an important role. For example, in the other MAGE-A3 trial 
mentioned, off-target neurological toxicities were demonstrated due to T cell recognition 
of a highly similar epitope derived from the related antigen MAGE-A12 in the brain, 
which varied from the MAGE-A3 peptide only at the anchor residue at position 2 (i.e. 
V2M)76. In a separate trial with gene-modified CTLs specific for MART1/HLA-A2, on-
target toxicities were demonstrated, presumably due to the expression of MART1 in 
normal melanocytes in the skin, eye, and ear79. To date, targeting of the WT1 antigen in 
both cancer vaccine and cell-based immunotherapies has not demonstrated 
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autoimmune reactions12,16,17, suggesting it is a desirable target for adoptive therapies 
that possibly include affinity-enhanced TCRs.  
A recent study by Schmitt and collegues17 proposed that the thymic selection 
process may be “overprotective,” and affinity-enhanced TCRs with affinities higher than 
the threshold of thymic selection (i.e. KD values < 1 µM) may be safe for gene therapy in 
adoptive cell therapies. In this study, the efficacy and safety of affinity-engineered 
receptors were tested against two tumor antigens, WT1 and the differentiation antigen 
mesothelin, in a murine model. In the case of WT1, two WT1-specific TCRs were 
engineered for improved affinity using T cell display40, and transduced into CD8+ T cells. 
As observed in previous studies with some high-affinity TCRs71,72, TCRs with higher 
binding affinity showed enhanced activation as measured by cytokine release in ex vivo 
assays. In order to demonstrate safety of the affinity-enhanced TCRs, CD8+ T cells 
were transduced with several WT1-specific TCRs, expanded, and infused into mice17. 
CTLs transduced with the higher-affinity receptors were not apparently stimulated by 
murine self-antigens. Furthermore, normal tissues were not targeted by the engineered 
TCRs even following in vivo activation of the WT1-specific CTLs through the introduction 
of Listeria expressing the WT1 peptide. Notably, the H2-Db-restricted WT1 peptide 
expressed in mice is identical to that in humans80,81. Finally, to examine whether affinity-
enhanced TCRs would be likely to be deleted during normal selection in thymus, 
hematopoietic stem cells were transduced with the affinity-enhanced TCR genes17. 
Despite the absence of self-reactivity in the periphery, T cell progenitors originating from 
engineered stem cells with the same affinity-enhanced TCRs were negatively selected. 
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This suggested that the process of central tolerance has evolved to have a lower 
threshold for the deletion of self-reactive TCRs. Studies with affinity-enhanced TCRs 
against mesothelin yielded similar results, suggesting that affinity engineered TCRs, in 
the case of these two targets, may be safe for use despite basal levels of expression of 
the tumor peptides. 
Despite these results, it is likely that TCRs of even higher affinity (i.e. KD values in 
the low nanomolar or picomolar range) would be more prone to off-target toxicities. 
Recent studies by our group and collaborators have utilized the well-characterized 2C 
mouse system to assess the role of TCR affinity for adoptive T cell therapies71,72. In 
these studies, the wild-type 2C TCR (KD = 30 µM for foreign antigen SIY/Kb) and high-
affinity variant m33 (KD = 30 nM for foreign antigen SIY/Kb)36 were used to assess the 
anti-tumor response in a B16-SIY murine melanoma model. Notably, the m33 affinity is 
significantly higher than the engineered TCRs currently used in TCR gene therapy trials 
to date; e.g., the affinity of the DMF5 TCR (KD = 40 µM) is >1,000-fold lower than m3347. 
Where the CD8+ T cells expressing the high-affinity m33 TCR were deleted in vivo, 
CD4+ cells expressing the m33 TCR were able to mediate a response against SIY-
positive tumors and persist in vivo72. Additionally, in a follow-up study the m33 TCR 
showed a significant advantage over its wild-type 2C counterpart in mediating 
destruction of B16-SIY melanomas in CD4+ T cells, resulting in long-term tumor control 
without tumor outgrowth71. These data suggest that use of high-affinity TCRs, in CD4+ T 
cells only, might provide additional efficacy and safety for gene therapy over the use of 
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CD8+ T cells71,72, particularly with TCR binding affinities (KD) below 1 µM that allow for 
co-receptor independent T cell activation33,34. 
One strategy that has been proposed to take advantage of the properties of both 
CD4+ and CD8+ T cells for adoptive cell immunotherapies includes transducing 
separated populations of CD4+ and CD8+ T cells with high-affinity (KD ≤ 1 µM; such as 
WT1-D13.1.1) and slightly enhanced-affinity (KD > 1 µM; such as WT1-D13.1) TCR 
variants, respectively, and using them together in adoptive cell infusions34,71,72,82. 
Recently, we described a strategy using a library of 2C and m33 TCR variants that 
varied at a single CDR2β position, Y46β, which when mutated to alanine shows a 100-
fold decrease in binding in the m33 TCR33. By allowing for any possible amino acid at 
the Y46β position in either the wild-type 2C (KD = 30 µM) and high-affinity m33 (KD = 30 
nM), a potential 10,000-fold range of TCRs that recognize SIY/Kb could be assessed 
when introduced into CD4+ or CD8+ T cells and introduced into mice with SIY-positive 
tumors82. Using high-throughput sequencing, it was shown that the highest affinity TCRs 
were preferentially expressed on the surface of CD4+ cells, with the same TCRs being 
deleted in CD8+ cells. Using a similar single-site mutagenesis strategy, it could be 
possible to generate antigen-specific TCR variants with lower affinities by mutating 
conserved residues in the CDR2 loops that could potentially decrease the TCR’s affinity 
for self-MHC helices34,83. 
In a recent study, I showed that an analogous residue in the human CDR2α (i.e. 
germline-derived, conserved residue Y51α) in three human Vα2-containing scTvs, when 
mutated to alanine, exhibited a 10 to 15-fold or greater decrease in binding in all three 
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TCRs examined38. Using a similar single-site library approach at CDR2α position Y51α 
in the human MART1-specific T1-S18.45 scTv in a yeast display library, I showed that 
selection for binding to MART1/HLA-A2 in vitro resulted in range of potential single-site 
substitution spanning an affinity range of >1,000 fold, as no binding was detected in the 
T1-S18.45 Y51Aα mutant when stained with concentrations up to 5 µM (wild-type KD = 
45 nM)38. Similarly in the current study, mutagenesis of the WT1-D13.1.1 to generate a 
Y51Aα mutant led to a significant decrease in binding (i.e. no detectable binding at 100 
nM WT1/HLA-A2-Ig binding). This suggests that a similar strategy could be used to 
generate WT1-D13.1.1 clones with decreased affinity for WT1/HLA-A2. Similarly, 
selection of single-codon WT1-D13.1.1 libraries at position Y51α suggest many possible 
substitutions could potentially reduce affinity to a range optimal for directing activity in 
either CD4+ or CD8+ T cells34.  
Preliminary studies with the affinity enhanced WT1-D13.1.1 variable fragments in 
adoptive T cell models are ongoing. To date, a full-length TCR using the variable 
fragments of the WT1-D13.1.1 scTv with mouse constant regions, was expressed on 
the surface of murine primary T cells. As the WT1-epitope recognized in mice is 
identical to that recognized in humans80,81, it provides the unique opportunity to address 
the safety features of the human high-affinity TCRs in both full length and chimeric 
antigen receptor (CAR) formats in a chimeric HLA-A2/Db transgenic murine model. 
In conclusion, the targeting of the WT1/HLA-A2 antigen using high-affinity TCRs, 
such as the WT1-D13.1.1 variant described in the current study or related mutants with 
modulated affinity properties could provide an efficacious strategy for directing adoptive 
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T cell therapies, particularly with CD4+ T cells. Additionally, because strategies to 
assess normal endogenous antigen expression in healthy tissues and associated cross-
reactivity of affinity or avidity-enhanced TCRs is on the forefront of the development of 
adoptive T cell strategies84, the WT1-specific engineered TCRs provide a convenient 
system to assess potential adverse effects of human TCRs in a murine model. 
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Figures 
 
 
Figure 3.1 | Crystal structure of WT1/HLA-A2. Top-down view of WT1/HLA-A2 upon which the TCR 
CDR loops dock. Although no crystal structures exist for the WT1-P20 or WT1-P22 clones that are used 
as templates for engineering in this study, virtually all TCRs contact pepMHC in an invariant diagonal 
docking orientation that positions the Vα region over the α2 MHC helix and the N-terminal end of the 
peptide, and the Vβ region over the α1 MHC helix and C-terminal end of the peptide. The WT1 peptide is 
pictured in blue, and the HLA-A2 helices are shown in gray from the WT/HLA-A2 crystal structure [PDB: 
3HPJ]85. Amino acid sequences are indicated. The crystal structure is visualized with PyMOL software 
(The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC)86. 
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Figure 3.2 | Sequence alignment of WT1-P20 and WT1-P22 template scTvs. The sequences of two 
WT1-specific TCRs isolated from WT1-reactive CTL lines by Greenberg and colleagues. The conserved 
immunoglobulin fold residues are shown in cyan, and the Vα S49 residue that has been shown to confer 
additional stability is shown in magenta58. Both TCRs were used as templates for error-prone yeast-
displayed libraries, although only one, WT1-P22, yielded highly stabilized TCR clones on the surface of 
yeast. TCR-variable residue numbering has been kept consistent with sequence alignments with 
previously published human Vα2-containing scTvs38,58. 
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Figure 3.3 | Yeast display and isolation of WT1-P22 scTvs. (a) Schematic of the scTv fusion of the 
human TCR, WT1-P22, which recognizes WT1 peptide presented in the context of HLA-A2. (b) The WT1-
P22 TCR was cloned as a scTv and expressed on the surface of yeast (first column). The scTv fusion 
was monitored on the surface of yeast for expression with an antibody against the HA epitope (first row). 
Antibodies that recognize the TCR variable regions were also used: anti-Vβ3 (Thermo Scientific) 
(conformation epitope; second row) and anti-Vα2 (linear epitope; third row). Binding to WT1/HLA-A2 was 
monitored through incubation of yeast with soluble WT1/HLA-A2-Ig dimers (fourth row). Finally, yeast 
were probed for possible truncations arising from premature stop codons by monitoring the C-terminal tag 
c-myc (fifth row). A random mutagenesis library was generated using the WT1-P22 scTv as a template 
and sorted with anti-Vβ3 antibody and goat anti-mouse IgG AlexaFluor 647 secondary antibody. Clones 
WT1-D13 (second column) and WT1-D15 (not shown) were isolated after three rounds of sorting. Site-
directed libraries were made in the CDR1α loop region using the wild-type WT1-P22 and stabilized WT1-
D13 and WT1-D15 clones as templates. The affinity-enhanced clone, WT1-D13.1, was isolated following 
five rounds of sorting with WT1/HLA-A2 dimer (third column). Finally, site-directed libraries were made in 
CDR3 loop regions of WT1-D13.1 for further affinity maturation. The high-affinity clone, WT1-D13.1.1, 
was isolated following three rounds of sorting with WT1/HLA-A2 dimer (third column). The negative peak 
is due to yeast that have lost plasmid, and serves as an internal control for each induced yeast sample. 
Gray indicates yeast cells stained with secondary antibody only. Histograms shown are representative of 
two or more experiments. 
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Figure 3.4 | Yeast display engineering of WT1-P22 scTv for stability. Flow cytometry histograms of 
the WT1-P20 (a) and WT1-P22 (b) scTv error-prone libraries after sorting with two antibodies that 
recognize conformation epitopes on Vβ3. The WT1-P20 and WT1-P22 error-prone libraries were sorted 
sequentially with Thermo hVβ3.1 FITC IgG and Beckman-Coulter (BC) hVβ3 FITC IgM antibodies, 
AlexaFluor 647 goat anti-mouse IgG and goat anti-mouse IgM APC, for a total of 3 sorts according to 
Table 3.1. Aliquots of yeast cells after each sort were then incubated with a Thermo hVβ3.1 FITC IgG, 
AlexaFluor 647 goat anti-mouse IgG. Gray indicates yeast cells stained with secondary antibody only. 
Histograms are representative of n=2. 
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Figure 3.5 | Sequences of engineered WT1-P22 scTv clones. The sequences of the WT1-specific 
template (P22), stabilized (WT1-D13 and WT1-D15) and affinity-enhanced (WT1-D13.1 and WT1-
D13.1.1) TCRs. The conserved immunoglobulin fold residues are shown in cyan, and the Vα S49 residue 
that has been shown to confer additional stability is shown in magenta58. Mutations isolated from error-
prone libraries are underlined and shown in green; mutations that resulted from PCR-based mutations are 
underlined and shown in orange; mutations isolated from affinity maturation libraries are boxed and the 
library residues varied are shown in yellow. TCR-variable residue numbering has been kept consistent 
with sequence alignments with previously published human Vα2-containing scTvs38,58. 
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Figure 3.6 | Affinity maturation of WT1-D13. (a) The wild-type WT1-P22 and stabilized clones WT1-
D13 and WT1-D15 isolated from error-prone libraries were used as templates for an affinity maturation 
library in CDR1α. The WT1-wt/D13/D15 CDR1α library was sorted sequentially with WT1/HLA-A2-Ig 
dimer, APC-conjugated goat anti-mouse secondary antibody, for a total of five sorts according to Table 
3.2. Aliquots of yeast cells after each sort were then incubated with 100 nM WT1/HLA-A2-Ig dimer 
followed by APC-conjugated goat anti-mouse secondary antibody. Gray indicates yeast cells stained with 
secondary antibody only. (b) The affinity-enhanced clone WT1-D13.1 isolated from WT1-wt/D13/D15 
CDR1α library was used as a template for CDR3 libraries. The WT1 D13.1 combined CDR3 libraries were 
sorted sequentially with WT1/HLA-A2-Ig, APC-conjugated goat anti-mouse secondary antibody, for a total 
of three sorts according to Table 3.3. Aliquots of yeast cells after each sort were then incubated with 100 
nM WT1/HLA-A2-Ig followed by APC-conjugated goat anti-mouse secondary antibody. Gray indicates 
yeast cells stained with secondary antibody only. Histograms are representative of n=2. 
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Figure 3.7 | Binding properties of the yeast-displayed WT1-D13.1 clone. Binding of the yeast-
displayed WT1-D13.1 to WT1/HLA-A2-A2 dimers. (a) Flow cytometry histograms of the enhanced-affinity 
scTv WT1 D13.1 stained with various concentrations of WT1/HLA-A2-Ig dimer, followed by fluorescently 
labeled goat anti-mouse IgG AlexaFluor 647 secondary antibody. Histograms are representative of n=3. 
(b) Plot of the mean fluorescence intensity (MFI) values of histograms versus WT1/HLA-A2 dimer 
concentration. An approximate EC50 value is indicated. 
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Figure 3.8 | Binding properties of the yeast-displayed WT1-D13.1.1 clone. Binding of the yeast-
displayed WT1-D13.1.1 to soluble pepMHC reagents. (a) Flow cytometry histograms of the high-affinity 
scTv WT1 D13.1.1 stained with various concentrations of WT1/HLA-A2-Ig dimer, followed by goat anti-
mouse IgG AlexaFluor 647 secondary antibody. Histograms are representative of n=3. (b) Flow cytometry 
histograms of the high-affinity scTv WT1 D13.1.1 stained with various concentrations of biotinylated 
WT1/HLA-A2 monomer, followed by SA-PE (1:100) secondary. Histograms are representative of n=2. (c) 
Plot of the mean fluorescence intensity (MFI) values of histograms versus WT1/HLA-A2 dimer 
concentration. An EC50 value is indicated. (d) Plot of the MFI values of histograms versus WT1/HLA-A2 
monomer concentration. An EC50 value is indicated.  
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Figure 3.9 | Binding titrations of the WT1-D13.1.1 and WT1-D13.0.1 scTvs. The WT1-D13.1.1 scTv 
(a) and WT1-D13.0.1 scTv (b) titrated with WT1/HLA-A2-Ig dimers at concentration ranging from 32 pM to 
500 nM, followed by goat anti-mouse IgG AlexaFluor 647 secondary antibody.   
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Figure 3.10 | Analysis of position Y51α  of the WT1-D13.1.1 scTv. (a) A yeast-displayed site-directed 
Y51Aα mutant was generated using WT1-D13.1.1 scTv as a template. The resultant yeast population was 
titrated with 0.1-100 nM WT1/HLA-A2-Ig dimer and analyzed by flow cytometry on the surface of yeast. 
Concentrations of WT1/HLA-A2 are indicated in the legend. (b) In vitro selected mutants of yeast-display 
position 51α library of the WT1-specific TCR, WT1-D13.1.1. Yeast display libraries at position 51 of the 
CDR2α of WT1-D13.1.1 were generated, stained with 100 nM WT1/HLA-A2-Ig dimer, and selected by 
FACS. The top staining (8-10%) clones were isolated, and amino acid distribution was determined by 454 
sequencing. Amino acid residues that were positively and negative selected are indicated on the y-axis as 
a function of the ratio of the logarithm of amino acid frequency post-selection divided by the frequency 
pre-selection. A total of 1,786 and 1,459 clones were sequenced pre- and post-selection, respectively. 
Bars with hash marks indicated that zero clones with the indicated amino acid were found post-selection, 
indicating they were strongly selected against. 
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Figure 3.11 | Soluble binding of the high-affinity WT1-D13.1.1 to WT1/HLA-A2 on the surface of 
APCs. The high-affinity TCR WT1 D13.1.1 was expressed in E. coli, refolded, and biotinylated in vitro. 
The soluble WT1-D13.1.1-biotin monomers were used to stain human T2 (HLA-A2+) cells following 
incubation with no peptide (a), null peptide Tax (b), null peptide MART-1 (c), or cognate peptide WT1 (d). 
(e) Plot of mean fluorescence intensity (MFI) versus concentration of titrated WT1-D13.1.1 scTv that show 
that the WT1-D13.1.1 scTv only bound to the WT1-loaded T2 cells and not to controls. Data is 
representative of n=2. 
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Tables 
Sort Conditions 
1 
Thermo Scientific hVβ3.1 FITC (1:10) 
AlexaFluor 647 goat anti-mouse IgG (1:100) 
AND 
Beckman Coulter hVβ3 FITC IgM (1:10) 
Goat anti-mouse IgM APC (1:4) 
2 
Thermo Scientific hVβ3.1 FITC (1:10) 
AlexaFluor 647 goat anti-mouse IgG (1:100) 
AND 
Beckman Coulter hVβ3 FITC IgM (1:10) 
Goat anti-mouse IgM APC (1:4) 
3 
Thermo Scientific hVβ3.1 FITC (1:10) 
AlexaFluor 647 goat anti-mouse IgG (1:100) 
AND 
Beckman Coulter hVβ3 FITC IgM (1:10) 
Goat anti-mouse IgM APC (1:4) 
 
 
Table 3.1 | Sorting conditions for selection of stable scTv variants from WT1 error-prone libraries. 
The antibodies and dilutions used are indicated for selection of stable variants from the WT1-P20 and 
WT1-P22 error-prone libraries. 
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Sort Conditions 
1 100 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG (1:100) 
2 100 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
3 100 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
4 100 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
5 200 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
 
 
Table 3.2 | Sorting conditions for selection of scTv variants with improved affinities for WT1/HLA-
A2. The concentrations of soluble WT1/HLA-A2-Ig dimer and secondary antibody used are indicated for 
selections of the WT1-wt/D13/D15 CDR1α affinity maturation library.  
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Sort Conditions 
1 100 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
2 100 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
3 10 nM WT1/HLA-A2-Ig dimer (DimerX; BD Pharmingen) AlexaFluor 647 goat anti-mouse IgG 
 
 
Table 3.3 | Sorting conditions for selection of scTv variants with high-affinity binding to WT1/HLA-
A2. The concentrations of soluble WT1/HLA-A2-Ig dimer and secondary antibody used are indicated for 
selections of the WT1-D13.1 CDR3 affinity maturation libraries. 
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CHAPTER FOUR 
 
 
 
ENGINEERING DESIGNER T CELL RECEPTORS THROUGH THE USE OF SINGLE-
CHAIN T CELL RECEPTOR SCAFFOLDS1 
 
 
Abstract 
Binding of a T cell receptor (TCR) to a peptide/major histocompatibility complex 
(pepMHC) is the key interaction involved in antigen specificity of T cells. The recognition 
involves up to six complementarity determining regions (CDR) of the TCR. Efforts to 
examine the structural basis of these interactions, and to exploit them in adoptive T cell 
therapies, has required the isolation of specific T cell clones and their clonotypic TCRs. 
Here we describe a strategy using in vitro, directed evolution of a single TCR to change 
its peptide specificity, thereby avoiding the need to isolate T cell clones. The human 
TCR A6, which recognizes the viral peptide Tax in complex with HLA-A2, was converted 
to TCR variants that recognized the cancer peptide MART1/HLA-A2. Mutational studies 
and molecular dynamics simulations identified CDR residues that were important in the 
specificity switch. Thus, in vitro engineering strategies alone can be used to discover 
TCRs with desired specificities. 
 
                                            
1Smith S.N., Wang Y., Baylon J.L., Singh N.K., Baker B.M., Tajkhorshid E., & Kranz D.M. Changing the 
peptide specificity of a human T cell receptor by directed evolution. 2014. In revision. 
 
Authors’ contribution statement: S.N.S. designed and performed experiments and Rosetta-based 
computational modeling under the guidance of D.M.K. J.L.B. and Y.W. designed and performed molecular 
dynamics simulations under the guidance of E.T. N.K.S. performed an independent SPR study under the 
guidance of B.M.B. Data interpretation, manuscript preparation, and manuscript editing were performed 
by all the authors. 
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Introduction 
Heterodimeric αβ T cell receptors are responsible for recognizing antigenic 
peptides presented in the context of a product of the major histocompatibility complex 
(MHC) on the surface of antigen presenting cells (APCs). The interaction of a TCR and 
a peptide/MHC (pepMHC) can drive the T cell into various states of activation, 
depending on the affinity (or dissociation rate) of binding. This recognition also operates 
during thymic development of a T cell in a process that selects for T cells with TCRs that 
bind with low affinity to self pepMHC complexes (positive selection), but deletes T cells 
with TCRs that bind too strongly to self pepMHC complexes (negative selection or 
tolerance)1,2. T cells exported to the periphery are thus positioned to discriminate 
between a normal, healthy cell and one that expresses aberrant pepMHC due to an 
infectious agent such as a virus or due to cell transformation to a cancerous state. 
TCRs contain six complementarity determining regions (CDRs), three (CDR1, 
CDR2, and CDR3) in each α and β chain, that are involved in binding pepMHC ligands. 
Based on the solved TCR:pepMHC structures3,4, a common diagonal docking 
orientation positions the TCR such that the CDR1 and CDR2 loops encoded by the 
germline variable (V) region genes are typically positioned over the helices of the MHC. 
The CDR3 loops of each chain are encoded by nucleotides at the junctions of 
somatically rearranged gene segments, and these hypervariable regions are 
appropriately positioned over the peptide (reviewed in3,4). Although it was originally 
thought that peptide specificity was determined in large part through interactions of 
CDR3 loops with the peptide, many studies have suggested that antigen specificity is 
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more complex. For example, in an early study of I-EK-restricted TCRs that recognized 
distinct peptides, transplantation of CDR3 loops was not sufficient to confer peptide 
reactivity, even when the same Vα chains were used by the two TCRs5. Based on 
current thinking, specificity in the TCR:pepMHC interaction can occur through various 
mechanisms, including: 1) residues in the germline-encoded CDR1 loops that make 
direct contact with peptide6-9, (2) CDR1 and CDR2 contacts with MHC that yield peptide-
specific interactions indirectly by altering MHC contact with the peptide4,10, (3) CDR3 
loops that modulate contacts between CDR1/CDR2 residues and MHC11-14, and (4) 
peptide influences that impact MHC interactions with CDR1, CDR2, or even CDR3 
residues15-17. 
Given the complexity of interloop interactions among CDRs, it is difficult to use 
computational approaches to predict the basis of peptide specificity by TCRs, let alone 
to design TCRs with novel specificties de novo. Directed evolution has been used to 
engineer TCRs with large improvements in binding affinity, while mantaining antigen 
specificity18-23. These studies have frequently targeted CDR3 regions for mutagenesis to 
accomplish affinity maturation, but mutations in CDR1 and CDR2 loops have also 
yielded improvements in affinity while mantaining peptide specificity20-22,24. Furthermore, 
computational approaches have been used to guide improvements in TCR affinity, with 
only subtle effects on specificity25-28.  
Although affinity maturation of TCRs has been achieved, there have not been 
reports in which the specificity of a TCR has been changed to a completely different 
peptide using directed evolution (i.e., from the cognate peptide to a non-cognate 
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peptide). Here we describe the successful in vitro engineering of the human TCR A6 
that recognizes a cognate nonameric peptide from the viral protein Tax, converting the 
TCR to one that specifically recognizes a non-cognate decameric peptide from the 
melanoma antigen MART1. A6 TCR residues in CDR loops that were predicted to be 
nearest the non-cognate peptides in structural models were mutated in yeast display 
libraries. A6 TCR libraries that contained degenerate residues in CDR1α, CDR3α, 
and/or CDR3β were selected with MART1/HLA-A2. One of the MART1-specific TCRs 
was further affinity matured to an affinity (KD) of about 100 nM. While some of the 
MART1-selected TCRs lost detectable binding to the cognate antigen, Tax, another 
class of selected-TCRs were peptide non-specific. Modeling of the highly-restricted CDR 
residues present in these clones suggests that they acted by enhancing interactions 
with HLA-A2 helices. 
To examine the underlying basis of the peptide specificity switch, we used site-
directed mutagenesis and comparative molecular dynamics simulations. These findings 
reveal how multiple residues across different CDRs could act in concert to generate 
peptide specificity. More generally, the study shows that it is possible to use directed 
evolution and in vitro approaches to engineer TCRs with alternative specificities, 
opening the possibility for rapid discovery of TCRs against a large array of cancer, viral 
and autoimmune antigens. 
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Materials & Methods 
Antibodies, pepHLA-A2, and flow cytometry reagents 
Antibodies and streptavidin-conjugates used to detect yeast surface expression 
included: anti-HA epitope tag (Clone HA.11; Covance), anti-c-myc epitope tag (A21281; 
Molecular Probes), goat anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody 
(Molecular Probes), goat anti-chicken IgG (H+L) Alexa Fluor 488 and 647 secondary 
antibodies (Molecular Probes), and streptavidin-phycoerythrin (SA-PE, BD 
Pharmingen). Peptides that bind to HLA-A2 [Tax11 – 19: LLFGYPVYV, MART126–35 A27L: 
ELAGIGILTV, WT1126-134: RMFPNAPYL, Survivin95–104: LTLGEFLKL, Survivin95-104 T2M: 
LMLGEFLKL, SL9/HIVgag77-85: SLYNTVATL, NYESO-Val157 – 165: SLLMWITNV, 
preproinsulin15-24: ALWGPDPAAA, Tel1p549–557: MLWGYLQYV, MDM253-60:VLFYLGQY, 
HBV_Env183–191: FLLTRILTI, and gp100209–217: ITDQVPFSV] were synthesized by 
standard F-moc (N-(9-fluorenyl)methoxycarbonyl) chemistry at the Macromolecular 
Core Facility at Penn State University College of Medicine (Hershey, PA, USA). 
Additionally, a UV cleavable peptide, KILGFVFJV, where J is the photolabile amino acid 
residue prepared by standard Fmoc-peptide solid phase synthesis using commercially 
available Fmoc-3-amino-3-(2-nitro)phenyl propionic acid as a building block, was 
synthesized at the University of Illinois Protein Sciences Facility as previously 
described29,30.  
HLA-A2 reagents include recombinant soluble dimeric HLA-A2-Ig fusion protein 
(BD DimerX), and expressed and refolded HLA-A2 monomers and tetramers. HLA-A2 
heavy chain was expressed as inclusion bodies in E. coli and refolded in vitro with a 
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UV-cleavable HLA-A2 binding peptide and human β-2 microglobulin as previously 
described8,29-31. The HLA-A2 heavy chain contained a biotinylation substrate sequence 
for in vitro biotinylation (Avidity, BirA enzyme). Peptide exchange with HLA-A2-biotin 
monomers containing the UV-cleavable peptide was achieved by exposure to UV light in 
the presence of excess peptide29,30. Monomers were converted to tetramers by 
incubation at a 4:1 molar ratio of HLA-A2 monomer:SA-PE. Staining of yeast cells (106) 
was performed on ice for 45-60 minutes, cells were washed with PBS/BSA (1%), and 
analyzed by flow cytometry with an Accuri C6 flow cytometer. 
 
A6 RD1, RD1.5, and RD2 library design 
Candidate residues for degeneracy were determined by measuring which CDR 
loop positions would be most likely to allow for contacts with a variety of non-cognate 
peptides using Rosetta Backrub flexible backbone modeling algorithms 
(https://kortemmelab.ucsf.edu/backrub/)32,33. Using the wild-type (wt) and high-affinity 
(c134) A6:Tax peptide/HLA-A2 crystal structures (PDB: 1AO7 and 4FTV, 
respectively)8,34 as input, Rosetta was used to model HLA-A2 restricted MART1 
peptides [MART126–35 A27L: ELAGIGILTV (called “MART1” unless otherwise specified), 
MART127-35: AAGIGILTV, and MART127-35 A28L: ALGIGILTV] and peptides WT1: 
RMFPNAPYL, SL9/HIV-gag: SLYNTVATL, and Survivin: LTLGEFLKL using the Rosetta 
Multiple Mutation Mutagenesis Module33. For modeling purposes, the residue at position 
“0” of the MART126–35 A27L 10-mer peptide was omitted from the prediction. Mutated 
residues were given a 10Å radius of effect for the flexible backbone modeling. PyMOL 
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was used to visualize and examine overlays of the lowest energy conformation of each 
model (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC)35, 
and CDR loop residues that were within hydrogen boding distance (2.5-3.5 Å) of the 
MART126–35 A27L peptide residues were identified. Based on these models, the frequency 
of residues within this distance was used to select five residue positions for codon 
degeneracy (NNS) using the A6-X15 scTCR, that contains stabilizing mutations for the 
display on the surface of yeast, as a template36. Residue numbering is consistent with 
crystal structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 
4FTV)34. 
An intermediary library (RD1.5) was designed based on the same Rosetta 
models used to guide the generation of the RD1 library. Five degenerate positions 
(NNS) included the TCRα positions Q30, T98, D99 and S100, and TCRβ position L98. 
In this library the four adjacent CDR3β loop residues in positions 99-102 of the A6-X15 
scTCR were reverted to the wild-type A6 residues (AGGR) and were not varied. 
Additionally, the arginine at position 27 in CDR1α was mutated to alanine as Rosetta 
models suggested it could cause potential steric and/or electrostatic clashes if bulkier 
residues were selected residues at nearby degenerate positions. Alanine-scanning of 
the R27α of the A6-X15 scTCR only led to a 3-fold change in binding with Tax/HLA-A2 
(Chapter 2)23. 
A second generation library (RD2) was based on visual inspection of the A6:Tax 
(LLFGYPVYV)/HLA-A2 crystal structure, selecting residues that were in close proximity 
to MART1 (ELAGIGILTV)/HLA-A2 and WT1 (RMFPNAPYL)/HLA-A2 in the overlaid 
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crystal structures. In RD2, five codon positions (TCRα D26, G28, S100, and W101; 
TCRβ L98) were made degenerate (NNK) with significant variance from the RD1 library. 
Positions D26α and G28α were chosen primarily due to their proximity (< 3.5 Å) to the 
R1 position of the WT1 peptide in the overlaid structures, and the S100α position was 
chosen due to its proximity (< 1Å) to the N5 position of the WT1 peptide in the overlaid 
structure. The W101α was varied as MD data had suggested that this position, if 
altered, could allow for more loop flexibility. Finally the L98β was varied as it participates 
in a key interaction driving the affinity and specificity of A6 for Tax. Based on results of 
RD1 library selections, TCRα residue 30 was generated as a binary position (wild-type 
glutamine or selected threonine) and positions 99-102 in CDR3β, were also binary (wild-
type A6 residues AAGR or high-affinity A6-X15 MSAQ). 
 
Generation, display, and selection of RD1, RD1.5, and RD2 yeast display libraries  
The A6 libraries were expressed in the yeast display plasmid pCT302 (in 
orientation Vβ-L-Vα)37,38. The RD1 and RD1.5 libraries were synthesized by Genscript 
(Piscataway, NJ, USA), and the RD2 library by DNA2.0 (Menlo Park, CA, USA) using 
A6-X15 as a template, which included five framework mutations (S33A, E59D, N62D, 
N66K, K120I, all in the Vβ domain) and two CDR mutations (A52V and Q106L, both in 
the Vβ domain) that were isolated previously in a stability screen of the scTCR36. The 
RD1 library also contained four CDR3β mutations (A99M, G100S, G101A, and R102Q) 
that yielded higher affinity binding to Tax/HLA-A220. The RD1.5 library also had a TCRα 
R27A mutation that did not reduce binding substantially in a panel of Vα2-containing 
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high-affinity scTCRs (Chapter 2)23. All library constructs consisted of the variable TCR 
fragments attached by the linker region GSADDAKKDAAKKDGKS36,39-41 using the A6-
X15 scTCR36 as a template. N-terminal HA and C-terminal c-myc epitope tags were 
added flanking the scTv gene to monitor for expression.  
The RD1 library was synthesized by Genscript (Piscataway, NJ, USA) with an 
added C-terminal c-myc epitope tag, where regions indicated by “X” were made 
degenerate by NNS codons and “*” indicates a stop codon: 
NAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMAWYRQDPGMGLRLIHYSVGVGITD
QGDVPDGYKVSRSTTEDFPLRLLSAAPSQTSVYFCASRPGXMSXQPELYFGPGTRLTV
TEDLINGSADDAKKDAAKKDGKSQKEVEQNSGPLSVPEGAIASLNCTYSDRGSXSFFW
YRQYSGKSPELIMSIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVTXX
SWGKLQFGAGTQVVVTPDEQKLISEEDL**. The gene was codon optimized for both 
yeast and E. coli with 5' sequence TCT GCT AGC and 3' sequence CTC GAG ATC 
TGA.  
For homologous recombination in yeast, pCT302 overhangs were added to the 
synthesized RD1 library using forward primer 5’-CAG GCT AGT GGT GGT GGT GGT 
TCT GGT GGT GGT GGT TCT GGT GGT GGT GGT TCT GCT AGC AAT GCT GGT 
GTA ACA CAA ACG CCA A-3’ and reverse primer 5’-GGA ACA AAG TCG ATT TTG 
TTA CAT CTA CAC TGT TGT TAA CAG ATC TCG AGT CAT TAT AAA TCT TCT TCA 
GAG ATC-3’. Yeast libraries were generated by homologous recombination in EBY100 
yeast by electroporation of PCR products along with NheI and XhoI digested yeast 
display plasmid, pCT30242-45. The resultant library size for RD1 was 6 X 106 .  
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The RD1 library was induced in galactose-containing media (SG-CAA) for 48 
hours, washed with 1 mL 1% PBS/BSA and stained with the following: Tax 
(LLFGYPVYV), MART1 (ELAGIGILTV), or WT1 (RMFPNAPYL) peptide/HLA-A2-Ig 
dimers, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100). Cells 
were washed (1 ml, 1% PBS/BSA), and the most fluorescent cells were selected using a 
FACS Aria (BD Bioscience). Selections were performed with Tax/HLA-A2-Ig dimer (sort 
1: 20 nM, sorts 2-4: 10 nM), MART1/HLA-A2-Ig dimer (sorts 1-2: 500 nM, sorts 3-4: 100 
nM, sort 5: 20 nM), and WT1/HLA-A2-Ig dimer (sorts 1-2: 500 nM, sorts 3-4: 100 nM). 
During the 3rd sort with MART1/HLA-A2 and WT1/HLA-A2, yeast cells were also 
stained with chicken anti-c-myc antibody, goat anti-chicken IgY AlexaFluor 488 
secondary antibody and double positives were isolated in order to exclude truncated 
clones. Expression was monitored with an anti-HA epitope tag (1:50), goat-anti-mouse 
IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100), and anti-cmyc (1:50), goat-anti-
chicken IgG (H+L) AlexaFluor 488 or 647 secondary antibody (1:100).  
The RD1.5 Library was synthesized by Genscript (Piscataway, NJ, USA) with an 
added C-terminal c-myc epitope tag, where regions indicated by “X” were made 
degenerate by NNS codons and “*” indicates a stop codon: 
NAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMAWYRQDPGMGLRLIHYSVGVGITD
QGDVPDGYKVSRSTTEDFPLRLLSAAPSQTSVYFCASRPGXAGGRPELYFGPGTRLTV
TEDLINGSADDAKKDAAKKDGKSQKEVEQNSGPLSVPEGAIASLNCTYSDAGSXSFFW
YRQYSGKSPELIMSIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVTXX
XWGKLQFGAGTQVVVTPDEQKLISEEDL**.  
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The gene was codon optimized for both yeast and E. coli, and the following 
flanking DNA sequences were added which contained overlap with the T7 and Splice4L 
cloning primers. N-terminal DNA sequence: 5’ – GGC AGC CCC ATA AAC ACA CAG 
TAT GTT TTT AAG GAC AAT AGC TCG ACG ATT GAA GGT AGA TAC CCA TAC 
GAC GTT CCA GAC TAC GCT CTG CAG GCT AGT GGT GGT GGT GGT TCT GGT 
GGT GGT GGT TCT GGT GGT GGT GGT TCT GCT AGC – 3’, and C-terminal DNA 
sequence: 5’ – CTC GAG ATC TGT TAA CAA CAG TGT AGA TGT AAC AAA ATC 
GAC TTT GTT CCC ACT GTA CTT TTA GCT CGT ACA AAA TAC AAT ATA CTT TTC 
ATT TCT CCG TAA ACA ACA TGT TTT CCC ATG TAA TAT CCT TTT CTA TTT TTC 
GTT CCG TTA CCA ACT TTA CAC ATA CTT TAT ATA GCT ATT CAC TTC TAT ACA 
CTA AAA AAC TAA GAC AAT TTT AAT TTT GCT GCC TGC CAT ATT TCA ATT TGT 
TAT AAA TTC CTA TAA TTT ATC CTA TTA GTA GCT AAA AAA AGA TGA ATG TGA 
ATC GAA TCC TAA GAG AAT TGA GCT CCA ATT CGC CCT ATA GTG AGT CGT 
ATT A. The delivered PCR product was amplified by PCR using the Splice4L and T7 
primers, and yeast libraries were generated by homologous recombination in EBY100 
yeast as described above42-45. The resultant library size for RD1.5 was 1.4 X 107.  
The RD1.5 library was induced in galactose-containing media (SG-CAA) for 48 
hours, washed with 1 mL 1% PBS/BSA, and stained with the following: Tax 
(LLFGYPVYV), MART1 (ELAGIGILTV), WT1 (RMFPNAPYL), Survivin (LTLGEFLKL), 
preproinsulin (PPI) (ALWGPDPAAA), and NYESO-Val (SLLMWITNV) peptide/HLA-A2-
Ig dimers, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100). 
Cells were washed (1 ml, 1% PBS/BSA), and the most fluorescent cells were selected 
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using a FACS Aria (BD Bioscience). Selections were performed with Tax/HLA-A2-Ig 
dimer, MART1/HLA-A2-Ig dimer, and WT1/HLA-A2-Ig dimer (sorts 1-2: 200 nM, sorts 3-
4: 100 nM); and Survivin/HLA-A2-Ig dimer, preproinsulin/HLA-A2-Ig dimer, and NYESO-
Val/HLA-A2-Ig dimer (sorts 1-4: 200 nM). Expression was monitored with anti-HA 
epitope tag (1:50), goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody 
(1:100), and anti-cmyc (1:50), goat-anti-chicken IgG (H+L) AlexaFluor 488 or 647 
secondary antibody (1:100). No clones with novel binding specificities were isolated 
during this screening progression. 
The RD2 Library was synthesized by DNA2.0 (Menlo Park, CA, USA), where 
positions indicated by “X” were made degenerate by NNK codons, the positions labeled 
“1234” were binary allowing for A6 wild-type CDR3β loop AGGR or A6-X15 CDR3β loop 
MSAQ, the position indicated by “#” was binary allowing for either wild-type residue 
glutamine or mutated threonine, and positions indicated by “*” were stop codons:  
NAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMAWYRQDPGMGLRLIHYSVGVGITD
QGDVPDGYKVSRSTTEDFPLRLLSAAPSQTSVYFCASRPGX1234PELYFGPGTRLTVT
EDLINGSADDAKKDAAKKDGKSKEVEQNSGPLSVPEGAIASLNCTYSXRXS#SFFWYR
QYSGKSPELIMSIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVTTDXX
GKLQFGAGTQVVVTPDIEQKLISEEDL**.  
The gene was codon optimized for yeast and the following flanking DNA 
sequences were added which contained overlap with the T7 and Splice4L cloning 
primers: N-terminal DNA sequence: 5’ – GGC AGC CCC ATA AAC ACA CAG TAT GTT 
TTT AAG GAC AAT AGC TCG ACG ATT GAA GGT AGA TAC CCA TAC GAC GTT 
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CCA GAC TAC GCT CTG CAG GCT AGT GGT GGT GGT GGT TCT GGT GGT GGT 
GGT TCT GGT GGT GGT GGT TCT GCT AGC – 3’, and C-terminal DNA sequence: 5’ 
– CTC GAG ATC TGT TAA CAA CAG TGT AGA TGT AAC AAA ATC GAC TTT GTT 
CCC ACT GTA CTT TTA GCT CGT ACA AAA TAC AAT ATA CTT TTC ATT TCT CCG 
TAA ACA ACA TGT TTT CCC ATG TAA TAT CCT TTT CTA TTT TTC GTT CCG TTA 
CCA ACT TTA CAC ATA CTT TAT ATA GCT ATT CAC TTC TAT ACA CTA AAA AAC 
TAA GAC AAT TTT AAT TTT GCT GCC TGC CAT ATT TCA ATT TGT TAT AAA TTC 
CTA TAA TTT ATC CTA TTA GTA GCT AAA AAA AGA TGA ATG TGA ATC GAA TCC 
TAA GAG AAT TGA GCT CCA ATT CGC CCT ATA GTG AGT CGT ATT A. The 
delivered PCR product was amplified via PCR using the Splice4L and T7 primers, and 
yeast libraries were generated by homologous recombination in EBY100 yeast as 
described above42-45. The resultant library size for RD2 was 2.4 X 108.  
The RD2 library was induced in galactose-containing media (SG-CAA) for 48 
hours, washed with 25 mL 1% PBS/BSA and stained with 5 µM Tax (LLFGYPVYV), 
MART1 (ELAGIGILTV), or WT1 (RMFPNAPYL)/HLA-A2 UV-exchanged HLA-A2 
monomers29,30. Magnetic bead selections were performed utilizing streptavidin MACS 
microbeads (Miltenyl Biotec), for a total of two selections using MACS LS columns on a 
QuadroMACS™ Separator (Miltenyl Biotec). Following two selections, the selected 
libraries were stained with the following: selecting peptide (Tax, MART1, or WT1)/HLA-
A2-Ig dimer, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100). 
Cells were washed (1 ml, 1% PBS/BSA), and the most fluorescent cells were selected 
using a FACS Aria (BD Bioscience) high-speed sorter. Selections were performed with 
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1 nM and 100 nM peptide/HLA-A2 for selecting cognate antigen Tax, and selecting, 
non-cognate antigens MART1 (ELAGIGILTV) or WT1 (RMFPNAPYL)/HLA-A2, 
respectively. Expression was monitored with anti-HA epitope tag (1:50), goat-anti-
mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100), and anti-cmyc (1:50), 
goat-anti-chicken IgG (H+L) AlexaFluor 647 secondary antibody (1:100). 
Finally, in order to determine whether any additional clones with redirected 
specificities could be isolated from the three libraries described (RD1, RD1.5, and RD2), 
a combined selection was performed where the RD1, RD1.5 and RD2 libraries were 
combined in equal cell numbers adjusted for library diversity and selected with a panel 
of peptide/HLA-A2 antigens. In order to eliminate clones that bound to the cognate 
ligand, Tax/HLA-A2, the library population was stained with Tax/HLA-A2 monomers (5 
µM) for 1 hour prior to adding anti-biotin MACS microbeads (Miltenyl Biotec) according 
to the manufacturer’s protocol and negatively selected with a MACS LS column on a 
QuadroMACS™ Separator (Miltenyl Biotec). Cells in the filtrate were expanded and an 
additional negative selection was performed with streptavidin MACS microbeads 
(Miltenyl Biotec) for a total of two negative selections. Negatively-selected cell 
populations were then subjected to positive selections with a panel of peptide/HLA-A2 
antigens which included the following: WT1 (RMFPNAPYL), SL9/HIVgag (SLYNTVATL), 
Survivin-T2M (LMLGEFLKL), NYESO-Val (SLLMWITNV), preproinsulin 
(ALWGPDPAAA), MDM2 (VLFYLGQY), Tel1p (MLWGYLQYV), and HBV Env 
(FLLTRILTI)/HLA-A2 monomers for 2-3 additional selections with 2-5 µM peptide/HLA-
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A2 monomers and alternating streptavidin and anti-biotin MACS microbeads (Miltenyl 
Biotec). No novel cross-reactive clones were isolated in this progression.  
 
Generation, display, and selection of RD-MART1 CDR3 yeast display libraries 
CDR3 libraries were generated by splicing by overlap extension (SOE) PCR 
spanning 5 adjacent codons at a time (two libraries in the CDR3β loop spanning 
residues 97-101 and 99-103; one library in the CDR3α loop spanning residues 98-
102)46 using the RD1-MART1 scTCR clone selected from the RD1 library as a template. 
For the affinity maturation of the RD1-MART1 TCR, pre-SOE PCR products were 
generated for each of the four libraries utilizing the following primer pairs. β1: 5'- GGC 
AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) and 5'- CGG ACG GGA AGC GCA 
GAA ATA CAC TGA GGT TTG AGA AGG TGC AGC GCT TAA CAG ACG CAG CGG -
3', and 5'- ACC TCA GTG TAT TTC TGC GCT TCC CGT CCG NNK NNK NNK NNK 
NNK CAG CCT GAA CTG TAC TTT GGT CCA GGC ACT AGA C -3' and 5'- TAA TAC 
GAC TCA CTA TAG GG -3' (T7); β2: Splice 4L and 5'- CGG ACG GGA AGC GCA GAA 
ATA CAC TGA GGT TTG AGA AGG TGC AGC GCT TAA CAG ACG CAG CGG -3', and 
5'- ACC TCA GTG TAT TTC TGC GCT TCC CGT CCG GGT TGG NNK NNK NNK NNK 
NNK GAA CTG TAC TTT GGT CCA GGC ACT AGA CTG ACC G -3' and T7; α: Splice 
4L and 5'- CGT AAC CGC GCA CAA GTA TGT GGC CGA ATC GGA AGG CTG GGA 
GTC ACG AAT CAG CAA ACT AAC ATA CTG GC -3', and 5'- TCC GAT TCG GCC 
ACA TAC TTG TGC GCG GTT ACG NNK NNK NNK NNK NNK AAA CTG CAA TTT 
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GGT GCG GGC ACC CAG GTT GTG G -3' and T7. SOE PCR was performed with each 
corresponding pre-SOE along with both T7 and Splice 4L for each library.  
Yeast libraries were generated by homologous recombination in EBY100 yeast 
as described above42-45. Library diversity was confirmed at all 5 degenerate positions 
following sequencing of 6 clones from each library. The resultant library sizes were β1: 
2.1 X 107, β2: 1.7 X 107, and α: 1.1 X 107. Libraries were pooled in equal cell numbers 
in ratios reflecting relative diversity and expanded in SD-CAA media. 
The combined library was induced in galactose-containing media (SG-CAA) for 
48 hours, washed with 1 mL 1% PBS/BSA, and stained with MART1 
(ELAGIGILTV)/HLA-A2-Ig dimer, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary 
antibody (1:100). Cells were washed (1 ml, 1% PBS/BSA), and the most fluorescent 
cells were selected using a FACS Aria (BD Bioscience) high-speed sorter. Selection 
was performed with MART1/HLA-A2 (ELAGIGILTV)/HLA-A2-Ig dimer (sort 1: 200 nM, 
sort 2: 1 nM). Expression was monitored with anti-HA epitope tag (1:50), goat-anti-
mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100), and anti-cmyc (1:50), 
goat-anti-chicken IgG (H+L) AlexaFluor 647 secondary antibody (1:100). 
 
Generation, display, and selection of RD2-WT1 yeast display libraries 
 Following the third selection of the RD2 library with WT1/HLA-A2, two additional 
selections were performed prior to generating the RD2-WT1 yeast display libraries 
(described below). First, a negative FACS selection was performed by incubating the 
induced cell population with 200 nM Tax/HLA-A2-Ig dimer, goat-anti-mouse IgG F(ab’)2 
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AlexaFluor 647 secondary antibody (1:100) and isolating cells that were negative for 
staining (i.e. sort 4). Next, a positive FACS selection with 200 nM WT1/HLA-A2-Ig 
dimer, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 secondary antibody (1:100) was 
performed (i.e. sort 5). Clones isolated from these two additional selection steps were all 
cross-reactive with the three pepMHC complexes tested (Tax/HLA-A2, MART1/HLA-A2, 
and WT1/HLA-A2) and contained scTCR sequences that resembled the cross-reactive 
clones examined after the third selection of the RD2 library (Fig. 4.2 and data not 
shown). 
Several cross-reactive clones were used as templates to generate degenerate 
libraries based on NNK nucleic acid composition in the CDR3β positions 98-102. These 
included two clones isolated from the 3rd sort of the RD2 library (RD2-WT1-S3-1 and 
RD2-WT1-S3-5) and one clone isolated following the 5th sort of the RD2 library (RD2-
WT1-S5-2). To generate libraries, pre-SOE PCR products were generated utilizing the 
following primer pairs. 5'- GGC AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) and 
5’ – GCC AGG TCT TGA AGC GCA AAA GTA GAC AGA AGT TTG AGA TGG TGC 
TGC GGA CAA TAA TCT AAG AGG – 3’, and 5’- CT GTC TAC TTT TGC GCT TCA 
AGA CCT GGC NNK NNK NNK NNK NNK CCA GAA CTC TAC TTC GGG CCA GGA 
ACT AGA TTA ACC G – 3’ and 5'- TAA TAC GAC TCA CTA TAG GG -3' (T7). SOE 
PCR was performed with each corresponding pre-SOE along with both T7 and Splice 4L 
for each library.  
Yeast libraries were generated by homologous recombination in EBY100 yeast 
as described above42-45. Library diversity was confirmed at all 5 degenerate positions 
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following sequencing of 10 clones, and the resultant library size was 7.2 X 106. The 
library was induced in galactose-containing media (SG-CAA) for 48 hours, washed with 
25 mL 1% PBS/BSA, and stained with 5 µm Tax UV-exchanged HLA-A2 monomers29,30. 
Negative selections were performed utilizing MACS microbeads (Miltenyl Biotec), for a 
total of two selections using streptavidin beads for the first selection and anti-biotin 
beads for the second using MACS LS columns on a QuadroMACS™ Separator (Miltenyl 
Biotec). Following negative selections, two positive selections were performed by 
staining with 5 µm MART1/HLA-A2 or WT1/HLA-A2 UV-exchanged HLA-A2 monomers, 
followed by incubation with streptavidin (1st selection) or anti-biotin (2nd selection) MACS 
microbeads (Miltenyl Biotec) and passing through MACS LS columns on a 
QuadroMACS™ Separator (Miltenyl Biotec). Following positive selections, one final 
negative selection was performed with 5 µM Tax/HLA-A2 monomers and streptavidin 
beads as before. Individual clones isolated following the final selection were stained 
individually, and plasmids were sequenced. As before, all isolated clones were cross-
reactive with all three pepMHCs. 
 In a further attempt to reverse engineer RD2-WT1 isolates for WT1-specificity, 
RD2-WT1 isolated clones used for the CDR3β library (RD2-WT1-S3-1, RD2-WT1-S3-5, 
and RD2-WT1-S5-2) were used in combination with the non-truncated cross-reactive 
clones isolated from the selections of the RD2-WT1-CDR3β library with MART1 and 
WT1/HLA-A2 for templates for the RD2-WT1-CDR1α and RD2-WT1-CDR3α libraries. 
The RD2-WT1-CDR1α library was degenerate based on NNK nucleic acid composition 
at positions D27 and G29 (amino acid from wild-type sequence), and the RD2-WT1-
 180 
CDR3α library was degenerate based on NNK nucleic acid composition at positions S99 
and W100 (amino acid from wild-type sequence). To generate the libraries, pre-SOE 
PCR products were generated utilizing the following primer pairs. CDR1α: 5'- GGC AGC 
CCC ATA AAC ACA CAG TAT -3' (Splice 4L) and 5’ – TGA GTA AGT ACA ATT CAA 
ACT AGC TAT CGC CCC TTC TGG AAC AGA TAG TGG ACC GGA GTT CTG – 3’, 
and 5’ – GCG ATA GCT AGT TTG AAT TGT ACT TAC TCA NNK AGA NNK TCT ACT 
TCC TTT TTC TGG TAC AGA CAA TAT TCT GG – 3’ and 5'- TAA TAC GAC TCA CTA 
TAG GG -3' (T7); CDR3α: 5'- GGC AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) 
and 5’ – ATC TGT CGT CAC CGC ACA CAA ATA AGT AGC TGA ATC AGA AGG TTG 
ACT ATC TCT TAT TAG C – 3’, and 5’ – GCT ACT TAT TTG TGT GCG GTG ACG 
ACA GAT NNK NNK GGC AAA TTA CAA TTC GGT GCT GGG ACC CAG GTG G – 3’ 
and 5'- TAA TAC GAC TCA CTA TAG GG -3' (T7). SOE PCR was performed with each 
corresponding pre-SOE along with both T7 and Splice 4L for each library. 
Yeast libraries were generated by homologous recombination in EBY100 yeast 
as described above42-45. Library diversity was confirmed at the degenerate positions 
following sequencing of six clones. The resultant library sizes were 3.5 X 107 for CDR1α 
and 3.6 X 107 for CDR3α. Libraries were pooled in equal cell numbers and expanded in 
SD-CAA media. The combined library was induced in galactose-containing media (SG-
CAA) for 48 hours, washed with 25 mL 1% PBS/BSA and stained with 5 µM Tax UV-
exchanged HLA-A2 monomers29,30. Negative selections were performed using MACS 
microbeads (Miltenyl Biotec), for a total of two selections using anti-biotin beads for the 
first selection and streptavidin beads for the second using MACS LS columns on a 
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QuadroMACS™ Separator (Miltenyl Biotec). Both the negatively selected library 
population and the unselected population were subjected to two positive selections by 
staining with 5 µM MART1/HLA-A2 or WT1/HLA-A2 UV-exchanged HLA-A2 monomers, 
followed by incubation with anti-biotin (1st selection) or streptavidin (2nd selection) MACS 
microbeads (Miltenyl Biotec) and passing through MACS LS columns on a 
QuadroMACS™ Separator (Miltenyl Biotec). Individual clones isolated following the final 
selections were stained individually, and plasmids were sequenced. 
 
Isolation and staining of high-affinity clones 
Following sorting with various selecting antigen, library colonies were isolated by 
plating limiting dilutions. Colonies were expanded and induced in galactose-containing 
media (SG-CAA) for 48 hours, washed with 1 mL 1% PBS/BSA and stained with various 
concentrations of peptide/HLA-A2-Ig dimer, goat-anti-mouse IgG F(ab’)2 AlexaFluor 647 
secondary antibody, or various concentrations of UV-exchanged peptide/HLA-A2 
monomers29,30, SA-PE. Cells were washed (1 ml, 1% PBS/BSA) and analyzed on an 
Accuri C6 flow cytometer. 
Plasmids were recovered using Zymoprep™ Yeast Plasmid Miniprep II Kit (Zymo 
Research) and introduced back into E. coli via heat shock transformation into 
Subcloning Efficiency™ DH5α™ Competent Cells (Invitrogen). E. coli cells were 
expanded and plasmids were isolated using QIAprep Spin Miniprep Kit (Qiagen). 
Sequences of individual clones were determined by Sanger sequencing.  
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Expression in E. coli, refolding, and biotinylation of soluble scTCR fragments 
RD1-MART1 and RD1-MART1HIGH were introduced into the pET28 expression 
vector with a C-terminal AviTag (Avidity) using NcoI and EcoRI restriction sites (forward 
primer: 5’ - TAT ACC ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC AGC 
GGC CTG GTG CCG CGC GGC AGC AAT GCT GGT GTA ACA CAA ACG CC - 3’, 
Reverse primer: 5’ - T TTA GAA TTC TTA TTC GTG CCA TTC GAT TTT CTG AGC 
CTC GAA GAT GTC GTT CAG ACC GCC ACC GTC TGG AGT GAC CAC AAC CTG 
GGT - 3’. Plasmids were transformed into the BL21-DE3 cell line (NEB), expanded, and 
induced for expression. Following induction, cells were passed through a microfluidizer 
(Microfluidics Corporation, Newton, MA, USA), inclusion bodies were isolated, and 
protein was purified as previously described47. Soluble scTCR were refolded and 
purified with Ni-NTA agarose resin (Qiagen, Valencia, CA) followed by gel filtration 
(Superdex 200, GE Healthcare). Folded scTCRs were biotinylated in vitro (Avidity, BirA 
enzyme). Biotinylation was verified by gel-shift with streptavidin by SDS-PAGE (data not 
shown). 
 
Binding of scTCR proteins measured by surface plasmon resonance  
The binding of purified refolded scTCR proteins to cognate peptide/HLA-A2 was 
monitored with surface plasmon resonance (SPR) using a Biacore 3000 instrument. 
Kinetic and equilibrium binding data were determined by immobilizing biotinylated 
peptide/MHC monomers on a neutravidin-coated CM5 sensor chip to 400-800 response 
units. A null peptide/MHC molecule was immobilized to the reference cell as a control. 
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Purified soluble scTCRs were diluted to various concentrations in Biacore buffer (10 mM 
HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Tween-20, pH 7.4) and flowed over the 
reference and experimental flow cells at 30 ml/min at 25°C. Binding of the scTCR to the 
null complex was subtracted from the scTCR binding to the experimental complex to 
correct for bulk shift and any non-specific binding. Additionally, data obtained from 
injections with no analyte were subtracted from each concentration. Curve fitting and 
determination of on-rates, off-rates and kinetic-based KD measurements were 
performed using BIAEvaluation 4.1.1 software. Equilibrium KD values were determined 
by calculating half-max values from non-linear regression analysis of plots of the 
maximum response units (RU) for each scTCR concentration. Values from repeated 
experiments were averaged and reported with standard deviations. For equilibrium SPR 
values in this orientation, n=3 for RD1-MART1 and n=2 for RD1-MART1HIGH. For kinetic 
SPR values in this orientation, n=1 for A6-X15 and RD1-MART1HIGH. 
Additionally an independent SPR experiment was performed in the reverse 
orientation (i.e. scTCR immobilized) to facilitate the use of multiple control pepMHC 
analytes. For this experiment, steady state binding was measured as previously 
described48. Experiments were performed at 25°C with solution conditions of 10 mM 
HEPES, 3 mM EDTA, 150 mM NaCl, 0.005% surfactant P20, pH 7.4. RD-MART1 and 
RD-MART1HIGH were coupled directly to the surface of a CM5 sensor chip via amine 
linkage to a density of approximately 1000 RU. Soluble MART1/HLA-A2, Tax/HLA-A2, 
and gp100/HLA-A2 were injected over the surface in a series of concentration points 
until steady state was attained. Each pepMHC concentration series was injected twice. 
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Data was processed in BiaEvaluation 4.1 and globally analyzed in Origin 7.5. Values 
from repeated experiments in both orientations were averaged and reported with 
standard deviations. 
 
Binding of scTCR fragments to peptide-pulsed APCs 
HLA-A2+ human cell line, T2 was incubated at 37°C for 2-3 hours with 1 μM 
MART1 (ELAGIGILTV) or Tax (LLFGYPVYV) peptide. Cells were washed with 1% 
PBS/BSA, and incubated on ice for 1 hour with biotinylated scTCR at various 
concentrations. Cells were again washed with 1% PBS/BSA, followed by incubation with 
SA-PE (1:100) for 30-45 min on ice. Cells were washed twice more and analyzed using 
an Accuri C6 Flow Cytometer. 
 
Site-directed mutagenesis of scTCRs 
Site-directed mutants at position 98 of TCRβ (A6-X15 L98W and L98M, RD1-
MART1 W98L, RD1-MART1HIGH W98L, and RD2-MART1-M98L) were made using a 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). Yeast cells 
displaying the single-site mutants were titrated with cognate-peptide exchanged HLA-A2 
SA-PE tetramers at 12.3 nM, 37.0 nM, 111 nM, 333 nM, and 1 µM and analyzed by flow 
cytometry. Values were normalized using non-linear regression analysis. Changes in 
binding affinity were approximated by determining the scTCR concentrations at one-half 
maximal wild-type binding. Independent experiments were performed with peptide/HLA-
A2-Ig dimers with similar results (data not shown).  
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Rosetta sequence tolerance 
 Rosetta sequence tolerance algorithms49,50 were used to predict the specificity of 
certain residues in the TCR:pepMHC interactions. The crystal structures for A6-c134 
(PDB: 4FTV) and DMF4 (PDB: 3QDG) were uploaded to the Rosetta server and used to 
generate an ensemble of 20 structures. Interacting partners taken into account of the 
sequence predictions included the TCRβ chain (chain E), peptide (chain C), and HLA-
A2 heavy chains (chain A), using self-interaction energies of 0.4, partner interacting 
energies of 1.0 and a Boltzmann Factor (kT) of 0.228, according to the published 
recommended values. The resultant frequencies are presented as a ranked list for the 
TCRβ positions indicated. 
 
Molecular dynamics simulations of A6 and modeled RD1-MART1  
 Four molecular complexes were modeled and simulated: A6:Tax/HLA-A2, 
A6:MART1/HLA-A2, RD1-MART1:Tax/HLA-A2, and RD1-MART1:MART1/HLA-A2. For 
A6:Tax/HLA-A2, the crystal structure of the high-affinity (c134) A6:Tax/HLA-A2 crystal 
structure (PDB: 4FTV)34 was used to construct the initial model for the simulation. The 
same crystal structure was also used as the template to model the RD1-
MART1:MART1/HLA-A2 complex, since no experimentally derived structure is currently 
available for this complex. However, given the presence of MART1/HLA-A2 in other 
crystal structures showing variable orientations between the TCR and MHC components 
[TCRs DMF5 (PDB: 3QDG)6, DMF4 (PDB: 3QDM)6, and Mel5 (PDB: 3HG1)7], four 
different orientations have been also modeled and simulated to investigate the 
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complexes that included MART1. These systems are referred to as the 4FTV/A6-c134, 
3QDG/DMF5, 3QDM/DMF4, and 3HG1/Mel5 orientations, respectively. 
In all the simulation systems that included Tax, the starting conformation was 
based on the crystal structure of A6-c134:Tax/HLA-A234 (PDB: 4FTV; denoted as the 
4FTV/A6-c134 orientation hereafter). The RD1-MART1 TCR structure was generated by 
introducing point mutations at respective sites in the A6-c134 TCR. The initial structures 
for Tax and MART1 peptides were taken from A6-c134:Tax/HLA-A2 (PDB: 4FTV)34 and 
DMF5:MART1/HLA-A2 (PDB: 3QDG)6 structures, respectively. An additional TCR-
pepMHC complex for A6-c134 was constructed starting from the A6 wild-type crystal 
structure (PDB entry 1AO7), by in silico mutation of positions 99-102 of the CDR3β loop 
(AGGR) to the A6-c134 sequence (MSAQ). In this system, the orientation of the TCR is 
similar to the 4FTV orientation, therefore this system is also considered to start from the 
4FTV/A6-c134 orientation. 
In order to reduce the size of the simulation system and thereby allow for better 
sampling and statistics of the dynamics and interactions at the interface, remote regions 
of MHC and TCR components were truncated. Thus, the MHC part was truncated to 
residues 1-182, and TCR α-and β-chain were truncated to residues 1-119 and 30-122, 
respectively. To preserve the binding orientation and scaffolding of the structures, 
positional restraints were applied at the truncation sites; in MHC, Cα atoms of residues 
30, 32, 96, 122, and 182 were harmonically restrained (force constant k = 1.0 
kcal/mol/Å2) to their initial positions in all the simulations. Additionally, backbone 
carbonyl carbons of residue 119 in CDRα and residue 122 in CDRβ were harmonically 
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restrained (force constant k = 1.0 kcal/mol/Å2) in the following simulations: A6-
c134:Tax/HLA-A2, A6-c134:MART1/HLA-A2 (4FTV/A6-c134 orientation), RD1-
MART1:Tax/HLA-A2 and RD1-MART1:MART1/HLA-A2 (4FTV/A6-c134 orientation), in 
order to preserve the binding orientation of the TCR subunit. 
All the simulations started from the 4FTV/A6-c134 orientation. Each simulation 
system was minimized for 1000 steps, followed by a 500-ps MD simulation under 
constant-volume, constant-temperature (NVT) conditions with all the backbone atoms 
restrained to their initial position (k = 10.0 kcal/mole/Å2). This was followed by a 4-ns 
MD simulation under constant pressure, constant temperature (NPT) conditions, during 
which the restraints were gradually decreased and eventually eliminated completely. 
After the initial equilibration phase, A6-c134:Tax/HLA-A2 and RD1-
MART1:Tax/HLA-A2 were simulated each for another 100 ns of production runs, while, 
A6-wt MSAQ was simulated for 40 ns of production run. For MART1 simulations, in 
addition to the 4FTV/A6-c134 orientation described above, three additional initial models 
were constructed and simulated. Bound MART1/HLA-A2 is present in several crystal 
structures in complex with other MART1/HLA-A2-specific TCRs, in which the docking 
orientation of the TCR on the pepMHC varies. In order to examine all experimentally 
observed orientations of MART1/HLA-A2 binding to MART1/HLA-A2-specific TCRs, in 
addition to the orientation based on the A6-c134:Tax/HLA-A2 structure (4FTV/A6-c134 
orientation), initial models representing orientations observed in PDB entries 3QDG6, 
3QDM6, and 3HG17, were also constructed using the protocol described below. We 
refer to these different orientations as 3QDG/DMF5, 3QDM/DMF4, and 3HG1/Mel5  
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 In order to generate the initial models for the three new orientations, in each case 
we started from the 4FTV/A6-c134 orientation described above. The model was then 
slowly morphed into the target orientation using biased simulations with system-specific 
collective variables (orientation quaternions)51. In the first step, a biasing potential with a 
force constant of k = 50,000 - 100,000 kcal/mol/radian2 was applied to the TCR subunit 
for 40 ns. This was then followed by a 60-ns relaxation simulation. In order to accelerate 
the relaxation to the new orientation, non-bonded interactions were scaled intermittently. 
The scaling factor was decreased from 1.0 to 0.8 and then increased back to 1.0, with a 
step size of 0.05. At each step, the structures were equilibrated for about 5 ns, followed 
by another 5 ns equilibration using a scaling factor 1.0. Once a relaxed structure was 
achieved, the systems were simulated for production runs: 100ns (for A6-
c134:MART1/HLA-A2 in the 4FTV/A6-c134 and 3QDG/DMF5 orientations), and 170ns 
(for RD1-MART1:MART1/HLA-A2 in the 4FTV/A6-c134, 3QDG/DMF5, 3QDM/DMF4, 
and 3HG1/Mel5 orientations). The A6-c134:MART1/HLA-A2 complex in the 3HG1/Mel5 
and 3QDM/DMF4 orientations was simulated for 50 ns only, since no significant binding 
interactions were evident for these complexes. 
System preparation was done using VMD52, and all the simulations were 
performed using NAMD53. CHARMM27 force field was used for protein and ions54. The 
simulations employed rigid bonds for bonds involving hydrogens (using SETTLE55 and 
RATTLE algorithms56), with a 2 fs time step and periodic boundary conditions. For non-
bonded interactions, a cut-off of 12 Å was used along with a switching function starting 
at 10 Å. Electrostatic interactions were computed using the particle mesh Ewald 
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method57. Temperature was kept constant at 310 K using the Langevin method58, with a 
damping coefficient of 1/ps. Pressure was maintained constant at 1.01325 bar with the 
isotropic Nosé-Hoover Langevin piston method59,60, with a barostat oscillation period of 
200 fs and damping time scale 50 fs. 
 
MD SASA Analysis 
The solvent accessible surface area (SASA) was calculated for the heavy atoms 
in positions W101α, W98β (for RD1-MART) or L99β (for A6-134), using the backbone of 
Tax or MART1 and HLA-A2 as the environment. The results were normalized by the 
SASA of the same residue type in a vacuum. The first 1 ns of the simulations for A6 
systems and the first 3 ns of the simulations of the RD1-MART1 systems were excluded 
from this analysis. 
The interaction distances were calculated using the minimum distance between 
the terminal heavy atoms (e.g., nitrogens in arginine and oxygens in a glutamate) in 
each trajectory frame. Then the resulting data were plotted with bin widths ranging 0.1-
0.2 Å. The peak location was used as the maximum likelihood interaction distance as 
shown in Fig. 4.22. The first 3 ns of the trajectories were excluded from the analysis. 
 
MD simulation and analysis of DMF5 position F100β 
The simulation of DMF5:MART1/HLA-A2 complex was prepared using crystal 
structure with PDB identifier: 3QDG. TCR and MHC were truncated in order to focus on 
relevant regions: TCRα residues 1 - 108, TCRβ residues 4 - 116 and MHC residues 1 - 
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182. In order to assess whether the insertion of the side-chain of F100β reoccurs, a 
rotation of 180° for χ1 dihedral angle and another rotation of 90° for χ2 dihedral angle 
were made for residue F100β. The following restraints were applied: The backbone of 
TCR and all heavy atoms in MART1/HLA-A2 were restrained with 1 kcal/mol/ Å2 force 
constant. The resulting simulation system was first energetically minimized for 1000 
steps and then run for ~4.3 ns under constant temperature, volume (NVT) condition.  
 For analysis, the root mean square deviation (RMSD) of the heavy atoms in the 
sidechain of F100β and the χ1 and χ2 dihedral angles were measured for comparison 
with the crystal structure. During the simulation, the aromatic ring of F100β flipped by 
180°. For better comparison with the crystal structure, the CD1/CE1 and CD2/CE2 atom 
names were switched in the crystal structure data file during the data analysis. 
 
Backrub modeling of RD2-WT1 
Rosetta Backrub flexible backbone modeling algorithms 
(https://kortemmelab.ucsf.edu/backrub/)32,33 were used to model the RD2-WT1 
mutations (D26Iα, G28Sα, S100Rα, W101Sα, and L98Vβ) into the wild-type A6 (PDB: 
1AO7)8 crystal structure along with the wild-type Tax, MART1-10mer (ELAGIGILTV), 
and WT1 (RMFPNAPYL) peptides. Mutated residues were given a 10Å radius of effect 
for the flexible backbone modeling. For modeling purposes, the residue at position “0” of 
the MART1 10-mer peptide was omitted from the prediction. PyMOL software was used 
to visualize overlays of the lowest two energy conformation of each model (The PyMOL 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC)35, and the measurement 
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tool was used to determine which HLA-A2 residues were within 3Å of mutated RD2-
WT1 residues. 
 
Results 
Features of TCR A6 and the HLA-A2-restricted peptides Tax, MART1, and WT1 
 In order to test whether the specificity of a TCR could be converted to a different 
MHC-restricted peptide by directed evolution, we used the human TCR A6, which was 
originally raised against the HTLV-1 peptide Tax (LLFGYPVYV)61. A6 was chosen due 
to its thorough structural and biochemical characterization8,15,16,62,63, and its prior 
expression as a stable single-chain TCR (Vβ-linker-Vα) in the yeast display system36. 
Our goal was to convert the A6 TCR from binding the cognate peptide Tax to binding 
cancer-associated MART1 peptides (nonamer, AAGIGILTV and an anchor modified 
decamer, ELAGIGILTV) or WT1 (RMFPNAPYL)64-66. One of the advantages of the 
MART1 system is that MART1-specific TCRs have shown a preference for Vα2 (IMGT: 
TRAV 12-2)67, the same Vα region (i.e., CDR1α and CDR2α) used by A6. Additionally, 
the Vα2-containing MART1-specific TCR DMF5 targets MART1/HLA-A2 with a similar 
docking mode to the A6 TCR7,28. The MART1 peptides differ from Tax at every position 
except the primary anchor near the C-terminus (Fig. 4.1a,b), and the WT1 peptide 
differs from Tax at every position except positions 3 (F) and 8 (Y) (Fig. 4.1a,c). Notably, 
MART1 lacks the aromatic residues of Tax (i.e., F3, Y5, and Y8) and exhibits a distinct 
backbone configuration. The anchor modified MART1 decamer (ELAGIGILTV) binds 
with higher affinity to HLA-A2 than the nonamer (AAGIGILTV), although the two are 
 192 
structurally divergent68. MART1-specific TCRs often cross-react with both (Fig. 
4.1b)69,70, and as a result the anchor-modified decamer was used for all selections due 
to its enhanced binding to HLA-A2. In summary, both MART1 and WT1 present unique 
surfaces to the TCR for examining the notion of whether a single TCR can be 
engineered to bind a non-cognate peptide. 
 In order to guide the mutagenesis strategy for the construction of A6 libraries, we 
examined, by modeling, which residues of the A6 CDR loops would be most likely to 
accommodate and provide binding energy to non-cognate peptides MART1 and WT1 in 
the HLA-A2 complex. Three MART1 peptide variants (MART126–35 A27L: ELAGIGILTV, 
MART127-35: AAGIGILTV27-35, MART127-35: ALGIGILTV27-35 A28L), the HLA-A2-binding 
peptide WT1 (RMFPNAPYL), and several other peptides (e.g., SL9/HIV-gag 
(SLYNTVATL) and Survivin (LTLGEFLKL)) were modeled into the wild-type 
A6:Tax/HLA-A2 (PDB: 1AO7)8 structure using the Rosetta Multiple Mutation 
Mutagenesis Module32,33. The lowest energy models for each peptide were examined 
with PyMOL35, and candidate residues for generating libraries were chosen by 
determining the A6 TCR residues that were less than 3.5 Å from the peptide in the 
lowest energy conformations of various modeled TCR:pepMHC complexes. Because 
yeast display libraries can be generated to completely cover sequence diversity of up to 
five codons (NNS or NNK, 325 = 3.3 x 107) or more, for the initial library (called RD1, 
rational design library 1) we selected five CDR positions that were the most commonly 
represented among the complexes within this distance: TCRα Q30, T98, and D99, and 
TCRβ L98 and G101 (A101 in the A6-X15 template) (Fig. 4.1d). 
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Isolation of RD1 library variants that bound cognate peptide Tax or non-cognate peptide 
MART1 
The RD1 library was generated by gene synthesis (Genscript), using as a 
template the single-chain (Vβ-linker-Vα) TCR called A6-X15, that contained four 
CDR3β mutations that conferred high-affinity for Tax/HLA-A2 and one CDR3β mutation 
that conferred increased stability for yeast display in the CDR3β (Fig. 4.2)36. In order to 
determine whether the RD1 library contained mutants that bound to MART1 or WT1, as 
well as to verify that the library contained mutants that bound to Tax, FACS was used 
for selections with Tax/HLA-A2-Ig, MART1/HLA-A2-Ig (using the anchor-modified 
decamer peptide), and WT1/HLA-A2-Ig dimers. As expected, the unselected RD1 library 
did not show detectable positive peaks with any ligand, but a positive population began 
to emerge for Tax/HLA-A2 and MART1/HLA-A2 after the second and fourth sorts, 
respectively (Fig. 4.3a,b). A positive peak did not emerge with WT1/HLA-A2 even after 
the fifth sort (data not shown) and thus only the Tax and MART1-reactive clones were 
pursued further. 
Six clones isolated from the RD1 library following the fourth sort with Tax 
revealed that 2 of 6 had identical amino acid sequences to A6-X15 (although the 
nucleotide sequences/codons varied) and 4 of 6 had a threonine substitution at position 
30 in CDR1α (Fig. 4.2 and Fig. 4.4). The similarities to A6-X15 suggest that there was 
strong selection for these residues in conferring high-affinity Tax binding. In addition, 
emergence of highly restricted residues through successive sorts also argued that the 
final high-affinity clones were evolved at these positions to optimize binding (Fig. 4.4). 
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To determine if the TCRs selected for binding to the Tax peptides exhibited specificity in 
their reaction with the selecting peptide, RD1-Tax-1 (Q30α, T98α, D99α, L98β, and 
A101β) was titrated with various concentrations of Tax and MART1/HLA-A2-Ig dimers at 
concentrations ranging from 4 to 500 nM (Fig. 4.5a, top panels). The Tax-selected TCR, 
RD1-Tax-1, bound only to the Tax complex, and not to the MART1 complex, with half-
maximal binding of Tax/HLA-A2-Ig dimer at approximately 110 nM (Fig. 4.5b). 
Five clones isolated from MART1 selection of the RD1 library following the fifth 
sort were also sequenced. All five clones had identical nucleotide sequences that 
encoded the following mutations: T30α, K98α, Y99α, W98β, and G101β (called RD1-
MART1) (Fig. 4.2 and Fig. 4.6). Except for T30α and G101β, these mutations differed 
with both the A6-wt and A6-c134 TCRs. Sequencing of clones following succesive sorts 
showed the emergence of selected residues (K/R) at position 98 of CDR3α during the 
third sort (Fig. 4.6). To determine if the TCR selected for binding to MART1 exhibited 
specificity, the RD1-MART1 clone was titrated with various concentrations of the 
MART1 and Tax/HLA-A2-Ig dimers (Fig. 4.5a, bottom panels). RD1-MART1 bound only 
to the MART1 complex, and not to the Tax complex, with half-maximal binding at 
approximately 130 nM (Fig. 4.5b). Thus, a higher affinity TCR mutant against a distinctly 
different peptide could be isolated from a degenerate library of a single TCR. 
 
Affinity maturation of the MART1-selected RD1 scaffold variant 
 In order to determine if RD1-MART1 could be engineered for even higher affinity 
and yet retain its specificity, degenerate libraries (NNK) were made in the CDR3 loops 
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of RD1-MART1 spanning 5-codon regions in CDR3α residues 98-102 and CDR3β 
residues 97-101 and 99-103 (Fig. 4.7). Two rounds of selection were performed with the 
pooled libraries, first with 200 nM MART1/HLA-A2-Ig dimers and then with 1 nM 
MART1/HLA-A2-Ig dimers, a concentration below the detectable limit for staining the 
parental RD1-MART1 (Fig. 4.5b). Each sort contained a positive population of yeast 
(Fig. 4.3c), and ten clones from the second sort were sequenced. Eight clones 
contained the parental RD1-MART1 sequence, one clone contained a Q81K PCR-
based mutation in the Vα region, and one clone, called RD1-MART1HIGH, had three 
mutations in CDR3β that differed from the parental sequence (S100A, Q102G, and 
P103V) (Fig. 4.2 and Fig. 4.7).  
RD1-MART1HIGH retained specificity for MART1 and showed significant binding 
with monomeric MART1/HLA-A2, whereas the RD1-MART1 only showed binding at the 
highest monomer concentrations (Fig. 4.5c and data not shown). Staining of RD1-
MART1HIGH with non-selecting cognate peptide Tax/HLA-A2 and other non-cognate 
peptides WT1 (RMFPNAPYL)/HLA-A2 and Survivin (LTLGEFLKL)/HLA-A2 showed no 
detectable signal even with 500 nM peptide/HLA-A2-Ig dimers, over 500-times the 
concentration of MART1/HLA-A2-Ig dimers that yielded detectable staining (Fig. 4.8). 
 
Design and selection of a second A6 scaffold library, RD2, with Tax, MART1, and WT1 
To determine if alternative diversity in the A6 scaffold could be used to generate 
TCR mutants that are specific for MART1/HLA-A2 or WT1/HLA-A2, a second library, 
RD2, was designed with five degenerate (NNK) positions: TCRα D26, G28, S100, and 
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W101 and TCRβ L98, a binary position at TCRα 30 (Q30 or T30) and a binary region in 
TCRβ 99-102 (AGGR or MSAQ) (Fig. 4.2 and Fig 4.9a). RD2 was screened with three 
pepMHC ligands, Tax/HLA-A2 (LLFGYPVYV; cognate), MART1/HLA-A2 (ELAGIGILTV; 
non-cognate) and WT/HLA-A2 (RMFPNAPYL; non-cognate), using two MACS 
selections followed by one round of FACS. Selections with the cognate antigen, Tax, 
and both non-cognate antigens, MART1 and WT1, showed the emergenge of positively 
staining populations (Fig. 4.10).  
Following selection with Tax/HLA-A2, six colonies were sequenced and 
analyzed. Although all six clones bound to Tax/HLA-A2 but not to MART1/HLA-A2 (data 
not shown), the two clones RD2-Tax-1 and RD2-Tax-2 showed improved staining in 
comparison to the high-affinity A6-X15 TCR36 when stained with Tax/HLA-A2-Ig dimers 
and monomers (Fig. 4.9b, left panels and data not shown). All six clones differed in 
sequence (Fig. 4.2), but each retained the four CDR3β residues MSAQ at TCRβ 
positions 99-102 (rather than the wild-type binary option AGGR) that were present in the 
high-affinity A6-X15 TCR. Two residues that were among the positions of complete 
degeneracy in the library, CDR3α W101 and CDR3β L98, were also highly restricted. 
Thus, this constellation of residues was highly selected for binding the Tax peptide, 
despite the fact that the residues were present in different CDR loops. The other 
positions (CDR1α 26, 28, 30 and CDR3α 98) in the degenerate library were biased 
toward particular residues, but variability at these positions suggested that different 
solutions for binding Tax/HLA-A2 existed.  
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Following selection with MART1/HLA-A2, five colonies were sequenced and 
analyzed. The clones all bound to MART1/HLA-2, but only three of them showed 
specificity for MART1 (i.e., did not bind to Tax or WT1) (Fig. 4.9b, center panels, and 
data not shown), whereas the other two also bound to Tax and WT1 (data not shown). 
Sequencing revealed that the three MART1-specific clones all had the same sequence 
(clones RD2-MART1-S3-1, -2, -3; called RD2-MART1), whereas the two clones that 
bound to MART1, Tax, and WT1 differed substantially from this sequence, but were 
similar to each other (clones RD2-MART1-S3-4 and -5) (Fig. 4.2). Interestingly, unlike 
the Tax-selected clones, all of the MART1-selected clones contained the four CDR3β 
residues (AGGR) of the wild-type A6 TCR at TCRβ positions 99-102. 
The MART1-specific clones contained residues S26, H28, and Q30 in CDR1α; 
residues L100 and W101 in CDR3α; and residue M98 in CDR3β. Each of these 
selected residues was distinctly different from the Tax-specific clones, except for the 
tryptophan in CDR3α (W101). This finding supports the view that all of these residues 
contributed either directly or indirectly to the peptide specificity of the TCRs. The 
MART1-specific clones also contained two mutations, to serine and proline at positions 
33 and 39, in framework region 2 (FR2) of the Vα chain that were likely incorporated 
through PCR errors (Fig. 4.2). The presence of a proline in framework regions has been 
observed in other TCR engineering studies39,41,71 and may be involved in stabilizing the 
V domains, thereby enhancing yeast cell surface levels.  
The two clones that cross-reacted with all three peptide/HLA-A2 complexes, 
RD2-MART1-S3-4 and -5, shared the same residues at CDR1α S28, CDR3α R100, and 
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CDR3α S101 but differed at CDR1α 26, CDR1α 30, and CDR3β 98. One of the clones 
also contained a single-site mutation to a proline at CDR1α 25. 
Following selection with WT1/HLA-A2, six colonies were sequenced and 
analyzed. All six clones bound to all three peptide ligands, WT1, Tax, and MART1 (Fig. 
4.9b, right panels), and thus showed a binding phenotype similar to the two cross-
reactive MART1-selected clones (RD2-MART1-S3-4 and -5) (Fig. 4.2). Interestingly, the 
sequences of all six clones were unique (Fig. 4.2), but they also shared significant 
similarities to the two MART1-selected, cross-reactive clones. The eight cross-reactive 
clones contained the CDR1α S28, CDR3α R100, and CDR3α S101 residues, 
suggesting that these were important in binding to the pep/HLA-A2 complexes 
regardless of the peptides. Three of the WT1-selected clones also contained the proline 
mutation at position 25 of CDR1α, and an aromatic residue at the adjacent amino acid, 
CDR1α 26. This pair of residues may be important in configuring the TCR to bind to the 
ligands, again independent of the peptide. Finally, one of the clones (RD2-WT1-S3-5) 
contained the CDR3β residues 99-102 (MSAQ) of the high-affinity Tax-specific TCR A6-
X15, suggesting that it was not absolutely critical to have the potentially more flexible 
CDR3β residues of the wild-type TCR A6 (i.e. AGGR) to generate cross-reactivity. 
However, the cross-reactive clones did contain residues with smaller side chains at 
position 98 of CDR3β, compared to the leucine, tryptophan, or methionine found with 
the Tax- or MART1-specific clones. 
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Attempted affinity maturation of cross-reactive RD2 library isolates 
 Following the third selection of the RD2 library with WT1/HLA-A2, two additional 
selections were performed in attempts to reduce the number of cross-reactive clones 
allowing for a population of WT1/HLA-A2 specific clones to emerge, if present. A 
negative magnetic selection was performed with Tax/HLA-A2 followed by an additional 
positive selection with WT1/HLA-A2. Clones isolated from these two additional selection 
steps were all cross-reactive with the three pepMHC complexes tested (Tax/HLA-A2, 
MART1/HLA-A2, and WT1/HLA-A2) and contained scTCR sequences that resembled 
the cross-reactive clones examined after the third selection of the RD2 library (Fig. 4.2 
and data not shown). 
 A further attempt was made to isolate WT1/HLA-A2-specific clones by generating 
a degenerate library in the CDR3β positions 98-102 using cross-reactive clones as a 
template, including two clones isolated from the 3rd sort of the RD2 library (RD2-WT1-
S3-1 and RD2-WT1-S3-5) and one clone isolated following the 5th sort of the RD2 library 
(RD2-WT1-S5-2) (Fig. 4.11). Two negative selections were performed with Tax/HLA-A2, 
followed by two positive selections with MART1/HLA-A2 or WT1/HLA-A2 and one last 
negative selection with Tax/HLA-A2. All full-length clones isolated showed similar cross-
reactivity to the template clones, staining positively for all three pepMHC complexes 
tested (Tax/HLA-A2, MART1/HLA-A2, and WT1/HLA-A2), although selected CDR3β 
residues varied (Fig. 4.11 and data not shown).  
 As a final attempt to engineer specificity among cross-reactive RD2 variants, two 
additional libraries were generated with degeneracies (NNK) in either the CDR1α or 
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CDR3α loops at positions selected in the original RD2 library that could account for 
cross-reactivity: positions D27 and G29 or positions S99 and W100, respectively 
(residue based on wild-type sequence) (Fig. 4.12 and Fig. 4.13). Templates used for the 
library included RD2-WT1 isolated clones used for the CDR3β library (RD2-WT1-S3-1, 
RD2-WT1-S3-5, and RD2-WT1-S5-2) as well as the non-truncated cross-reactive clones 
isolated from the selections of the RD2-WT1-CDR3β library with MART1 and WT1/HLA-
A2. As before, two negative selections were performed with Tax/HLA-A2. Following the 
negative selections, both the unselected library and the negatively selected populations 
were subjected to two positive selections with either MART1/HLA-A2 or WT1/HLA-A2. 
Similarly, all clones isolated after the final selections were cross-reactive independent of 
selecting ligand (MART1/HLA-A2 or WT1/HLA-A2) or whether or not they underwent 
negative selections (data not shown). Sequencing of isolated clones following final 
selections revealed the strong bias for template amino acids at these positions, although 
some structurally similar variations occurred, e.g. F27α in RD2-WT1-CDR1/3α-MART1-
S4-1 and 6, or W27α in RD2-WT1-CDR1/3α-WT1-S4-3; T29α in RD2-WT1-CDR1/3α-
MART1-S4-1, RD2-WT1-CDR1/3α-WT1-S2-4, RD2-WT1-CDR1/3α-WT1-S4-3 and 5 
(Fig. 4.12 and Fig. 4.13). 
 
Additional scaffold library design and selection attempts 
 In addition to the RD1 and RD2 libraries described, an intermediary library, called 
RD1.5, was generated and selected, but did not yield clones with redirected specificity. 
The RD1.5 library was designed with five degenerate (NNS) positions: TCRα Q30, T98, 
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D99, and S100 and TCRβ L98 (Fig. 4.14). The TCRβ residues at position 99-102 were 
restricted to the wild-type sequence, AGGR. Dynamics studies have shown that the 
CDR3β loop of A6 is highly flexible and the presence of small residues such as alanine 
and glycine were predicted to reduce potential steric hindrance when bulkier residues 
were selected at the adjacent L98β position72. Because structural models suggested 
that the arginine at position 27 in CDR1α could cause potential steric and/or 
electrostatic clashes if bulkier residues were selected residues at nearby degenerate 
positions, it was mutated to alanine. An alanine scanning study of a panel of high-affinity 
scTCRs including A6-X15 did not show a significant loss of binding when the arginine at 
position 27 of TCRα was mutated to alanine (discussed in chapter 2)23.  
The RD1.5 library was screened with six pepMHC ligands in four FACS 
selections: Tax/HLA-A2 (LLFGYPVYV; cognate), MART1/HLA-A2 (ELAGIGILTV; non-
cognate), WT1 (RMFPNAPYL; non-cognate), Survivin (LTLGEFLKL; non-cognate), 
preproinsulin (ALWGPDPAAA; non-cognate), and NYESO-Val (SLLMWITNV; non-
cognate)/HLA-A2. Clones isolated following the forth FACS selections did not show 
redirected specificity to non-cognate antigens, although staining suggested that several 
clones with positive staining were non-specifically binding to the IgG F(ab’)2 AlexaFluor 
647 secondary antibody through progressive sorts (data not shown). 
Additionally, an attempt to isolate additional clones from the three libraries 
described was performed by combining the RD1, RD1.5, and RD2 libraries. In order to 
exclude clones which bound to the cognate antigen Tax/HLA-A2, two negative magnetic 
selections were performed prior to selecting with the following pepMHC antigens for 2-3 
 202 
positive magnetic selections: WT1(RMFPNAPYL; non-cognate), SL9/HIVgag 
(SLYNTVATL; non-cognate), Survivin-T2M (LMLGEFLKL; non-cognate), NYESO-Val 
(SLLMWITNV; non-cognate), preproinsulin (ALWGPDPAAA; non-cognate), MDM2 
(VLFYLGQY; non-cognate), HBV Env (FLLTRILTI; non-cognate)/HLA-A2, and Tel1p 
(MLWGYLQYV; cognate). No additional clones with redirected specificities were 
isolated in this sorting progression as well. Control studies suggested that the high 
concentration of DMSO required to maintain insoluble peptides in solution may have 
negatively impacted yeast cell viability and/or the integrity of the peptide/MHC 
complexes throughout the sorting progression (data not shown). 
  
Site-directed mutagenesis of RD scaffold variants at position 98β  
 Examination of the sequences of isolated RD variants suggested that TCRβ 
position 98 might be important in the specificity of the isolated scaffold variants, as all 
Tax-specific variants in this study selected the wild-type leucine at CDR3β position 98 
whereas MART1-specific variants selected an alternate residue at this position (Trp in 
RD1 and Met in RD2). In order to assess whether this residue was pivotal in the 
specificity switch, converting A6-X15 into a MART1-specific TCR, this position was 
reverted to leucine in the MART1-specific scaffold variants (W98L for RD1-MART1 and 
RD1-MART1HIGH, and M98L for RD2-MART1). Conversely, the RD1-Tax-1 clone 
(identical to A6-X15) was mutated to the residues selected in the MART1-specific 
variants (L98W and L98M). The yeast-displayed mutants were stained with various 
concentrations of peptide/HLA-A2 tetramers and analyzed by flow cytometry (Fig. 4.15).  
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The results showed that the residue selected at position 98 was critical for 
binding. The only exceptions were that: 1) the L98M mutation in A6-X15 resulted in 
binding to Tax/HLA-A2, but at a reduced level (Fig. 4.15a), and 2) the M98L reversion 
mutation of RD2-MART1 maintained specific binding to MART1. In no case was the 
specificity of the original TCR reverted to high-affinity binding of the alternative peptide, 
even at concentrations of pep/HLA-A2 tetramers that were 20-fold above detectable 
levels with the original clone. We conclude that residues at position 98 were important 
for high-affinity binding and specificity of the Tax or MART1 complexes (except for the 
RD2-MART1 clone), but this mutation alone was not responsible for the switch in 
peptide specificity. Consistent with this, the MART1-specific TCR DMF5 has a leucine at 
position β98, but mutation of this position to Trp enhanced affinity by > 3-fold28. 
To further examine the role of A6 residue L98β in specificity for Tax/HLA-A2, 
Rosetta sequence tolerance algorithms were used to determine if residues other than 
the wild-type leucine had a significant probability of tolerance at the A6-c134:Tax/HLA-
A2 interface (Fig. 4.16). The results showed that leucine was by far the most tolerated 
amino acid (predicted frequency of 90-100%), whereas all other amino acids combined 
yielded a frequency of less than 10%. 
 
Binding studies of soluble RD1 scaffold variants 
To further examine the binding properties of selected, peptide-specific TCR 
clones, the single-chain genes encoding RD1-Tax-1 (identical to A6-X15), RD1-MART1, 
and RD1-MART1HIGH were cloned into an E. coli expression vector and proteins were 
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refolded from inclusion bodies. Soluble scTCRs were examined for binding to antigen 
presenting cell line T2 cells loaded with peptides, and/or by surface plasmon resonance 
(SPR). The binding of soluble RD1-MART1 and RD1-MART1HIGH to MART1/HLA-A2 
complexes on T2 was measured using biotinylated single-chain TCRs (scTCR genes 
were cloned with the C-terminal AviTag, and purified proteins were biotinylated in vitro 
with BirA enzyme). Peptide-loaded T2 cells were incubated with various concentrations 
of biotinylated TCRs, followed by washing and incubated with SA-PE. The RD1-MART1 
clone yielded positive staining above 500 nM, whereas the RD1-MARTHIGH TCR yielded 
positive staining at low nanomolar concentrations, with half-maximum staining at 30 nM. 
No staining was observed with Tax/HLA-A2 even at the highest concentration of TCRs 
(Fig. 4.17). 
SPR was performed by flowing single-chain TCR proteins over immobilized 
pepMHC complexes or flowing pepMHC over immobilized scTCR. Similar to previous 
studies with the A6-X15 scTCR36, the RD1-Tax-1 TCR exhibited a KD value of 84 nM for 
Tax/HLA-A2 based on equilibrium measurements (Table 4.1). The first generation 
MART1-specific TCR, RD1-MART1, exhibited a KD value of 3.1 µM based on 
equilibrium measurements. The affinity-matured TCR RD1-MART1HIGH exhibited a KD 
value of 68 nM based on kinetic measurements and 247 nM based on equilibrium 
measurements. An equilibrium titration of RD1-MART1 and RD1-MART1HIGH with 
MART1/HLA-A2 or negative controls is shown in Fig. 4.18. 
Yeast display, flow cytometry-based titrations with ligands have now been used 
in various studies as a method for examining binding affinities73,74. The results of SPR 
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studies were consistent with various experiments in which monomers or multimers of 
the pep/HLA-A2 complexes were used to stain the yeast-displayed forms of these TCRs 
and half-maximal binding concentrations were determined (Table 4.1). Specificity of the 
yeast-displayed scTCR variants for their respective peptides was verified, as even the 
highest concentrations of pepMHC multimers did not bind to the null pepMHC ligands.  
 
Specificity analysis of A6-X15 and RD1-MART1 by molecular dynamics simulations  
In order to gain further insight into the underlying molecular mechanism of 
differential peptide specificity, comparative molecular dynamics (MD) simulations were 
performed on two complexes, A6:Tax/HLA-A2 and RD1-MART1:MART1/HLA-A2. In 
order to determine if MD was a valid method to analyze possible mechanisms of 
specificity of the RD1 variants, two sets of validation simulations were performed. First, 
we determined whether MD simulations would correctly predict the backbone and side 
chain orientations of the CDR3β loop of high-affinity TCR A6-c134 derived from A6. For 
this, the A6 wild-type crystal structure (PDB: 1AO7)8 was mutated to the CDR3β loop of 
A6-c134 (i.e. positions 99-102 mutated from AGGR to MSAQ). Following mutagenesis, 
the structure of the A6 wild-type with ‘MSAQ’ was subjected to a 40 ns simulation. The 
resultant conformations were overlaid with the experimentally characterized A6-c134 
high-affinity crystal structure (PDB: 4FTV)34 and root mean square deviations (RMSDs) 
were calculated (Fig. 4.19). Among the configurations sampled during the simulation, 
there was significant CDR3β loop-overlap between simulated orientations and the A6-
c134 crystal structure (RMSD < 1.5 Å for 44.3% of the trajectory) (Fig. 4.19).  
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In a second validation experiment, we determined if MD simulations could 
accurately predict the insertion of the side chain of residue F100β in the DMF5 TCR 
(PDB: 3QDG)6. In the crystal structure, this residue inserts into a hydrophobic pocket 
formed between the HLA-A2 α1 helix and the MART1 peptide. In this MD simulation, the 
conformation of F100β was initially manipulated to move this residue out of the pocket 
(180° rotation of χ1 dihedral angle and a 90° rotation for χ2 dihedral angle prior the start 
of the simulation). Residue F100β was selected due to its predicted key interaction with 
MART1/HLA-A2 and its similar proposed mechanism of binding for the CDR3 
tryptophans (W98β - 3HG1/Mel5-orientation or W100α - 3QDG/DMF5-orientation) of 
RD1-MART1 (Fig. 4.20 and see below). Within 0.1 ns into the simulation, the F100β re-
inserts into the binding pocket of MART1/HLA-A2 and remains in this position for the 
remainder of the simulation (4.3 ns). This rapid reorganization suggests that the F100β 
side-chain insertion is a critical feature of the interaction between DMF5 and 
MART1/HLA-A2. The consistency between the results of these two test simulations and 
the prior structural studies, as well as the success of earlier MD simulations in 
replicating structural and dynamic properties of TCRs and their complexes72,75 help 
reassure the validity of MD in exploring the determinants of specificity. 
For MD simulations of RD1-MART1:MART1/HLA-A2, four different initial models 
were constructed based on the A6-c134:Tax/HLA-A2 orientation (PDB: 4FTV) as well as 
three different orientations observed for decameric MART1/HLA-A2 in complex with 
different MART1-specific TCRs (DMF5, DMF4, and Mel5; PDBs: 3QDG, 3QDM, and 
3HG1, respectively)6,7,34 (see Materials & Methods for details). Two distinct peptide:TCR 
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interaction patterns were observed for A6 and RD1-MART1, which could account for 
their differential peptide binding specificity and affinity. Key interactions in the 
A6:Tax/HLA-A2 complex identified by screening for hydrogen bonding and electrostatic 
interactions included three hydrogen bonds, namely, Y5Tax-R95β, Y5Tax-S31α, and 
Y8Tax-E30β (Fig. 4.21a, and Fig. 4.22). A recent mutational study suggested that A6 
interactions with Y8Tax provided significant binding energy16. Consistent with this, the 
L98β mutations in the present study likely influenced a van der Waals interaction 
between Y8Tax and L98β. Our simulations also identified a key hydrogen bond between 
Y8Tax and E30β. 
The MD simulations also identified A6-c134:HLA-A2 interactions involving a salt 
bridge between D99α and R65 of HLA-A2. Additionally, a salt bridge between D99α and 
K66 of HLA-A2 occasionally formed during the simulations, with the orientation of the 
D99α side chain being further stabilized by the hydroxyl group of T98α (Fig. 4.22). 
These contacts likely play a role in further enhancing TCR:HLA-A2 interactions (Fig. 
4.22). The importance of T98α and D99α in A6 TCR recognition has recently been 
established by mutational analysis16. Interestingly, the selection of T98α and D99α by 
Tax/HLA-A2, but not by MART1/HLA-A2 (where K98α and Y99α were selected), also 
indicates that the peptide has a strong influence on these TCR:HLA-A2 interactions.  
In contrast to the A6-c134:Tax/HLA-A2 complex, the major stabilizing interaction 
in RD1-MART1 complexes appeared to be the insertion of a tryptophan side chain from 
RD1-MART1 (W101α in the 3QDG/DMF5-orientation or W98β in the 3HG1/Mel5-
orientation) into the extra space provided by the highly curved topology of the MART1 
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peptide (Fig. 4.21b-d). This insertion of a tryptophan side chain was not observed in the 
4FTV/A6-c134 or 3QDM/DMF4 orientations (Fig. 4.23), a finding also supported by 
calculations of the solvent accessible surface area (SASA) (Fig. 4.24). This suggests 
that the 4FTV/A6-c134 and 3QDM/DMF4 orientations are unlikely to represent optimally 
bound configurations for the complex, and that the more likely mode of interaction is 
similar to those observed in the 3QDG/DMF5 or 3HG1/Mel5 crystal structures. The 
exclusion of a 3QDM/DMF4-like orientation is further consistent with the structural data, 
as the DMF4 TCR does not use the Vα2 gene segment. The 4FTV/A6-c134 and 
3QDM/DMF4 orientations were also characterized by a counter-clockwise rotation 
(when viewed from the top of the TCR) with regard to the other two orientations. The 
orientation in 3QDG/DMF5 (but not 3HG1/Mel5) allows the establishment of two salt 
bridges, K55α with E154MHC of HLA-A2 and D56β with R65MHC of HLA-A2, which have 
interaction probabilities of 51.1% and 97.5%, respectively (Fig. 4.21e and Fig. 4.22). 
Thus, although both 3QDG/DMF5 and 3HG1/Mel5 orientations show tryptophan 
insertion, only the former orientation simultaneously maintains both of these inter-
domain salt-bridges, making the 3QDG/DMF5 orientation the more likely representative 
of the complex (Fig. 4.21d,e). These CDR2 interactions (K55α/E154MHC and 
D56β/R65MHC) have been described in several TCR complexes15,76, and they help 
facilitate the conserved TCR diagonal orientation observed for most TCR:pepMHC 
complexes4,76. 
It is interesting to note that the DMF5:MART1/HLA-A2 structure (PDB: 3QDG), 
similar to the modeled RD1-MART1:MART1/HLA-A2 complex, also contains the Vα2 
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region, MART1, and HLA-A2. Although the TCR (DMF5) in the 3QDG/DMF5 structure 
does not contain a tryptophan in either CDR3, a phenylalanine at position 100 in the 
CDR3β inserts into the same area of the MART1/HLA-A2 ligand as predicted by the MD 
simulations (Fig. 4.25). Rosetta sequence tolerance algorithms were also used to 
determine if this phenylalanine was highly restricted in this position. This result showed 
a strong preference for tyrosine and phenylalanine (Fig. 4.16). Although the salt bridges 
described above are not present, R65MHC of HLA-A2 plays a key role, as it does in most 
other complexes6,76. 
Finally, we examined what would happen if MART1 were replaced by Tax in the 
MD simulations of the RD1-MART1:MART1/HLA-A2 complexes. In this simulation, the 
tryptophan insertion could not be established due to the different backbone topology of 
the Tax peptide (Fig. 4.21f). In addition, neither of the salt-bridges mentioned above 
formed, and the triple hydrogen bonding pattern observed in the A6-Tax/HLA-A2 
complex was absent in the MD simulation of the RD1-MART1:Tax/HLA-A2 complex. 
Additionally, when MART1 is replaced by Tax in a model of the complex with A6-c134, 
A6 was found in the simulation to lose not only the triple hydrogen bonds, but also the 
D98α-K66MHC salt bridge. Collectively, these effects likely account for the differential 
affinity of A6 and RD1-MART1 for MART1/HLA-A2 and Tax/HLA-A2. 
 
Discussion 
 The peripheral T cell repertoire is shaped by positive and negative selection in 
the thymus, whereby T cells with TCRs that do not bind to self-pepMHC, or with TCRs 
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that bind too strongly, are deleted1,2. The wild-type TCRs that have been isolated and 
characterized biochemically and structurally have been derived from T cells that have 
made it through these stringent in vivo selection processes. In this study, we created 
repertoires of TCRs in yeast display libraries that could be selected for pepMHC binding 
in vitro, without the in vivo “filters” that are involved in thymic or peripheral T cell 
processes. We believe that this in vitro selection approach can provide additional 
information about the fundamental basis of pepMHC specificity of TCRs. In addition, the 
strategy represents a high-throughput system to generate specific TCR leads against 
the thousands of potential targets represented by viral or cancer peptides, without the 
need to isolate T cell clones for each one.  
Our primary goal in the present study was not to affinity-mature a wild-type TCR 
against its cognate antigen18-23,25-28, but to use directed evolution to isolate TCRs with 
novel specificities against non-cognate antigens. We chose the human TCR A6 as an 
initial scaffold based on the wealth of biochemical and structural information available 
for this TCR, and previous findings that it is amenable to yeast display and directed 
evolution36. The A6 TCR recognizes at least three distinct HLA-A2-restricted ligands, 
Tax (LLFGYPVYV) derived from HTLV-1, and two structural mimics of Tax called Tel1p 
(MLWGYLQYV) and HuD (LGYGFVNYI)6,15,77. Studies of A6 binding to these and 
various other mutant Tax peptides have shown significant plasticity in CDR3 loops to 
accommodate a variety of substitutions in the Tax structure62,72,78. The use of an in vitro 
directed evolution approach as described here is also founded on the now well 
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established ability of a single TCR to cross-react with multiple pepMHC ligands79, a 
feature that has been attributed to a variety of mechanisms (reviewed in13,80,81).  
Two different libraries of the A6 TCR resulted in TCR variants that bound to the 
non-cognate antigen MART1/HLA-A2. To the best of our knowledge this is the first 
report of “switching” the specificity of a TCR to a completely different peptide by directed 
evolution. The MART1-specific TCRs from both of the libraries contained similar 
mutations within the CDR3 loops. In RD1-MART1, a tryptophan (98β) replaced the 
leucine of the wild-type A6 TCR, and mutagenesis results showed that the W98β played 
a key role in binding. In RD2-MART1, a tryptophan at position 101 of the CDR3α was 
selected, and it is possible that it functions in a manner similar to the W98β (see 
discussion of MD simulations, below). In RD1-MART1, a lysine was selected at position 
98 of the CDR3α, whereas in RD1-MART1, an arginine was selected at position 102 of 
CDR3β. Strikingly, the affinity-matured variant of RD1-MART1 (RD1-MART1HIGH) 
evolved four residues in CDR3β (MAGG, 99-102) that were also selected, in a one-
amino-acid register shift, in the RD2-MART1 clone (MAGG, 98-101). While a structure 
of these mutants will be required to fully understand the underlying molecular basis of 
MART1 specificity, it is likely that it involves the unique contribution of these residues 
from both CDR3 loops. 
The two different libraries reported here also yielded higher-affinity TCRs for 
binding to the Tax/HLA-A2 complex. Here, as with the MART1-specific clones, there 
was strong selection for specific residues in the CDR3β, including 4 residues at 
positions 99-102 (MSAQ), which have been identified previously as yielding a high-
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affinity phenotype. However, in the context of these residues, there was also strong 
selective pressure for Tax binding evidenced in the preference for residues in CDR3α. 
For example, four CDR3α residues within the two different libraries (T98 and D99 in 
RD1, and S100 and W101 in RD2) were highly restricted in Tax selections, and these 
are the same residues found in the wild-type A6 TCR. This finding supports the idea that 
both CDR3 loops operate in concert to provide specificity, and higher affinity, for Tax. 
Interestingly, WT1-specific TCRs were not isolated, despite the presence at 
position 8 in both Tax and WT1 of a tyrosine that is predicted to be a key residue for 
binding by A616. The absence of TCR variants that bound WT1 among the A6 libraries 
again supports the view that multiple regions across the TCR interface are involved in 
conferring specificity (i.e., not only those near the Y8 in these two peptides). It is 
possible that alternative libraries, with degeneracies in other CDR residues, could yield 
solutions to WT1 binding. 
The basis of the specificity switch from Tax to MART1 was also investigated by 
MD simulations of known structures, or of models of the selected TCRs docked onto 
structures of these pep/HLA-A2 ligands. MD has previously been used to assess the 
role of conformational heterogeneity in TCR/pepMHC interactions72,82. To validate the 
use of MD simulations to probe functionally relevant TCR:pepMHC interactions, three 
analyses were performed. First, MD was used to assess the CDR3β side chain 
orientation sampled for a modeled A6-c134 TCR using the wild-type A6 crystal structure 
as a template for computational mutagenesis. The resulting structures demonstrate that 
the orientation observed in the published A6-c134 crystal structure is adopted in 44.3% 
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of the trajectory (RMSD < 1.5 Å). Second, we showed the ability of MD simulations to 
correctly predict hydrophobic insertion of a TCR CDR3β side chain in an interaction with 
MART1/HLA-A2 through the F100β position of the DMF5 TCR. Finally, an MD 
simulation was performed using the A6:Tax/HLA-A2 structure to verify known 
interactions. The resultant simulation was in agreement with previously reported results 
using a variety of biophysical and mutational approaches15,16. The simulation results 
indicate that major interactions between the A6 TCR and the Tax/HLA-A2 complex 
involved Tax residues Y5 and Y8 and HLA-A2 residue R65, along with key TCR 
residues, S31α, T98α, D99α, E30β, and L98β. Interestingly, although CDR3α residues 
T98 and D99 interacted with R65/K66 of HLA-A2 and they were highly conserved in 
selection with Tax/HLA-A2, this restriction was completely dependent on the peptide. 
Thus, selection of the RD1 library with MART1 yielded only CDR3α residues K98 and 
Y99, which must provide very different modes of interaction with the MART1/HLA-A2 
complex. 
The MD simulations of the RD1-MART1 TCR revealed a quite striking mode of 
interaction that could account for a substantial binding difference between MART1 and 
Tax complexes. A tryptophan in either CDR3α or CDR3β was inserted into the space 
created by the curved position of the MART1 backbone, providing significant 
hydrophobic stabilization. This positioning also oriented the outside of the periphery of 
the TCR binding surface, through the two CDR2 loops, to form two salt bridges (one 
with each HLA-A2 helix). The specificity of RD1-MART1 for MART1 was accounted for 
in part by the inability of Tax to accommodate this tryptophan conformation and thus to 
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allow optimal orientation and interaction between the TCR and the Tax/HLA-A2 
complex. Further MD simulations and structural studies with the RD1-MART1 TCR and 
RD2-MART1 isolated here are in progress. 
One of the libraries (RD2) yielded TCR variants that were cross-reactive with 
different pep/HLA-A2 ligands. These cross-reactive clones were selected with either 
non-cognate ligand, MART1/HLA-A2 or WT1/HLA-A2. The sequences of the cross-
reactive clones revealed diversity, but highly restricted residues were selected at 
particular positions of CDR1α, CDR3α, and CDR3β. The consensus sequence of these 
clones, as represented by clone RD2-WT1, involved the following five residues: I26α, 
S28α, R100α, S101α, and V98β. To gain insight into the basis of the binding of these 
cross-reactive TCRs, and their peptide independence, Rosetta Backrub models were 
generated for various complexes of this canonical mutant TCR, based on the A6 
structure. The wild-type A6:Tax/HLA-A2 structure was compared to the models of the 
RD2-WT1 TCR docked onto Tax/HLA-A2, MART1/HLA-A2 or WT1/HLA-A2 (Fig. 4.26a). 
None of the five residues in A6 were less than 3.2Å from the nearest HLA-A2 residues, 
although several were involved in contacts with Tax. In striking contrast, all five of the 
RD2-WT1 residues were predicted to be positioned within 3Å of the HLA helices, 
including the following paired residues [TCR residue:HLA-A2 residue(s)]: I26α:E58, 
S28α:Y59/W167, R100α:A69/Q72, S101α:R65, and V98β:T73 (Fig. 4.26b,c). 
In order to further explore the basis of cross-reactivity in this class of isolates as 
well as to attempt to reverse engineer cross-reactive clones from the RD2-WT1 
selections for specificity for either WT1/HLA-A2 or MART1/HLA-A2, CDR3β libraries 
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were generated using several cross-reactive RD2-WT1 clones as templates. Selected 
clones maintained cross-reactivity, although there was a strong preference for aromatic 
residues (i.e. tyrosine, phenylalanine or tryptophan) surrounded by smaller side chains 
(e.g. glycine, alanine, leucine, serine) and occasionally arginine. The generation of the 
CDR1α and CDR3α libraries from both these and the original RD2-WT1-selected clones 
showed a strong preference at RD2-degenerate positions (i.e. TCRα 27, 29, 99, and 
100) for the residues selected in the cross-reactive class of RD2 isolates. This suggests 
that these positions in particular are likely to account for the cross-reactivity of this class 
of TCRs, perhaps through non-specific interactions with the HLA-A2 α1 and α2 helices 
predicted to be within proximity in Rosetta models (Fig. 4.26). This also could account 
for the inability to reverse engineer cross-reactive clones from the RD2-WT1 selections 
for specificity for either WT1/HLA-A2 or MART1/HLA-A2. 
The highly restricted nature of each of these residues in the cross-reactive TCRs, 
across three different loops, suggests that they act in concert to contribute to binding of 
the HLA-A2 molecule. Importantly, all five residues are predicted to be at a sufficient 
distance from each peptide to avoid steric clashes that would prevent binding. T cells 
that expressed TCRs such as these RD2 clones would likely have been negatively 
selected in the thymus. In fact, relevant to this, transgenic mice containing a single 
peptide/MHC as selecting ligand yielded T cells with TCRs that exhibited similar cross-
reactive behavior83. In addition, the highly restricted sequences of these TCRs, and 
those selected with specificity for Tax or MART1, are similar to the dominance of some 
TCRs that arise from positive selection on self-peptides in the thymus2,84.  
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In summary, using a single TCR scaffold we have shown that it is possible to 
generate novel TCRs against non-cognate pep/MHC ligands. To improve the likelihood 
of isolating specific TCRs de novo against other peptide/HLA-A2 complexes (such as 
WT1), several approaches can be applied to the design of additional libraries, including 
the use of a collection of TCR templates with different Vα2 and Vβ regions, 
degeneracies at other CDR positions and the use of synthetic CDR3 loops with varying 
amino acid lengths. In addition, it may be possible to optimize negative selections to 
remove cross-reactive TCRs such as RD2-WT1 variants that have a basal affinity for 
most peptide/HLA-A2 complexes. These libraries could be engineered for specificity by 
diversifying CDR residues that could provide specific binding energy with peptide 
residues unique to the peptide of interest.  
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Figures 
 
Figure 4.1 | Structures of Tax, MART1 and WT1 peptides and design of the first generation TCR 
scaffold library RD1. (a) Structure of the HLA-A2-bound Tax peptide (LLFGYPVYV) (PDB: 1DUZ)85, 
black. (b) Structural alignment of the HLA-A2-bound decamer MART1 peptide (ELAGIGILTV) (PDB: 
1JF1)86, magenta, and the HLA-A2-bound nonamer MART1 peptide (PDB: 2GUO)68, blue. (c) Structure of 
the HLA-A2-bound WT1 peptide (RMFPNAPYL) (PDB: 3HPJ)87, cyan. (d) Five residues, Q30α, T98α, 
D99α, L98β, and A101β (G in the wild-type A6), generated as degenerate codons in the RD1 library as 
found in the structure of the A6-c134:Tax/HLA-A2 complex (PDB: 4FTV)34, green. A6-c134 contains the 
same CDRβ sequence at positions 99-102 as the single-chain A6-X1536 that was used as the RD1 library 
template. The Tax peptide is shown in black, the MART1 decamer peptide from the aligned 
Mel5:MART1/HLA-A2 structure (PDB: 3HG1)7 is shown in magenta, and the WT1 peptide from the 
aligned WT1/HLA-A2 structure (PDB: 3HPJ)87 is  shown in cyan. 
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Figure 4.2 | Amino acid sequences from CDR1α , CDR3α , CDR3β  and framework region 2α  (FR2α) 
of various RD-derived TCR clones. Residues of the A6 wild-type TCR8 and the high-affinity variant A6-
X1536 are shown. Positions of degeneracy in the RD1 and RD2 libraries are highlighted, where X 
represents any amino acid (based on NNS or NNK nucleic acid composition in yellow and cyan, 
respectively). RD2 position 30 indicated with “†” in magenta indicates a binary position where either wild-
type Q or a T was present in the library. RD2 positions 99-102 in CDR3β indicated by four consecutive 
“*”s indicate a binary string where the four adjacent residues were either A6 wild-type (AAGR) or A6-X15 
(MSAQ). PCR-based mutations in selected TCR mutants are highlighted in orange. Mutants isolated from 
the RD1 selections are shown (RD1-Tax-1, RD1-Tax-2, and RD1-MART1) as well as the affinity-matured 
RD1-MART1 variant, RD1-MART1HIGH (selected residues from affinity maturation are highlighted in gray). 
Sequences of other RD1 isolates are shown in Figs. 4.4 and 4.7). Variants selected from the RD2 library 
following the third sorts are shown. RD2-Tax-S3-1 to S3-6 clones were specific for Tax, and RD2-MART1-
S3-1 to S3-3 clones were identical and specific for MART1 (also called RD2-MART1). The RD2-MART1-
S3-4 and S3-5 clones listed separately showed binding to all three peptide complexes (i.e. Tax, MART1, 
and WT1), as did all six clones isolated with WT1/HLA-A2 (RD2-WT1-S3-1 to S3-6). Residue numbering 
is consistent with the crystal structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 
4FTV)34. TCR variants’ names are colored according to their determined specificities: Tax/HLA-A2 (red), 
MART1/HLA-A2 (blue), and cross-reactive (green).  
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RD2-WT1-S3-4 - P Y - S - T - - - - - - - - - - - - R S - - - - - - - - - S A G G R - - L -
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Figure 4.3 | Flow cytometry histograms of the selections of the RD1 library with cognate antigen 
Tax/HLA-A2 and non-cognate antigen MART1/HLA-A2, and affinity maturation of RD1-MART1. (a) 
The RD1 library was sorted sequentially with Tax/HLA-A2-Ig dimer. Aliquots of yeast cells after each sort 
were then incubated with 100 nM Tax /HLA-A2-Ig dimer followed by APC-conjugated goat anti-mouse 
secondary antibody. (b) The RD1 library was sorted sequentially with MART1 (ELAGIGILTV)/HLA-A2-Ig 
dimer for a total of five sorts. During the 3rd sort, yeast cells were also stained with chicken anti-c-myc 
antibody, goat anti-chicken IgY alexa 488 secondary antibody and double positives were isolated in order 
to exclude truncated clones (not shown). Aliquots of yeast cells after each sort were then incubated with 
100 nM MART1 (ELAGIGILTV)/HLA-A2-Ig dimer followed by APC-conjugated goat anti-mouse secondary 
antibody. (c) RD1-MART1 was used as a template for affinity maturation libraries in CDR3 loops, and 
combined libraries were sorted sequentially with MART1/(ELAGIGILTV)/HLA-A2-Ig dimer for a total of two 
sorts. Aliquots of yeast cells after each sort were then incubated with 50 nM MART1 (ELAGIGILTV)/HLA-
A2-Ig dimer, followed by APC-conjugated goat anti-mouse secondary antibody. Data is representative of 
2 experiments with similar results. 
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Figure 4.4 | Sequence alignment of clones isolated from the RD1 library, following each round of 
selection with Tax/HLA-A2. The sequences of the A6-X15 template and RD1 library are shown, and 
degenerate residues in the RD1 library are highlighted in yellow. Clones isolated from each of the rounds 
of sorting are indicated by S1 to S4. The two Tax-specific variants referenced in Fig. 4.2, RD1-Tax-1 and 
RD1-Tax-2, are repeated in the bottom two rows. Residue numbering is consistent with the crystal 
structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
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Figure 4.5 | Binding of selected TCR clones from the RD1 library to Tax/HLA-A2 or MART1/HLA-
A2. Following four sorts of the RD1 library with Tax (LLFGYPVYV)/HLA-A2 and five sorts of the RD1 
library with MART1 (ELAGIGILTV)/HLA-A2 as shown in (Fig. 4.3a,b), individual yeast clones were 
analyzed for peptide/HLA-A2 binding. (a) The RD1-Tax-1 clone isolated from Tax selections (top panels), 
that was identical in amino acid sequence to A6-X15, and the RD1-MART1 clone isolated from MART1 
selections (bottom panels), were stained with various concentrations of the Tax/HLA-A2-Ig dimer (left 
panels) or MART1/HLA-A2-Ig dimer (right panels) at the indicated concentrations. Gray filled histograms 
were yeast cells stained with secondary antibody only. (b) Plot of the mean fluorescence intensity (MFI) 
from staining RD1-Tax-1 and RD1-MART1 with various concentrations of Tax/HLA-A2-Ig dimers (left) and 
MART1 (ELAGIGILTV)/HLA-A2-Ig dimers (right) at 4 to 500 nM. The half maximal effective concentration 
(EC50) determined by nonlinear regression analysis is indicated. (c) The RD1-MART1HIGH clone, isolated 
by affinity maturation of the RD1-MART1 clone, was stained with various concentrations of Tax/HLA-A2 
monomers (left panel) or MART1/HLA-A2 monomers (right panel) at the indicated concentrations. Gray 
filled histograms are yeast cells stained with secondary antibody only. Data is representative of 4 
experiments with similar results. 
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Figure 4.6 | Sequence alignment of clones isolated from the RD1 library following each round of 
selection with MART1/HLA-A2. The sequences of the A6-X15 template and RD1 library are shown, and 
residues made degenerate in the RD1 library are highlighted in yellow. Clones isolated from each round 
of sorting are indicated by S1 to S5. The MART1-specific variant referenced in Fig. 4.2, RD1-MART1, is 
repeated in the bottom row. Residue numbering is consistent with the crystal structures of A6:Tax/HLA-A2 
(PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
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RD1-MART1-S4-4 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S4-5 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S4-6 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S5-1 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S5-2 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S5-3 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S5-4 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-S5-5 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1 - - - - - - T - - - K Y - - - - - - - - - - - W M S G Q - - L -
CDR 1α CDR 3α CDR 3β
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Figure 4.7 | Sequence alignment of clones isolated from the RD1-MART1 CDR3 affinity maturation 
library following two selections with MART1/HLA-A2. Three five-codon (NNK) libraries, CDR3α, 
CDR3β-1, and CDR3β-2, shown in gray were generated and combined to create the RD1-MART1 CDR3 
affinity-maturation library. Following two selections with MART1/HLA-A2 dimer (200 nM and 1 nM), 10 
clones were isolated and sequenced (shown as RD1-MART1-CDR3 #1-10). Eight clones were parental, 
one clone called RD1-MART1-CDR3-8 contained a Q81K PCR-based framework mutation in the Vα-
domain (shown in orange), and one clone, called RD1-MART1HIGH, was derived from the CDR3α library 
and had three mutations that differed from the parental sequence (S100A, Q102G, and P103V; shown in 
gray). Residue numbering is consistent with the crystal structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 and 
A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
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A6 wild-type Y S D R G S Q S F Q T T D S W G K L Q A S R P G L A G G R P E Q Y
RD1-MART1 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1 CDR3α Library - - - - - - T - - - - X X X X X - - - - - - - - W M S G Q - - L -
RD1-MART1 CDR3β-1 Library - - - - - - T - - - - K Y - - - - - - - - - - X X X X X Q - - L -
RD1-MART1 CDR3β-2 Library - - - - - - T - - - - K Y - - - - - - - - - - - W X X X X X - L -
RD1-MART1-CDR3-1 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-2 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-3 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-4 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-5 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-6 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-7 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-8 - - - - - - T - - K - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-9 - - - - - - T - - - - K Y - - - - - - - - - - - W M S G Q - - L -
RD1-MART1-CDR3-10 - - - - - - T - - - - K Y - - - - - - - - - - - W M A G G V - L -
RD1-MART1-HIGH - - - - - - T - - - - K Y - - - - - - - - - - - W M A G G V - L -
CDR 1α CDR 3α CDR 3β
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Figure 4.8 | Staining of the RD1-MART1HIGH clone to assess cross reactivity with other HLA-A2 
restricted peptides. The yeast-displayed RD1-MART1HIGH clone was stained with 10 nM MART1/HLA-
A2-Ig dimer (a) or 500 nM Tax/HLA-A2-Ig dimer (b), WT1/HLA-A2-Ig dimer (c), or Survivin/HLA-A2-Ig 
dimer (d), followed by APC-conjugated goat anti-mouse secondary antibody. Gray indicated histograms of 
yeast stained with secondary reagent only. Data is representative of 2 experiments with similar results. 
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Figure 4.9 | Binding of selected TCR clones from the RD2 library to Tax/HLA-A2 or MART1/HLA-
A2. (a) Residues of the A6 TCR used in the design of the RD2 library. The structure of the aligned wild-
type A6:Tax/HLA-A2 (PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34, that contained the CDR 
sequences used as templates for the RD2 library, are shown with degenerate positions at D26α, G28α, 
S100α, W101α, and L98β (green). The binary residues (Gln or Thr) at position Q30α is shown in red, and 
the backbone of the binary string of wild-type “AGGR” or high-affinity “MSAQ” in positions 99-102β is 
shown in yellow. The Tax peptide is in black, the MART1-peptide from the aligned Mel5:MART1/HLA-A2 
structure (PDB: 3HG1)7 is in green, and the WT1 peptide from the aligned WT1/HLA-A2 structure (PDB: 
3HPJ)87 is in cyan (b) A Tax-selected clone (RD2-Tax-S3-1) (left panels), a MART1-selected clone (RD2-
MART1) (middle panels), and a WT1-selected clone (RD2-WT1-1) isolated from the RD2 library were 
each stained with various concentrations of the indicated peptide/HLA-A2-Ig dimers. Gray filled 
histograms were yeast cells stained with secondary antibody only. Data is representative of 3 
experiments with similar results. 
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Figure 4.10 | Selection of a second A6 library called RD2. Two sequential magnetic bead selections of 
the RD2 library were performed following incubation with 1 µM Tax/HLA-A2 or 5 µM MART1 or WT1/HLA-
A2 UV-exchanged monomers and streptavidin MACS beads (Miltenyi Biotec). A third selection was 
performed with FACS following incubation with 1 nM Tax/HLA-A2-Ig dimer or 100 nM MART1 or 
WT1/HLA-A2-Ig dimer, respectively. Aliquots of yeast cells after each selection were incubated with 50 
nM selecting/HLA-A2-Ig dimer, APC-conjugated goat anti-mouse secondary antibody. (a) Flow cytometry 
histograms of the RD2 library after sorting with the cognate antigen, Tax (LLFGYPVYV)/HLA-A2. Gray 
indicates histograms of yeast cells stained with secondary antibody only. (b) Flow cytometry histograms 
of the RD2 library after sorting with the non-cognate antigen, MART1 (ELAGIGILTV)/HLA-A2. (c) Flow 
cytometry histograms of the RD2 library after sorting with the non-cognate antigen, WT1 
(RMFPNAPYL)/HLA-A2. Data is representative of 2 experiments with similar results. 
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Figure 4.11 | Sequence alignment of clones isolated from the RD2-WT1-CDR3β  library. The five-
codon (NNK) library generated with three RD2 cross-reactive template clones (RD2-WT1-S3-1, RD2-
WT1-S3-5, and RD2-WT1-S5-2) is shown in gray. Degenerate residues are indicated with “X.” The five 
clones isolated from magnetic selections with either MART1/HLA-A2 or WT1/HLA-A2 following 5 sorts 
(negative sorts 1, 2, and 5 used 5 µM Tax/HLA-A2; positive sorts 3 and 4 used 5 µM selecting ligand) are 
shown (#1-5). An underscore (_) indicates the selection of a stop codon. Residue numbering is consistent 
with the crystal structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
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A6 wild-type Y S D R G S Q S F T T D S W G K L Q A S R P G L A G G R P E Q Y
A6-X15 - - - - - - - - - - - - - - - - - - - - - - - - M S A Q - - L -
RD2 Library - - X - X - † - - - - - X X - - - - - - - - - X * * * * - - L -
RD2-WT1-S3-1 - - I - S - T - - - - - R S - - - - - - - - - V A G G R - - L -
RD2-WT1-S3-5 - P Y - S - T - - - - - R S - - - - - - - - - V M S A Q - - L -
RD2-WT1-S5-2 - - V - S - T - - - - - R S - - - - - - - - - A A G G R - - L -
RD2-WT1-CDR3β-Library - X X - S - T - - - - - R S - - - - - - - - - X X X X X - - L -
RD2-WT1-CDR3β-MART1-S5-1 - P Y - S - T - - - - - R S - - - - - - - - - V V W G S - - L -
RD2-WT1-CDR3β-MART1-S5-2 - - V - S - T - - - - - R S - - - - - - - - - A W A A G - - L -
RD2-WT1-CDR3β-MART1-S5-3 - - I - S - T - - - - - R S - - - - - - - - - S W R A G - - L -
RD2-WT1-CDR3β-MART1-S5-4 - P Y - S - T - - - - - R S - - - - - - - - - R G W G G - - L -
RD2-WT1-CDR3β-MART1-S5-5  - - I - S - T - - - - - R S - - - - - - - - - V V G C R - - L -
RD2-WT1-CDR3β-WT1-S5-1 - - I - S - T - - - - - R S - - - - - - - - - L Y S R D - - L -
RD2-WT1-CDR3β-WT1-S5-2 - - I - S - T - - - - - R S - - - - - - - - - F W R _ W - - L -
RD2-WT1-CDR3β-WT1-S5-3 - - I - S - T - - - - - R S - - - - - - - - - L F P A S - - L -
RD2-WT1-CDR3β-WT1-S5-4 - P Y - S - T - - - - - R S - - - - - - - - - L Y S R S - - L -
RD2-WT1-CDR3β-WT1-S5-5 - - I - S - T - - - - - R S - - - - - - - - - T W K A G - - L -
CDR 1α CDR 3α CDR 3β
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Figure 4.12 | Sequence alignment of clones isolated from the combined RD2-WT1-CDR1α  and 3α  
libraries with MART1. The two-codon (NNK) libraries generated from templates including three RD2 
cross-reactive clones (RD2-WT1-S3-1, RD2-WT1-S3-5, and RD2-WT1-S5-2) and non-truncated RD2-
CDR3β library isolates (MART1/WT1-S5 #1-5) are shown. Degenerate residues (NNK) are indicated with 
“X,” and positions that varied in the library based on multiple templates are highlighted in blue. The RD2-
WT1-CDR1α and RD2-WT1-CDR3α libraries were combined in equal cell numbers prior to selections. 
The first group of clones shown (S2) were isolated following two positive magnetic selections with 5 µM 
MART1/HLA-A2. The second group of clones shown (S4) were first subjected to two negative selections 
with 5 µM Tax/HLA-A2 before two positive selections with 5 µM MART1/HLA-A2. PCR-based mutations 
are highlighted in orange. Residue numbering is consistent with the crystal structures of A6:Tax/HLA-A2 
(PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
 
25 26 27 28 29 30 31 32 33 92 97 98 99 10
0
10
1
10
2
10
3
10
4
94 95 96 97 98 99 10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
A6 wild-type Y S D R G S Q S F T T D S W G K L Q A S R P G L A G G R P E Q Y -
A6-X15 - - - - - - - - - - - - - - - - - - - - - - - - M S A Q - - L - -
RD2 Library - - X - X - † - - - - - X X - - - - - - - - - X * * * * - - L - -
RD2-WT1-CDR3β-Library - X X - S - T - - - - - R S - - - - - - - - - X X X X X - - L - -
RD2-WT1-S3-4 - - I - S - T - - - - - R S - - - - - - - - - V A G G R - - L - -
RD2-WT1-S3-5 - P Y - S - T - - - - - R S - - - - - - - - - V M S A Q - - L - -
RD2-WT1-S5-2 - - V - S - T - - - - - R S - - - - - - - - - A A G G R - - L - -
RD2-WT1-CDR3β-MART1-S5-1 - P Y - S - T - - - - - R S - - - - - - - - - V V W G S - - L - -
RD2-WT1-CDR3β-MART1-S5-2 - - V - S - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR3β-MART1-S5-3 - - I - S - T - - - - - R S - - - - - - - - - S W R A G - - L - -
RD2-WT1-CDR3β-MART1-S5-4 - P Y - S - T - - - - - R S - - - - - - - - - R G W G G - - L - -
RD2-WT1-CDR3β-MART1-S5-5 - - I - S - T - - - - - R S - - - - - - - - - V V G C R - - L - -
RD2-WT1-CDR3β-WT1-S5-1 - - I - S - T - - - - - R S - - - - - - - - - L Y S R D - - L - -
RD2-WT1-CDR3β-WT1-S5-3 - - I - S - T - - - - - R S - - - - - - - - - L F P A S - - L - -
RD2-WT1-CDR3β-WT1-S5-4 - P Y - S - T - - - - - R S - - - - - - - - - L Y S R S - - L - -
RD2-WT1-CDR3β-WT1-S5-5 - - I - S - T - - - - - R S - - - - - - - - - T W K A G - - L - -
RD2-WT1-CDR1α-Library - - X - X - T - - - - - R S - - - - - - - - - - - - - - - - L - -
RD2-WT1-CDR3α-Library - - X - X - T - - - - - X X - - - - - - - - - - - - - - - - L - -
RD2-WT1-CDR1/3α-MART1-S2-1 - P Y - S - T - - - - - R S - - - - - - - - - V V W G S - - L - -
RD2-WT1-CDR1/3α-MART1-S2-2 - P Y - S - T - - - - - R S - - - - - - - - - L Y S R S - - L - -
RD2-WT1-CDR1/3α-MART1-S2-3 - P Y - S - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR1/3α-MART1-S2-4 - - I - S - T - - - - - R S - - - - - - - - - S W R A G - - L - -
RD2-WT1-CDR1/3α-MART1-S2-5 - P Y - S - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR1/3α-MART1-S4-1 - - F - T - T - - - - - R S - - - - - - - - - T W K A G - - L - -
RD2-WT1-CDR1/3α-MART1-S4-2 - P Y - S - T - - - - - R S - - - - - - - - - V V W G S - - L - -
RD2-WT1-CDR1/3α-MART1-S4-3 - - V - S - T - - - - - S V - - - - - - - - - L Y S R D - - L - R95Kβ
RD2-WT1-CDR1/3α-MART1-S4-4 - P Y - S - T - - - - - S L - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR1/3α-MART1-S4-5 - - I - S - T - - - - - S V - - - - - - - - - L F P A S - - L - -
RD2-WT1-CDR1/3α-MART1-S4-6 - - F - S - T - - - - - R S - - - - - - - - - L Y S R S - - L - -
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Figure 4.13 | Sequence alignment of clones isolated from the combined RD2-WT1-CDR1α  and 3α  
libraries with WT1. The two-codon (NNK) libraries generated from templates including three RD2 cross-
reactive clones (RD2-WT1-S3-1, RD2-WT1-S3-5, and RD2-WT1-S5-2) and non-truncated RD2-CDR3β 
library isolates (MART1/WT1-S5 #1-5) are shown. Degenerate residues (NNK) are indicated with “X,” and 
positions that varied in the library based on multiple templates are highlighted in blue. The RD2-WT1-
CDR1α and RD2-WT1-CDR3α libraries were combined in equal cell numbers prior to selections. The first 
group of clones shown (S2) were isolated following two positive magnetic selections with 5 µM WT1/HLA-
A2. The second group of clones shown (S4) were first subjected to two negative selections with 5 µM 
Tax/HLA-A2 before two positive selections with 5 µM WT1/HLA-A2. PCR-based mutations are highlighted 
in orange. Residue numbering is consistent with the crystal structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 
and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
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A6 wild-type Y S D R G S Q S F T T D S W G K L Q A S R P G L A G G R P E Q Y -
A6-X15 - - - - - - - - - - - - - - - - - - - - - - - - M S A Q - - L - -
RD2 Library - - X - X - † - - - - - X X - - - - - - - - - X * * * * - - L - -
RD2-WT1-CDR3β-Library - X X - S - T - - - - - R S - - - - - - - - - X X X X X - - L - -
RD2-WT1-S3-4 - - I - S - T - - - - - R S - - - - - - - - - V A G G R - - L - -
RD2-WT1-S3-5 - P Y - S - T - - - - - R S - - - - - - - - - V M S A Q - - L - -
RD2-WT1-S5-2 - - V - S - T - - - - - R S - - - - - - - - - A A G G R - - L - -
RD2-WT1-CDR3β-MART1-S5-1 - P Y - S - T - - - - - R S - - - - - - - - - V V W G S - - L - -
RD2-WT1-CDR3β-MART1-S5-2 - - V - S - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR3β-MART1-S5-3 - - I - S - T - - - - - R S - - - - - - - - - S W R A G - - L - -
RD2-WT1-CDR3β-MART1-S5-4 - P Y - S - T - - - - - R S - - - - - - - - - R G W G G - - L - -
RD2-WT1-CDR3β-MART1-S5-5 - - I - S - T - - - - - R S - - - - - - - - - V V G C R - - L - -
RD2-WT1-CDR3β-WT1-S5-1 - - I - S - T - - - - - R S - - - - - - - - - L Y S R D - - L - -
RD2-WT1-CDR3β-WT1-S5-3 - - I - S - T - - - - - R S - - - - - - - - - L F P A S - - L - -
RD2-WT1-CDR3β-WT1-S5-4 - P Y - S - T - - - - - R S - - - - - - - - - L Y S R S - - L - -
RD2-WT1-CDR3β-WT1-S5-5 - - I - S - T - - - - - R S - - - - - - - - - T W K A G - - L - -
RD2-WT1-CDR1α-Library - - X - X - T - - - - - R S - - - - - - - - - - - - - - - - L - -
RD2-WT1-CDR3α-Library - - X - X - T - - - - - X X - - - - - - - - - - - - - - - - L - -
RD2-WT1-CDR1/3α-WT1-S2-1 - P Y - S - T - - - - - R S - - - - - - - - - L F P A S - - L - -
RD2-WT1-CDR1/3α-WT1-S2-2 - P Y - S - T - - - - - R S - - - - - - - - - L Y S R S - - L - P13Tα
RD2-WT1-CDR1/3α-WT1-S2-3 - - V - S - T - - - - - R S - - - - - - - - - S W R A G - - L - -
RD2-WT1-CDR1/3α-WT1-S2-4 - - L - T - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR1/3α-WT1-S2-5 - P Y - S - T - - - - - R S - - - - - - - - - L Y S R S - - L - -
RD2-WT1-CDR1/3α-WT1-S2-6 - - I - S - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR1/3α-WT1-S4-1 - - V - S - T - - - - - R S - - - - - - - - - V V W G S - - L - A11TLinker
RD2-WT1-CDR1/3α-WT1-S4-2 - - I - S - T - - - - - R S - - - - - - - - - L F P A S - - L - -
RD2-WT1-CDR1/3α-WT1-S4-3 - - W - T - T - - - - - R S - - - - - - - - - S W R A G - - L - E117Dβ
RD2-WT1-CDR1/3α-WT1-S4-4 - - V - S - T - - - - - R S - - - - - - - - - A W A A G - - L - -
RD2-WT1-CDR1/3α-WT1-S4-5 - - V - T - T - - - - - R S - - - - - - - - - T W K A G - - L - -
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Figure 4.14 | Sequence alignment showing the RD1 and RD2 libraries aligned with the RD1.5 
library. Residues of A6 wild-type TCR8 and the high-affinity variant A6-X1536 are shown. Positions of 
degeneracy in the RD1.5 library are highlighted in gray, where X represents any amino acid (based on 
NNS nucleic acid composition). RD1.5 position 27α which was mutated to alanine is shown in orange. No 
clones with redirected specificities were isolated from the RD1.5 library. Residue numbering is consistent 
with the crystal structures of A6:Tax/HLA-A2 (PDB: 1AO7)8 and A6-c134:Tax/HLA-A2 (PDB: 4FTV)34. 
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Figure 4.15 | Binding analysis of various position 98β  mutants of selected TCRs. Binding titrations 
of the indicated mutants of A6-X15 (a), RD1-MART1 (b), RD1-MART1HIGH (c), and RD2-MART1 (d). 
Mutants were stained with 12.3 nM, 37.0 nM, 111 nM, 333 nM, and 1 μM Tax and MART/HLA-A2 PE-
conjugated streptavidin tetramers. Normalized percent max mean fluorescence intensity (MFI) is plotted 
against peptide/HLA-A2 tetramer concentration. This experiment was also performed with pepMHC-Ig 
dimers with similar results (data not shown). 
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Figure 4.16 | Prediction of TCR reaction specificity using Rosetta sequence tolerance algorithms. 
Crystal structures of the A6-c134 (PDB: 4FTV) (a) and DMF5 (PDB: 3QDG) (b) were used as input for 
Rosetta sequence tolerance algorithms49,50. Structural models of the predicted 10 lowest energy level 
configurations were made and mutated to the other possible 19 amino acids. The average predicted 
frequencies of each amino acid at the indicated TCRβ positions in the ensemble are presented as a 
ranked list with ranges specified by color. The top 5 residues are indicated by a dotted line. According to 
Smith and Kortemme49,50, 42-82% of amino acids from experimental phage display data occur above the 
dashed line in experimental validation datasets. 
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Figure 4.17 | Binding of soluble TCRs (RD1-MART1 and RD1-MART1HIGH) to human T2 cells loaded 
with Tax or MART1. T2 cells were loaded with Tax or MART1, followed by incubation with biotin-labeled 
RD1-MART1 (left) or RD1-MART1HIGH (right) scTCR at the indicated concentrations. The shaded gray 
histograms show staining with the null Tax-loaded T2 cells at the maximum concentration of TCR for each 
experiment (2 µM and 5 µM, respectively). Data is representative of 2 experiments with similar results. 
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Figure 4.18 | Equilibrium Binding of RD1-MART1 and RD1-MART1HIGH. SPR binding of immobilized 
RD1-MART1 (a) and RD1-MART1HIGH (b) scTCRs with MART1/HLA-A2 (selecting, non-cognate; black), 
Tax/HLA-A2 (non-selecting, cognate; purple), and gp100 (non-selecting, non-cognate; red). Data at each 
concentration are representative of two injections. Averages and standard deviations of all SPR 
experiments (including those in the reverse orientation) are shown in Table 4.1. 
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Figure 4.19 | MD simulation of the modeled A6-c134 CDR3β  loop. (a) Root mean square deviation 
(RMSD) of the CDR3β modeled positions 99-102 (based on the A6 wild-type crystal structure, PDB: 
1AO7) over 40 ns. The A6-c134 crystal structure (4FTV) was employed as the reference. An RMSD of 
<1.5 Å suggests a good sidechain overlap with respect to the crystal structure at the indicated positions. 
Raw data is shown in lighter color, and the block-averaged data are shown by the darker line. (b) Overlay 
of the backbone configurations of the A6-wt ‘MSAQ’ trajectory are shown in red, with the starting A6 wild-
type configuration (green) and A6-c134 crystal structure (blue). (c) Sidechain orientations of an A6-wt 
‘MSAQ’ trajectory configuration (RMSD of 0.6 Å) compared to their orientations in the A6-c134 crystal 
structure (4FTV). 
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Figure 4.20 | MD of DMF5 TCR Residue F100β .  (a) Snapshots of DMF5 residue F100β from the 
simulations compared with the original crystal structure conformation. The conformation of F100β from 
the crystal is shown in red, the starting conformation is shown in yellow, the final conformation is shown in 
cyan, and the intermediates are also shown in cyan in stick representation. (b) Root mean square 
deviation (RMSD) of the heavy atoms of the F100β sidechain from the crystal structure orientation. (c) χ1 
and χ2 dihedral angles of F100β. For both (b) and (c) raw data is shown in lighter color, and the block-
averaged data are shown by darker lines. 
a 
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Figure 4.21 | Snapshots of TCR:peptide/HLA-A2 interactions based on MD simulations. (a) Specific 
hydrogen bonding and salt-bridge interactions are shown for A6-c134:Tax/HLA-A2. (b) A superposition of 
A6-c134:Tax/HLA-A2 and RD1-MART1:MART1/HLA-A2 (3QDG/DMF5-orientation), highlighting the extra 
space created by the curvature of MART1 but not by Tax. (c) Insertion of tryptophan W101α of RD1-
MART1 into the interface between MART1 and HLA-A2 in the 3QDG/DMF5-orientation. (d) Insertion of 
tryptophan W98β of RD1-MART1 into the interface between MART1 and HLA-A2 in the 3HG1/Mel5-
orientation. (e) Salt bridge interactions that occur in the 3QDG/DMF5-orientation of the RD1-
MART1:MART1/HLA-A2 complex. (f) The absence of tryptophan insertion in RD1-MART1 when Tax 
replaces MART1 in the HLA-A2 complex (4FTV/A6-c134-orientation). 
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Figure 4.22 | MD predicted interactions between TCR and peptide or MHC. The colors indicate the 
probability of strong interaction, which is measured by the fraction of time residues interact with a distance 
less than 3.5 Å during the simulation. The size of each marker is also proportional to the interaction 
probability. The optimal interaction distance during interactions is indicated on the y-axis.  
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Figure 4.23 | MD of interactions of alternative RD1-MART1 orientations. No significant hydrophobic 
interactions exist between W98β and W101α and MART1 peptide when RD1-MART1 is in 4FTV/A6-
c134-orientation (a) or 3QDM/DMF4-orientation (b). 
b a 
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Figure 4.24 | MD of solvent accessible surface area in modeled complexes. Hydrophobic 
interactions between W98β (a,c) or W101α (b,d) and the peptide-MHC complex, indicated by solvent 
accessible surface area (relative). The A6-c134 (c,d) and RD1-MART1 (a,b) TCRs are abbreviated as A6 
and RD1, respectively. 
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Figure 4.25 | Overlay of RD1-MART1 models and the DMF TCR. Superposition of the DMF5 TCR with 
RD1-MART1 in the 3QDG/DMF5-orientation and RD1-MART1 in the 3HG1/Mel5-orientation, using MHC 
as an alignment reference. The key aromatic residue at position 98β (for the 3HG1/Mel5-orientation) and 
101α (for the 3QDG/DMF5-orientation) are highlighted in red and green, respectively. The aromatic 
F100β of the aligned DMF5 TCR crystal structure is in yellow. The MART1 peptide in each structure or 
model is shown with matching color. 
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Figure 4.26 | Modeling of RD2-WT1 that yielded cross-reactivity with non-selecting ligands. 
Rosetta Backrub flexible backbone modeling algorithms were used to model the RD2-WT1 mutations 
(D26αI, red; G28αS, orange; S100αR, yellow; W101αS, green; and L98βV, blue) into the wild-type A6 
crystal structure (PDB: 1AO7)8. HLA-A2 residues within 3.2 Å of RD2-WT1 residues are labeled in italics 
and shown as sticks (gray) (a) The wild-type A6 crystal structure (PDB: 1AO7)8 showing RD2-WT1 
positions prior to mutation. (b) The A6 crystal structure (PDB: 1AO7)8 with mutated RD2-WT1 residues. 
Tax peptide is shown in black. (c) The A6 crystal structure (PDB: 1AO7)8 with mutated RD2-WT1 
residues and mutated WT1 peptide in the HLA-A2 binding groove (cyan).  
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Table 
TCR Variant pepMHC KD equilibrium 
(kinetic) 
EC50  
HLA-A2 monomer 
EC50  
HLA-A2 Ig dimer 
RD1-Tax-1 Tax/HLA-A2 84 nM  
(34 nM) 
297 nM 110 nM 
RD1-MART1 MART1/HLA-A2 3.1 ± 3.9 µM > 5.0 µM 130 nM 
RD1-MART1HIGH MART1/HLA-A2 250 ± 120 nM  
(68 nM) 
52 nM 2 nM 
T1-S18.45 MART1/HLA-A2 45 nM   167 nM 12 nM 
 
Table 4.1 | Binding properties of RD1 library-derived TCR clones. SPR experiments were performed 
at 25°C with peptide/HLA-A2 monomers immobilized on a sensor chip and soluble scTCR flowed over in 
solution. For one replicate with RD1-MART1 and RD1-MART1HIGH scTCRs, the orientation was reversed 
such that soluble scTCR was immobilized on a sensor chip and soluble pepMHC was flowed over in 
solution (curves shown in Fig. 4.18). The MART1 peptide used for these experiments was the anchor 
modified decamer MART1 variant (i.e. MART126–35 A27L: ELAGIGILTV). For equilibrium SPR values, n=4 
for RD1-MART1 and n=3 for RD1-MART1HIGH. For kinetic SPR values, n=1 for A6-X15 and RD1-
MART1HIGH. EC50 values for titrations on the surface of yeast with soluble peptide/HLA-A2 monomers and 
Ig dimers are reported with n=1. The A6-X15 TCR (sequence identical to RD1-Tax1) value was previously 
measured to be 53.4 nM by SPR36. T1-S18.45 is a MART1-specific TCR, previously engineered for higher 
affinity with a measured affinity of 45 nM23. Typically EC50 values are higher than SPR values at affinities 
(KD) >100 nM due to wash steps prior to flow cytometry analysis; A possible explanation for the 
discrepancy of RD1-MART1HIGH is that the scTCR protein was less stable in solution at high 
concentrations. 
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APPENDIX A 
 
 
 
GENES, LIBRARIES & PRIMERS 
 
 
 
A.1 Synthesized gene constructs 
 
1.1 T1 scTv gene (from INRi-T1 T cell clone) 
 
Source: Genscript 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ16 
Notes: codon optimized for yeast, synthesized with F49Sα mutation for stability 
 
N-terminal flanking sequence: 5’ – ggtggttctgctagc – 3’ 
C-terminal flanking sequence: 5' – ctcgagatctgt – 3’ 
 
scTv construct (Vβ-Linker-Vα): 
 
gaagctggtgttactcaattcccatctcattcagttattgaaaagggtcagaccgtgact     
 E  A  G  V  T  Q  F  P  S  H  S  V  I  E  K  G  Q  T  V  T  
ctgcgctgtgatccgatttctggtcatgataatctgtattggtatcgtagagttatgggt   
 L  R  C  D  P  I  S  G  H  D  N  L  Y  W  Y  R  R  V  M  G  
aaagaaattaaattcctgctgcatttcgtgaaggaatctaagcaagatgaatctggtatg   
 K  E  I  K  F  L  L  H  F  V  K  E  S  K  Q  D  E  S  G  M  
ccaaataaccgctttctggcagaacgtaccggtggtacttattctaccctgaaagttcaa   
 P  N  N  R  F  L  A  E  R  T  G  G  T  Y  S  T  L  K  V  Q  
ccggccgaactggaagattctggtgtgtatttttgcgcctcttcacatgcgggtctgggt   
 P  A  E  L  E  D  S  G  V  Y  F  C  A  S  S  H  A  G  L  G  
gttgaacagtattttggtccaggtacccgtctgaccgtgactgaagatttgaaaaatggt   
 V  E  Q  Y  F  G  P  G  T  R  L  T  V  T  E  D  L  K  N  G  
tctgctgatgatgctaagaaagatgctgctaagaaagatggtaaatcacaaaaggaagtt   
 S  A  D  D  A  K  K  D  A  A  K  K  D  G  K  S  Q  K  E  V  
gaacagaactctggtccactgtcagtgccggaaggtgccattgcgtctctgaactgtact   
 E  Q  N  S  G  P  L  S  V  P  E  G  A  I  A  S  L  N  C  T  
tattcagatagaggttctcaatctttcttttggtatcgccagtattctggtaaatcaccg   
 Y  S  D  R  G  S  Q  S  F  F  W  Y  R  Q  Y  S  G  K  S  P  
gaactgatcatgtctatctattcaaacggcgataaggaagatggtcgttttaccgctcaa   
 E  L  I  M  S  I  Y  S  N  G  D  K  E  D  G  R  F  T  A  Q  
ctgaacaaagcatctcagtatgtttcactgctgattagagattctcaaccatctgattca   
 L  N  K  A  S  Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  S   
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gccacttatctgtgcgcggtgaatgataacgctcgtctgatgtttggcgatggtacccag   
 A  T  Y  L  C  A  V  N  D  N  A  R  L  M  F  G  D  G  T  Q  
ctggttgtgaaaccgaatatttaatag  
 L  V  V  K  P  N  I  -  -  
 
 
 
1.2 R1 scTv gene (from INRi T cell clone) 
 
Source: Genscript 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ14 
Notes: codon optimized for yeast 
 
N-terminal flanking sequence: 5’ – ggtggttctgctagc – 3’ 
C-terminal flanking sequence: 5' – ctcgagatctgt – 3’ 
 
scTv construct (Vβ-Linker-Vα): 
 
gaagcccaagttacccagaatccacgctatctgattaccgttactggtaaaaagctgacc   
 E  A  Q  V  T  Q  N  P  R  Y  L  I  T  V  T  G  K  K  L  T  
gtgacttgttctcaaaacatgaaccatgaatacatgtcatggtatcgccaagatccgggt   
 V  T  C  S  Q  N  M  N  H  E  Y  M  S  W  Y  R  Q  D  P  G  
ctgggtctgcgtcaaatctattactctatgaacgttgaagtgactgataaaggcgatgtt   
 L  G  L  R  Q  I  Y  Y  S  M  N  V  E  V  T  D  K  G  D  V  
ccagaaggttacaaagtgtcacgtaaagaaaaacgtaattttccgctgattctggaatct   
 P  E  G  Y  K  V  S  R  K  E  K  R  N  F  P  L  I  L  E  S  
ccatcaccgaaccagacctctctgtatttttgtgcttctggcgataattcaccactgcat   
 P  S  P  N  Q  T  S  L  Y  F  C  A  S  G  D  N  S  P  L  H  
tttggtaacggtactcgtctgaccgtgactgaagatttgaacaaaggttctgctgatgat   
 F  G  N  G  T  R  L  T  V  T  E  D  L  N  K  G  S  A  D  D  
gctaagaaagatgctgctaagaaagatggtaaatcacaaaaggaagttgaacagaactct   
 A  K  K  D  A  A  K  K  D  G  K  S  Q  K  E  V  E  Q  N  S  
ggtccactgtcagtgccggaaggtgccattgcgtctctgaactgcacctattcagataga   
 G  P  L  S  V  P  E  G  A  I  A  S  L  N  C  T  Y  S  D  R  
ggttctcaatctttcttttggtatcgccagtattctggtaaatcaccggaactgatcatg   
 G  S  Q  S  F  F  W  Y  R  Q  Y  S  G  K  S  P  E  L  I  M  
tctatctattcaaacggcgataaggaagatggtcgttttactgcccaactgaacaaagcg   
 S  I  Y  S  N  G  D  K  E  D  G  R  F  T  A  Q  L  N  K  A  
tctcagtatgtttcactgctgattagagattctcaaccatctgattcagctacctatctg   
 S  Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  S  A  T  Y  L  
tgtgcaggtactctgggttttggtaacgtgctgcattgcggttcaggtacccaggttatt   
 C  A  G  T  L  G  F  G  N  V  L  H  C  G  S  G  T  Q  V  I  
gtgctgccgcatatttaatag  
 V  L  P  H  I  -  -  
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1.3 Survivin71 scTv gene 
 
Source: Genscript 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ20 
Notes: codon optimized for yeast, synthesized with F49Sα mutation for stability 
 
N-terminal flanking sequence: 5’ – ggtggttctgctagc – 3’ 
C-terminal flanking sequence: 5' – ctcgagatctgt – 3’ 
 
scTv construct (Vβ-Linker-Vα): 
 
tctcaaaccattcatcagtggccagccactctggttcaaccagtgggttctccgctgtca   
 S  Q  T  I  H  Q  W  P  A  T  L  V  Q  P  V  G  S  P  L  S  
ctggaatgtaccgttgaaggtacttctaatccgaacctgtattggtatcgccaagctgca   
 L  E  C  T  V  E  G  T  S  N  P  N  L  Y  W  Y  R  Q  A  A  
ggtcgtggtctgcagctgctgttttattcagttggtatcggtcaaatttcttcagaagtg   
 G  R  G  L  Q  L  L  F  Y  S  V  G  I  G  Q  I  S  S  E  V  
ccacagaatctgtctgcgtcacgtccgcaagatagacagtttattctgtcttctaagaaa   
 P  Q  N  L  S  A  S  R  P  Q  D  R  Q  F  I  L  S  S  K  K  
ctgctgctgtctgattcaggtttttatctgtgtgcctggtctattggtgcggaacagttt   
 L  L  L  S  D  S  G  F  Y  L  C  A  W  S  I  G  A  E  Q  F  
ttcggtccaggtacccgcctgactgtgctggaagatttgaaaaatggttctgccgatgat   
 F  G  P  G  T  R  L  T  V  L  E  D  L  K  N  G  S  A  D  D  
gctaagaaagatgccgctaagaaagatggtaaatcacaaaaggaagttgaacagaactct   
 A  K  K  D  A  A  K  K  D  G  K  S  Q  K  E  V  E  Q  N  S  
ggtccactgtcagtgccggaaggtgctattgcatctctgaactgcacctattcagataga   
 G  P  L  S  V  P  E  G  A  I  A  S  L  N  C  T  Y  S  D  R  
ggttctcaatctttcttttggtatcgccagtattctggtaaatcaccggaactgatcatg   
 G  S  Q  S  F  F  W  Y  R  Q  Y  S  G  K  S  P  E  L  I  M  
tctatctattcaaacggcgataaggaagatggtcgttttactgctcaactgaacaaagca   
 S  I  Y  S  N  G  D  K  E  D  G  R  F  T  A  Q  L  N  K  A  
tctcagtatgtttcactgctgattagagattctcaaccatctgattcagctacctatctg   
 S  Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  S  A  T  Y  L  
tgcgctgtgaataacgcacgtctgatgtttggcgatggtactcagctggttgtgaaaccg   
 C  A  V  N  N  A  R  L  M  F  G  D  G  T  Q  L  V  V  K  P  
aatatttaatag  
 N  I  -  -  
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1.4 WT1-P20 scTv gene 
 
Source: Genscript 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ3 
Notes: codon optimized for yeast, added a c-myc tag (EQKLISEEDL) 
 
N-terminal flanking sequence: 5’ – ggtggttctgctagc – 3’ 
C-terminal flanking sequence: 5' – ctcgagatctgtgcgt – 3’ 
 
scTv construct (Vβ-Linker-Vα): 
 
gatgttaaagtgacacaatcttcacgttatctggtgaaaagaacgggtgaaaaggtcttt   
 D  V  K  V  T  Q  S  S  R  Y  L  V  K  R  T  G  E  K  V  F  
ttagaatgtgttcaagatatggatcatgaaaacatgttctggtacagacaggatcctggt   
 L  E  C  V  Q  D  M  D  H  E  N  M  F  W  Y  R  Q  D  P  G  
ttaggcttgcgcctgatctatttctcctacgatgttaagatgaaggaaaaaggcgatatc   
 L  G  L  R  L  I  Y  F  S  Y  D  V  K  M  K  E  K  G  D  I  
ccagaaggctattctgtttctcgtgaaaagaaagaacgtttctctttgatcttggaatcc   
 P  E  G  Y  S  V  S  R  E  K  K  E  R  F  S  L  I  L  E  S  
gcctctaccaatcagacttctatgtacctgtgtgcgacctcacatcaaccacagcacttt   
 A  S  T  N  Q  T  S  M  Y  L  C  A  T  S  H  Q  P  Q  H  F  
ggcgatggcactagactgagcatcttagaagatttgaacaaaggtagtgctgatgatgct   
 G  D  G  T  R  L  S  I  L  E  D  L  N  K  G  S  A  D  D  A  
aagaaagatgctgctaagaaagatggcaaatctcaaaaggaagtggaacaaaattctggt   
 K  K  D  A  A  K  K  D  G  K  S  Q  K  E  V  E  Q  N  S  G  
ccattgtctgtcccggaaggcgccattgcgagtctgaactgcacatattccgatcgtggt   
 P  L  S  V  P  E  G  A  I  A  S  L  N  C  T  Y  S  D  R  G  
tcacaaagctttttctggtatagacagtactctggcaaatcaccggaattaattatgagc   
 S  Q  S  F  F  W  Y  R  Q  Y  S  G  K  S  P  E  L  I  M  S  
atctacagtaatggcgataaagaagatggccgcttcactgcccaactgaacaaagcgtca   
 I  Y  S  N  G  D  K  E  D  G  R  F  T  A  Q  L  N  K  A  S  
cagtatgtcagcctgttaatccgtgattcacaacctagtgattccgctacatacctgtgc   
 Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  S  A  T  Y  L  C  
gcagtcttagaaggccagaaattgctgtttgctcgcggcacgatgttgaaagttgatctg   
 A  V  L  E  G  Q  K  L  L  F  A  R  G  T  M  L  K  V  D  L  
aacattgaacaaaaattaatcagtgaagaagatttgtaataa   
 N  I  E  Q  K  L  I  S  E  E  D  L  -  -   
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1.5 WT1-P22 scTv gene 
 
Source: Genscript 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ3 
Notes: codon optimized for yeast, added a c-myc tag (EQKLISEEDL) 
 
N-terminal flanking sequence: 5’ – ggtggttctgctagc – 3’ 
C-terminal flanking sequence: 5' – catatgctcgagatctgtgcgt – 3’ 
 
scTv construct (Vβ-Linker-Vα): 
 
gatgttaaagtgacacaatcttcacgttatttggttaaaagaacgggtgaaaaagtcttt   
 D  V  K  V  T  Q  S  S  R  Y  L  V  K  R  T  G  E  K  V  F  
ctggaatgtgttcaagatatggatcatgaaaacatgttctggtacagacaggatcctggc   
 L  E  C  V  Q  D  M  D  H  E  N  M  F  W  Y  R  Q  D  P  G  
ttgggtctgcgcttgatctatttctcatacgatgttaagatgaaagaaaaaggcgatatc   
 L  G  L  R  L  I  Y  F  S  Y  D  V  K  M  K  E  K  G  D  I  
ccagaaggttattctgtttctcgtgaaaagaaagaacgtttcagtttgattctggaaagc   
 P  E  G  Y  S  V  S  R  E  K  K  E  R  F  S  L  I  L  E  S  
gctagtaccaatcaaacttccatgtacctgtgtgcaagcagttccatcaacgaacagttt   
 A  S  T  N  Q  T  S  M  Y  L  C  A  S  S  S  I  N  E  Q  F  
ttcggcccaggtacaagattaacggtgctggaagatttgaaaaatggctctgccgatgat   
 F  G  P  G  T  R  L  T  V  L  E  D  L  K  N  G  S  A  D  D  
gctaagaaagatgctgctaagaaagatggtaaatcacaaaaggaagtggaacagaatagc   
 A  K  K  D  A  A  K  K  D  G  K  S  Q  K  E  V  E  Q  N  S  
ggcccattaagtgtcccggaaggtgctattgcatcattgaactgcacctatagcgatcgt   
 G  P  L  S  V  P  E  G  A  I  A  S  L  N  C  T  Y  S  D  R  
gtctcccaatctttcttttggtatagacagtacagtggcaaatccccggaactgattatg   
 V  S  Q  S  F  F  W  Y  R  Q  Y  S  G  K  S  P  E  L  I  M  
tctatctactcaaatggcgataaagaagatggtcgctttaccgctcaattaaacaaagca   
 S  I  Y  S  N  G  D  K  E  D  G  R  F  T  A  Q  L  N  K  A  
tcccagtatgtctctctgttaatccgtgatagccaaccgtcagatagcgccacttacctg   
 S  Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  S  A  T  Y  L  
tgcgccgcgaataacgcgggtaatatgctgaccttcggtggcggtactcgcttaatggtt   
 C  A  A  N  N  A  G  N  M  L  T  F  G  G  G  T  R  L  M  V  
aagcctcacatcgaacagaagttgatctctgaagaagatttgtaataa   
 K  P  H  I  E  Q  K  L  I  S  E  E  D  L  -  -   
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1.6 HLA-A2 α1α2 module 
 
Source: Genscript 
Notes: codon optimized for yeast, added a c-myc tag (EQKLISEEDL) 
 
N-terminal flanking sequence: 5’ – tctgctagc – 3’ 
C-terminal flanking sequence: 5' – tagtagctcgagatctga – 3’ 
 
HLA-A2 module construct (α1-α2): 
 
ggctctcattctatgcgctacttctttacttccgtcagtcgccctggccgtggtgaacct   
 G  S  H  S  M  R  Y  F  F  T  S  V  S  R  P  G  R  G  E  P  
cgctttattgctgtcggttatgtggatgatacacaatttgttagattcgattctgacgct   
 R  F  I  A  V  G  Y  V  D  D  T  Q  F  V  R  F  D  S  D  A  
gcatcacagagaatggaaccacgcgctccgtggattgaacaagaaggtcctgaatattgg   
 A  S  Q  R  M  E  P  R  A  P  W  I  E  Q  E  G  P  E  Y  W   
gatggcgaaacacgcaaagtcaaggcacattcacagacacaccgtgttgatctgggcacg   
 D  G  E  T  R  K  V  K  A  H  S  Q  T  H  R  V  D  L  G  T  
ttaagaggctattacaatcaaagcgaagctggtagtcatacggttcagcgtatgtacggt   
 L  R  G  Y  Y  N  Q  S  E  A  G  S  H  T  V  Q  R  M  Y  G  
tgtgatgtgggctccgactggcgctttctgcgtggttatcaccaatatgcctacgatggc   
 C  D  V  G  S  D  W  R  F  L  R  G  Y  H  Q  Y  A  Y  D  G  
aaagactacatcgcgttgaaggaagatttgcgctcgtggaccgcagcagacatggctgca   
 K  D  Y  I  A  L  K  E  D  L  R  S  W  T  A  A  D  M  A  A  
cagaccactaaacataagtgggaagccgcgcacgttgctgaacaattacgtgcatatttg   
 Q  T  T  K  H  K  W  E  A  A  H  V  A  E  Q  L  R  A  Y  L  
gaaggcacttgcgtggaatggctgcgtagatacttagaaaacggcaaagaaacattacaa   
 E  G  T  C  V  E  W  L  R  R  Y  L  E  N  G  K  E  T  L  Q  
cgcaccgaacaaaaattgattagcgaagaagacttg   
 R  T  E  Q  K  L  I  S  E  E  D  L  
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A.2 Synthesized libraries 
 
2.1 Rational design library 1 (RD1) 
 
Source: Genscript 
Scaffold template: A6-X15 scTv 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ13 
Notes: codon optimized for yeast, added a c-myc tag (EQKLISEEDL) 
 
N-terminal flanking sequence: 5’ – tctgctagc – 3’ 
C-terminal flanking sequence: 5’ – ctcgagatctga – 3’ 
 
Degeneracies: NNS degenerate codons are indicated in bold and underlined. 
 
scTv library (Vβ-Linker-Vα): 
 
aatgctggtgtaacacaaacgccaaaattccaggttttaaagacaggccaatccatgacg   
 N  A  G  V  T  Q  T  P  K  F  Q  V  L  K  T  G  Q  S  M  T  
ttgcaatgtgctcaggacatgaaccatgaatatatggcatggtaccgtcaggatccgggt   
 L  Q  C  A  Q  D  M  N  H  E  Y  M  A  W  Y  R  Q  D  P  G  
atgggcttaagattgattcactattcagtaggtgttggcatcactgatcaaggtgacgtg   
 M  G  L  R  L  I  H  Y  S  V  G  V  G  I  T  D  Q  G  D  V  
ccggatggctacaaagtctctcgctcaaccactgaagattttccgctgcgtctgttaagc   
 P  D  G  Y  K  V  S  R  S  T  T  E  D  F  P  L  R  L  L  S  
gctgcaccttctcaaacctcagtgtatttctgcgcttcccgtccgggtnnsatgtcgnns   
 A  A  P  S  Q  T  S  V  Y  F  C  A  S  R  P  G  X  M  S  X  
cagcctgaactgtactttggtccaggcactagactgaccgtcactgaagatttaattaat   
 Q  P  E  L  Y  F  G  P  G  T  R  L  T  V  T  E  D  L  I  N  
ggtagcgccgatgacgcgaaaaaggacgccgcgaaaaaggatggcaaaagtcaaaaggaa   
 G  S  A  D  D  A  K  K  D  A  A  K  K  D  G  K  S  Q  K  E  
gtggaacaaaattctggtccactgtcagtcccggaaggcgccatcgcgtctttaaactgt   
 V  E  Q  N  S  G  P  L  S  V  P  E  G  A  I  A  S  L  N  C  
acatattcagatagaggtagcnnstctttcttttggtatcgccagtacagcggcaaaagt   
 T  Y  S  D  R  G  S  X  S  F  F  W  Y  R  Q  Y  S  G  K  S  
cctgaattaattatgtccatctactcgaatggtgacaaagaagatggccgcttcacggct   
 P  E  L  I  M  S  I  Y  S  N  G  D  K  E  D  G  R  F  T  A  
caactgaacaaggcaagccagtatgttagtttgctgattcgtgactcccagccttccgat   
 Q  L  N  K  A  S  Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  
tcggccacatacttgtgcgcggttacgnnsnnstcgtggggtaaactgcaatttggtgcg   
 S  A  T  Y  L  C  A  V  T  X  X  S  W  G  K  L  Q  F  G  A  
ggcacccaggttgtggtcactccagacgaacaaaagttgatctctgaagaagatttataa   
 G  T  Q  V  V  V  T  P  D  E  Q  K  L  I  S  E  E  D  L  -  
tga  
 -  
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2.2 Rational design library 1.5 (RD1.5) 
 
Source: Genscript 
Scaffold template: A6-wt scTv 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ13 
Notes: codon optimized for yeast, added a c-myc tag (EQKLISEEDL), introduced an 
R27Aα mutation (italicized and bolded below)  
 
N-terminal flanking sequence:  
5’ –
ggcagccccataaacacacagtatgtttttaaggacaatagctcgacgattgaaggtagata
cccatacgacgttccagactacgctctgcaggctagtggtggtggtggttctggtggtggtg
gttctggtggtggtggttctgctagc  
– 3’ 
 
C-terminal flanking sequence:  
 
5’ – 
ctcgagatctgttaacaacagtgtagatgtaacaaaatcgactttgttcccactgtactttt
agctcgtacaaaatacaatatacttttcatttctccgtaaacaacatgttttcccatgtaat
atccttttctatttttcgttccgttaccaactttacacatactttatatagctattcacttc
tatacactaaaaaactaagacaattttaattttgctgcctgccatatttcaatttgttataa
attcctataatttatcctattagtagctaaaaaaagatgaatgtgaatcgaatcctaagaga
attgagctccaattcgccctatagtgagtcgtatta  
– 3’ 
 
Degeneracies: NNS degenerate codons are indicated in bold and underlined. 
 
scTv library (Vβ-Linker-Vα): 
 
aacgcgggtgttactcagacgccgaagttccaagttttgaagacaggccaaagcatgaca   
 N  A  G  V  T  Q  T  P  K  F  Q  V  L  K  T  G  Q  S  M  T  
ttacagtgcgctcaggatatgaatcacgaatatatggcttggtaccgccaagacccgggt   
 L  Q  C  A  Q  D  M  N  H  E  Y  M  A  W  Y  R  Q  D  P  G  
atgggcttacgtttgattcattatagcgttggtgtgggcatcaccgatcagggtgacgtc   
 M  G  L  R  L  I  H  Y  S  V  G  V  G  I  T  D  Q  G  D  V  
cctgatggctacaaagtaagcagaagtaccactgaagattttcctctgcgcctgttaagt   
 P  D  G  Y  K  V  S  R  S  T  T  E  D  F  P  L  R  L  L  S  
gctgcaccatctcaaacatcagtctatttttgtgcttctcgtcctggtnnsgcaggtggc   
 A  A  P  S  Q  T  S  V  Y  F  C  A  S  R  P  G  X  A  G  G  
agaccagaactgtacttcggtcctggtacgcgtctgacagtgacggaagatttgattaat   
 R  P  E  L  Y  F  G  P  G  T  R  L  T  V  T  E  D  L  I  N  
ggttctgccgatgacgcgaaaaaggacgccgcgaaaaaggatggcaaatcacaaaaggaa   
 G  S  A  D  D  A  K  K  D  A  A  K  K  D  G  K  S  Q  K  E   
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gttgaacaaaattctggtccattatcagtgccggaaggcgctatcgcatccttgaactgt   
 V  E  Q  N  S  G  P  L  S  V  P  E  G  A  I  A  S  L  N  C  
acctattcggatgccggttctnnstcatttttctggtatcgtcagtacagcggcaaaagt   
 T  Y  S  D  A  G  S  X  S  F  F  W  Y  R  Q  Y  S  G  K  S  
ccagaactgattatgtccatctactcgaatggtgacaaagaagatggccgttttactgcc   
 P  E  L  I  M  S  I  Y  S  N  G  D  K  E  D  G  R  F  T  A  
caattaaacaaggcgagccagtatgtcagtttgctgattagagactctcaaccatccgat   
 Q  L  N  K  A  S  Q  Y  V  S  L  L  I  R  D  S  Q  P  S  D  
tcggctacctacttgtgcgcagtaactnnsnnsnnstggggtaaactgcagttcggtgcg   
 S  A  T  Y  L  C  A  V  T  X  X  X  W  G  K  L  Q  F  G  A  
ggcacccaggtcgtggtgacgcctgatgaacagaagctgatttccgaagaagacttatga   
 G  T  Q  V  V  V  T  P  D  E  Q  K  L  I  S  E  E  D  L  -  
tga  
 -  
 
 
2.3 Rational design library 2 (RD2) 
 
Source: DNA2.0 
Scaffold template: A6-wt and A6-X15 scTv 
TCR α−chain usage: Vα2 
TCB β−chain usage: Vβ13 
Notes: codon optimized for yeast, added a c-myc tag (EQKLISEEDL) 
 
N-terminal flanking sequence:  
5’ –
ggcagccccataaacacacagtatgtttttaaggacaatagctcgacgattgaaggtagata
cccatacgacgttccagactacgctctgcaggctagtggtggtggtggttctggtggtggtg
gttctggtggtggtggttctgctagc  
– 3’ 
 
C-terminal flanking sequence:  
 
5’ – 
ctcgagatctgttaacaacagtgtagatgtaacaaaatcgactttgttcccactgtactttt
agctcgtacaaaatacaatatacttttcatttctccgtaaacaacatgttttcccatgtaat
atccttttctatttttcgttccgttaccaactttacacatactttatatagctattcacttc
tatacactaaaaaactaagacaattttaattttgctgcctgccatatttcaatttgttataa
attcctataatttatcctattagtagctaaaaaaagatgaatgtgaatcgaatcctaagaga
attgagctccaattcgccctatagtgagtcgtatta  
– 3’ 
 
Degeneracies: NNK degenerate codons are indicated in bold and underlined; codon 
indicated by ‘^^^’ indicates a binary position where either T or Q can be selected; 
codons indicated by ‘***’ and ‘1234’ indicate a binary string where either the wild-
type A6 (i.e. AGGR) or A6-X15 (i.e. MSAQ) CDR3β positions 99-102 can be 
selected. 
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scTv library (Vβ-Linker-Vα): 
 
aacgccggagtatacgctctgcaggctagtggtggtggtggttctggtggtggtggttct   
 N  A  G  V  Y  A  L  Q  A  S  G  G  G  G  S  G  G  G  G  S  
ggtggtggtggttctgctagcaacgccggagtaacacaaaccccaaagtttcaggttcta   
 G  G  G  G  S  A  S  N  A  G  V  T  Q  T  P  K  F  Q  V  L  
aaaacagggcaaagcatgacattacaatgtgctcaagacatgaatcacgaatacatggct   
 K  T  G  Q  S  M  T  L  Q  C  A  Q  D  M  N  H  E  Y  M  A  
tggtacaggcaagatccaggtatgggcctgagacttatccattattctgtcggcgtcggt   
 W  Y  R  Q  D  P  G  M  G  L  R  L  I  H  Y  S  V  G  V  G  
atcacagaccaaggagatgttcctgacggctataaggtatctcgttccactacagaagat   
 I  T  D  Q  G  D  V  P  D  G  Y  K  V  S  R  S  T  T  E  D  
tttcctcttagattattgtccgcagcaccatctcaaacttctgtctacttttgcgcttca   
 F  P  L  R  L  L  S  A  A  P  S  Q  T  S  V  Y  F  C  A  S  
agacctggcNNK************ccagaactctacttcgggccaggaactagattaacc   
 R  P  G  X  1  2  3  4  P  E  L  Y  F  G  P  G  T  R  L  T   
gttacggaagatttgatcaacggttcagcagacgatgctaaaaaggatgcagccaaaaag   
 V  T  E  D  L  I  N  G  S  A  D  D  A  K  K  D  A  A  K  K  
gacggcaaaagtaaagaggtggaacagaactccggtccactatctgttccagaaggggcg   
 D  G  K  S  K  E  V  E  Q  N  S  G  P  L  S  V  P  E  G  A  
atagctagtttgaattgtacttactcaNNKagaNNKtct^^^tcctttttctggtacaga   
 I  A  S  L  N  C  T  Y  S  X  R  X  S Q/T  S  F  F  W  Y  R  
caatattctggtaaaagcccagaacttattatgtcaatctactctaatggtgacaaggag   
 Q  Y  S  G  K  S  P  E  L  I  M  S  I  Y  S  N  G  D  K  E  
gatggtcgttttacagcccagttgaataaggcatcacaatacgtttcattgctaataaga   
 D  G  R  F  T  A  Q  L  N  K  A  S  Q  Y  V  S  L  L  I  R  
gatagtcaaccttctgattcagctacttatttgtgtgcggtgacgacagatNNKNNKggc   
 D  S  Q  P  S  D  S  A  T  Y  L  C  A  V  T  T  D  X  X  G  
aaattacaattcggtgctgggacccaggtggttgtaacacctgatattgaacaaaaactg   
 K  L  Q  F  G  A  G  T  Q  V  V  V  T  P  D  I  E  Q  K  L  
atttctgaagaggatctctgataa  
 I  S  E  E  D  L  -  -  
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A.3 Primers for library synthesis, site-directed mutagenesis, and sub-cloning 
All primers were obtained from Integrated DNA Technologies (IDT). Primers are listed 
by template in the order of date purchased. 
 
 
3.1 Templates based on the 868 scTv and variants 
 
Template 
Clone(s) 
Type Date Purpose Primer Sequences 
868-Z11 SDM 26 
JUL 
2011 
Generate 
868-Z11 
R28Aα 
FOR: 5'- CTT CTT TGA ACT GTA CTT ACT CTG ATG CAG 
GTT CTC AAT CTT TCT TTT GG -3' 
REV: 5'- CCA AAA GAA AGA TTG AGA ACC TGC ATC AGA 
GTA AGT ACA GTT CAA AGA AG -3' 
868-Z11 SDM 26 
JUL 
2011 
Generate 
868-Z11 
Q31Aα 
FOR: 5'- CTG TAC TTA CTC TGA TAG AGG TTC TGC ATC 
TTT CTT TTG GTA CAG ACA ATA C -3' 
REV: 5'- GTA TTG TCT GTA CCA AAA GAA AGA TGC AGA 
ACC TCT ATC AGA GTA AGT ACA G -3' 
868-Z11 SDM 26 
JUL 
2011 
Generate 
868-Z11 
Y51Aα 
FOR: 5'- CTC CAG AAT TGA TCA TGT CCA TCG CCT CTA 
ATG GTG ACA AAG AAG ATG -3' 
REV: 5'- CAT CTT CTT TGT CAC CAT TAG AGG CGA TGG 
ACA TGA TCA ATT CTG GAG -3' 
868-Z11 SDM 26 
JUL 
2011 
Generate 
868-Z11 
S52Aα 
FOR: 5'- GAA TTG ATC ATG TCC ATC TAC GCT AAT GGT 
GAC AAA GAA GAT G -3' 
REV: 5'- CAT CTT CTT TGT CAC CAT TAG CGT AGA TGG 
ACA TGA TCA ATT C -3' 
868-Z11 SDM 28 
JUN 
2012 
Generate 
868-Z11 
D27Aα 
FOR: 5'- TTC TTT GAA CTG TAC TTA CTC TGC TAG AGG 
TTC TCA ATC TTT CTT TT -3' 
REV: 5'- AAA AGA AAG ATT GAG AAC CTC TAG CAG AGT 
AAG TAC AGT TCA AAG AA -3' 
868-Z11 SDM 28 
JUN 
2012 
Generate 
868-Z11 
D27Yα 
FOR: 5'- CTT CTT TGA ACT GTA CTT ACT CTT ATA GAG 
GTT CTC AAT CTT TCT TT -3' 
REV: 5'- AAA GAA AGA TTG AGA ACC TCT ATA AGA GTA 
AGT ACA GTT CAA AGA AG -3' 
868-Z11 SDM 28 
JUN 
2012 
Generate 
868-Z11 
D27Wα 
FOR: 5'- AAG GTG CTA TTG CTT CTT TGA ACT GTA CTT 
ACT CTT GGA GAG GTT CTC AAT CTT TC -3' 
REV: 5'- GAA AGA TTG AGA ACC TCT CCA AGA GTA AGT 
ACA GTT CAA AGA AGC AAT AGC ACC TT -3' 
868c SC 22 
MAR 
2013 
Sub-
cloning 
into 
pET28 
FOR: 5'- TAT ACC ATG GGC AGC AGC CAT CAT CAT CAT 
CAT CAC AGC AGC GGC CTG GTG CCG CGC GGC AGC 
GAA GCT GGT GTT ACC CAA TCT CCA ACC C -3' 
REV: 5'- TTT AGA ATT CTT AGA TAT GTG GGG TAA CCA 
GCA GAG AGG TAC C -3' 
Types of primers: 
- 454 = Amplicon primers for 454 sequencing 
- DL = Primers to generate degenerate libraries 
o N = Mix of A, T, C, and G 
o S = Mix of C and G 
o K = Mix of G and T 
- SC = Sub-cloning  
- SDM = Site-directed mutagenesis primers 
-  
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868c SDM 22 
MAR 
2013 
Generate 
868c 
Y51Aα in 
pET28 
FOR: 5'- TCT CCA GAA CTG ATT ATG TTT ATC GCC TCT 
AAT GGT GAC AAA GAA GAT GG -3' 
REV: 5'- CCA TCT TCT TTG TCA CCA TTA GAG GCG ATA 
AAC ATA ATC AGT TCT GGA GA -3' 
 
 
3.2 Templates based on the A6 scTv and rational design library (RD1 and RD2) 
variants 
 
Template 
Clone(s) 
Type Date Purpose Primer Sequences 
RD1 library SC 22 
JUN 
2011 
Add pCT302 
overhangs 
to 
synthesized 
RD1 library 
FOR: 5'- CAG GCT AGT GGT GGT GGT GGT TCT GGT 
GGT GGT GGT TCT GGT GGT GGT GGT TCT GCT 
AGC AAT GCT GGT GTA ACA CAA ACG CCA A -3' 
REV: 5'-	  GGA ACA AAG TCG ATT TTG TTA CAT CTA 
CAC TGT TGT TAA CAG ATC TCG AGT CAT TAT AAA 
TCT TCT TCA GAG ATC -3' 
A6-X15 SDM 26 
JUL 
2011 
Generate 
A6-X15 
R28Aα  
FOR: 5'- GCT TCT TTG AAC TGT ACT TAC TCA GAT 
GCA GGC TCC CAA TCA TT -3' 
REV: 5'- AAT GAT TGG GAG CCT GCA TCT GAG TAA 
GTA CAG TTC AAA GAA GC -3' 
A6-X15 SDM 26 
JUL 
2011 
Generate 
A6-X15 
Q31Aα 
FOR: 5'- TAC TTA CTC AGA TAG AGG CTC CGC ATC 
ATT TTT CTG GTA TAG ACA G -3' 
REV: 5'- CTG TCT ATA CCA GAA AAA TGA TGC GGA 
GCC TCT ATC TGA GTA AGT A -3' 
A6-X15 SDM 26 
JUL 
2011 
Generate 
A6-X15 
Y51Aα 
FOR: 5'- CCA GAA TTG ATC ATG TCT ATC GCT AGC 
AAC GGT GAT AAG GAG GA -3' 
REV: 5'- TCC TCC TTA TCA CCG TTG CTA GCG ATA 
GAC ATG ATC AAT TCT GG -3' 
A6-X15 SDM 26 
JUL 
2011 
Generate 
A6-X15 
S52Aα 
FOR: 5'- AGC CCA GAA TTG ATC ATG TCT ATC TAT 
GCC AAC GGT GAT AAG GA -3' 
REV: 5'- TCC TTA TCA CCG TTG GCA TAG ATA GAC 
ATG ATC AAT TCT GGG CT -3' 
A6-X15 SDM 28 
JUN 
2012 
Generate 
A6-X15 
D27Aα 
FOR: 5'- CTT TGA ACT GTA CTT ACT CAG CTA GAG 
GCT CCC AAT CAT TTT T -3' 
REV: 5'- AAA AAT GAT TGG GAG CCT CTA GCT GAG 
TAA GTA CAG TTC AAA G -3' 
A6-X15 SDM 28 
JUN 
2012 
Generate 
A6-X15 
D27Yα 
FOR: 5'- CTT CTT TGA ACT GTA CTT ACT CAT ATA 
GAG GCT CCC AAT CAT TTT TC -3' 
REV: 5'- GAA AAA TGA TTG GGA GCC TCT ATA TGA 
GTA AGT ACA GTT CAA AGA AG -3' 
A6-X15 SDM 28 
JUN 
2012 
Generate 
A6-X15 
D27Wα 
FOR: 5'- TGC GAT TGC TTC TTT GAA CTG TAC TTA 
CTC ATG GAG AGG CTC CCA ATC AT -3' 
REV: 5'- ATG ATT GGG AGC CTC TCC ATG AGT AAG 
TAC AGT TCA AAG AAG CAA TCG CA -3' 
RD1-
MART1 
RD1-
MART1HIGH 
SC 14 
MAR 
2012 
Sub-cloning 
into pET28 
FOR: 5'- TAT ACC ATG GGC AGC AGC CAT CAT CAT 
CAT CAT CAC AGC AGC GGC CTG GTG CCG CGC 
GGC AGC AAT GCT GGT GTA ACA CAA ACG CC -3' 
REV: 5'- TTT AGA ATT CTT AGT CTG GAG TGA CCA 
CAA CCT GGG T -3' 
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RD1-
MART1 
RD1-
MART1HIGH 
SC 09 
OCT 
2012 
Sub-cloning 
into pET28 
with BirA tag 
FOR: (same as above from 14-MAR-2012) 
REV: 5'- TTT AGA ATT CTT ATT CGT GCC ATT CGA 
TTT TCT GAG CCT CGA AGA TGT CGT TCA GAC 
CGC CAC CGT CTG GAG TGA CCA CAA CCT GGG T -
3' 
RD1-Tax-
S4-3 
DL 12 
DEC 
2012 
Attempt to 
generate the 
RD2 library 
with multiple 
primers and 
overlaps 
(i.e. O1, O2, 
& O3); 
library 
ended up 
being 
synthesized 
by DNA2.0 
REV from O1 (to Splice4L): 5'- ACC CGG ACG GGA 
AGC GCA GAA ATA CAC TGA GGT TTG AGA AGG 
TGC AGC GCT TAA CAG ACG CAG CGG -3' 
FOR from O1 to O2 (A6-X15): 5'- ACC TCA GTG TAT 
TTC TGC GCT TCC CGT CCG GGT NNS ATG TCG 
GCC CAG CCT GAA CTG TAC TTT GGT CCA GGC 
ACT AGA CTG -3' 
FOR from O1 to O2 (A6-wt): 5'- ACC TCA GTG TAT 
TTC TGC GCT TCC CGT CCG GGT NNS GCA GGT 
GGC AGA CCT GAA CTG TAC TTT GGT CCA GGC 
ACT AGA CTG -3' 
REV from O2 to O1 (A6-wt & A6-X15): 5'- TGA ATA 
TGT ACA GTT TAA AGA CGC GAT GGC GCC TTC 
CGG GAC TGA CAG TGG ACC AGA ATT TTG TTC 
CAC -3' 
FOR from O2 to O3 (Q31α): 5'- CCC GGA AGG CGC 
CAT CGC GTC TTT AAA CTG TAC ATA TTC ANN SAG 
ANN SAG CCA GTC TTT CTT TTG GTA TCG CCA GTA 
CAG CGG C -3' 
FOR from O2 to O3 (T31α): 5'- CCC GGA AGG CGC 
CAT CGC GTC TTT AAA CTG TAC ATA TTC ANN SAG 
ANN SAG CAC CTC TTT CTT TTG GTA TCG CCA GTA 
CAG CGG C -3' 
REV from O3 to O2 (Q31/T31α): 5'- GTC GGT CGT 
AAC CGC GCA CAA GTA TGT GGC CGA ATC GGA 
AGG CTG GGA GTC ACG AAT CAG CAA AC -3' 
FOR to O3 (to T7): 5'- TCG GCC ACA TAC TTG TGC 
GCG GTT ACG ACC GAC NNS NNS GGT AAA CTG 
CAA TTT GGT GCG GGC ACC CAG GTT GTG G -3' 
RD1-
MART1 
DL 14 
FEB 
2013 
Generation 
of the RD1-
MART1 
CDR3α 
library  
FOR: 5'- TCC GAT TCG GCC ACA TAC TTG TGC GCG 
GTT ACG NNK NNK NNK NNK NNK AAA CTG CAA 
TTT GGT GCG GGC ACC CAG GTT GTG G -3' 
REV: 5'- CGT AAC CGC GCA CAA GTA TGT GGC CGA 
ATC GGA AGG CTG GGA GTC ACG AAT CAG CAA 
ACT AAC ATA CTG GC -3' 
RD1-
MART1 
DL 14 
FEB 
2013 
Generation 
of the RD1-
MART1 
CDR3β-1 
library  
FOR: 5'- ACC TCA GTG TAT TTC TGC GCT TCC CGT 
CCG NNK NNK NNK NNK NNK CAG CCT GAA CTG 
TAC TTT GGT CCA GGC ACT AGA C -3' 
REV: 5'- CGG ACG GGA AGC GCA GAA ATA CAC TGA 
GGT TTG AGA AGG TGC AGC GCT TAA CAG ACG 
CAG CGG -3' 
RD1-
MART1 
DL 14 
FEB 
2013 
Generation 
of the RD1-
MART1 
CDR3β-2 
library  
FOR: 5'- ACC TCA GTG TAT TTC TGC GCT TCC CGT 
CCG GGT TGG NNK NNK NNK NNK NNK GAA CTG 
TAC TTT GGT CCA GGC ACT AGA CTG ACC G -3' 
REV: 5'- CGG ACG GGA AGC GCA GAA ATA CAC TGA 
GGT TTG AGA AGG TGC AGC GCT TAA CAG ACG 
CAG CGG -3' 
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A6-X15 SDM 22 
MAR 
2013 
Mutagenesis 
of A6-X15 in 
pET28 and 
pCT302 
CDR3β 
residues 99-
102 ‘MSAQ’ 
to ‘AGGR’ 
FOR: 5'- CTT TTG TGC ATC CAG ACC AGG GTT GGC 
GGG TGG CAG ACC AGA ACT ATA TTT TGG TCC 
AGG C -3' 
REV: 5'- GCC TGG ACC AAA ATA TAG TTC TGG TCT 
GCC ACC CGC CAA CCC TGG TCT GGA TGC ACA 
AAA G -3' 
A6-wt SDM 22 
MAR 
2013 
Generate 
A6-wt 
Y51Aα in 
pET28 
FOR: 5'- CCA GAA TTG ATC ATG TCT ATC GCT AGC 
AAC GGT GAT AAG GAG GA -3' 
REV: 5'- TCC TCC TTA TCA CCG TTG CTA GCG ATA 
GAC ATG ATC AAT TCT GG -3' 
A6-X15 SDM 09 
AUG 
2013 
Generate 
A6-X15 
L98Wβ (crys
tal structure 
numbering) 
FOR: 5'- CAT CCA GAC CAG GGT GGA TGA GTG CCC 
AAC C -3' 
REV: 5'- GGT TGG GCA CTC ATC CAC CCT GGT CTG 
GAT G -3' 
A6-X15 SDM 09 
AUG 
2013 
Generate 
A6-X15 
L98Mβ (crys
tal structure 
numbering) 
FOR: 5'- GCA TCC AGA CCA GGG ATG ATG AGT GCC 
CAA C -3' 
REV: 5'- GTT GGG CAC TCA TCA TCC CTG GTC TGG 
ATG C -3' 
RD1-
MART1 
SDM 09 
AUG 
2013 
Generate 
RD1-MART1 
W98Lβ 
FOR: 5'- CCC GTC CGG GTT TGA TGT CGG GCC A -3' 
REV: 5'- TGG CCC GAC ATC AAA CCC GGA CGG G -3'  
RD1-
MART1HIGH 
SDM 09 
AUG 
2013 
Generate 
RD1-
MART1HIGH 
W98Lβ 
FOR: 5'- CCG TCC GGG TTT GAT GGC GGG GG -3' 
REV: 5'- CCC CCG CCA TCA AAC CCG GAC GG -3' 
RD2-
MART1 
SDM 09 
AUG 
2013 
Generate 
RD2-MART1 
M98Lβ 
FOR: 5'- TTC AAG ACC TGG CTT GGC CGG TGG ACG 
-3' 
REV: 5'- CGT CCA CCG GCC AAG CCA GGT CTT GAA 
-3'  
Various 
RD2-WT1 
Clones 
DL 06 
DEC 
2013 
Generation 
of the RD2-
WT1 CDR3β 
library 
FOR: 5'- CTG TCT ACT TTT GCG CTT CAA GAC CTG 
GCN NKN NKN NKN NKN NKC CAG AAC TCT ACT 
TCG GGC CAG GAA CTA GAT TAA CCG -3' 
REV: 5'- GCC AGG TCT TGA AGC GCA AAA GTA GAC 
AGA AGT TTG AGA TGG TGC TGC GGA CAA TAA 
TCT AAG AGG -3' 
A6-wt SDM 13 
FEB 
2014 
Generate 
A6-wt 
Q30Tα 
(crystal 
structure 
numbering) 
for template 
for LL-
libraries 
FOR: 5'- GAA TAC TGT CTA TAC CAG AAA AAT GAC 
GTG GAG CCT CTA TCT GAG TAA GTA CAG T -3' 
REV: 5'- ACT GTA CTT ACT CAG ATA GAG GCT CCA 
CGT CAT TTT TCT GGT ATA GAC AGT ATT C -3' 
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A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 18-
FEB 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLβ(n) 
FOR: 5'- CCC TCA CAA ACT AGC GTT TAC TTT TGT 
GCA TCC AGA CCA GGG NNK NNK NNK NNK NNK 
CCA GAA CTA TAT TTT GGT CCA GGC ACC CGG -3' 
REV: 5'- CCC TGG TCT GGA TGC ACA AAA GTA AAC 
GCT AGT TTG TGA GGG AGC AGC GGA TAA TAG 
TCT TAA TGG GAA ATC CTC -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 18-
FEB 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLβ(n-1) 
FOR: 5'- CCC TCA CAA ACT AGC GTT TAC TTT TGT 
GCA TCC AGA CCA GGG NNK NNK NNK NNK CCA 
GAA CTA TAT TTT GGT CCA GGC ACC CGG -3' 
REV: 5'- CCC TGG TCT GGA TGC ACA AAA GTA AAC 
GCT AGT TTG TGA GGG AGC AGC GGA TAA TAG 
TCT TAA TGG GAA ATC CTC -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 18-
FEB 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLβ(n-2) 
FOR: 5'- CCC TCA CAA ACT AGC GTT TAC TTT TGT 
GCA TCC AGA CCA GGG NNK NNK NNK NNK GAA 
CTA TAT TTT GGT CCA GGC ACC CGG -3' 
REV: 5'- CCC TGG TCT GGA TGC ACA AAA GTA AAC 
GCT AGT TTG TGA GGG AGC AGC GGA TAA TAG 
TCT TAA TGG GAA ATC CTC -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 18-
FEB 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLβ(n-3) 
FOR: 5'- CCC TCA CAA ACT AGC GTT TAC TTT TGT 
GCA TCC AGA CCA GGG NNK NNK NNK GAA CTA 
TAT TTT GGT CCA GGC ACC CGG -3' 
REV: 5'- CCC TGG TCT GGA TGC ACA AAA GTA AAC 
GCT AGT TTG TGA GGG AGC AGC GGA TAA TAG 
TCT TAA TGG GAA ATC CTC -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 18-
FEB 
2014 
For 
generating 
combina-
torial A6 
loop length 
libraries, A6-
LL_Comb1 
FOR: 5'- CCT CCT TTT GAG ATT TAC CAT CTT TCT 
TAG CTG CAT CTT TCT TTG CAT CAT CTG CGC TTC 
C -3' 
REV: 5'- GGA AGC GCA GAT GAT GCA AAG AAA GAT 
GCA GCT AAG AAA GAT GGT AAA TCT CAA AAG 
GAG G -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 06 
MAR 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLα(n) 
FOR: 5'- CCG TCT GAT TCA GCC ACA TAT CTA TGT 
GCA GTG ACT NNK NNK NNK NNK NNK AAA CTA 
CAA TTT GGA GCA GGT ACG CAG GTG G -3' 
REV: 5'- CAC TGC ACA TAG ATA TGT GGC TGA ATC 
AGA CGG TTG ACT GTC TCT GAT CAA TAA GGA 
CAC -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 06 
MAR 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLα(n-1) 
FOR: 5'­ CCG TCT GAT TCA GCC ACA TAT CTA TGT 
GCA GTG ACT NNK NNK NNK NNK AAA CTA CAA TTT 
GGA GCA GGT ACG CAG GTG G ­3' 
REV: 5'- CAC TGC ACA TAG ATA TGT GGC TGA ATC 
AGA CGG TTG ACT GTC TCT GAT CAA TAA GGA 
CAC -3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 06 
MAR 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLα(n-2) 
FOR: 5'- CCG TCT GAT TCA GCC ACA TAT CTA TGT 
GCA GTG NNK NNK NNK NNK AAA CTA CAA TTT 
GGA GCA GGT ACG CAG GTG G -3' 
REV: 5'- CAC TGC ACA TAG ATA TGT GGC TGA ATC 
AGA CGG TTG ACT GTC TCT GAT CAA TAA GGA 
CAC -3' 
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A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 06 
MAR 
2014 
Generate 
the A6 loop 
length 
library, A6-
LLα(n-3) 
FOR: 5'- CCG TCT GAT TCA GCC ACA TAT CTA TGT 
GCA GTG NNK NNK NNK NNK CTA CAA TTT GGA 
GCA GGT ACG CAG GTG G ­3' 
REV: 5'- CAC TGC ACA TAG ATA TGT GGC TGA ATC 
AGA CGG TTG ACT GTC TCT GAT CAA TAA GGA 
CAC -3' 
Various 
RD2-WT1 
and RD2-
WT1 
CDR3β 
Clones 
DL 06 
MAR 
2014 
Generation 
of the RD2-
WT1 
CDR1α 
library 
FOR: 5'­ GCG ATA GCT AGT TTG AAT TGT ACT TAC 
TCA NNK AGA NNK TCT ACT TCC TTT TTC TGG TAC 
AGA CAA TAT TCT GG -3' 
REV: 5'- TGA GTA AGT ACA ATT CAA ACT AGC TAT 
CGC CCC TTC TGG AAC AGA TAG TGG AC 
C GGA GTT CTG ­3' 
Various 
RD2-WT1 
and RD2-
WT1 
CDR3β 
Clones 
DL 06 
MAR 
2014 
Generation 
of the RD2-
WT1 
CDR3α 
library 
FOR: 5'­ GCT ACT TAT TTG TGT GCG GTG ACG ACA 
GAT NNK NNK GGC AAA TTA CAA TTC GGT GCT 
GGG ACC CAG GTG G ­3' 
REV: 5'- ATC TGT CGT CAC CGC ACA CAA ATA AGT 
AGC TGA ATC AGA AGG TTG ACT ATC TC 
T TAT TAG C ­3' 
A6-wt 
A6-D27A 
A6-R28A 
A6-Q31A 
A6-Q31T 
DL 04 
APR 
2014 
For 
generating 
combina-
torial A6 
loop length 
libraries, A6-
LL_Comb2 
FOR: 5'- GCA ACG GTG ATA AGG AGG ACG GTC 
GGT TTA CTG CTC -3' 
REV: 5' GAG CAG TAA ACC GAC CGT CCT CCT TAT 
CAC CGT TGC 3' 
 
 
 
3.3 Templates based on the T1 scTv and variants 
 
Template 
Clone(s) 
Type Date Purpose Primer Sequences 
T1-S8 SDM 11 
FEB 
2010 
Introduce 
Q80Rα 
mutation to 
determine if 
stability is 
conferred 
FOR: 5'- TCA GTA TGT TTC ACT GCT GAT TAG AGA 
TTC TAG ACC ATC TGA TTC AGC C -3' 
REV: 5'- GGC TGA ATC AGA TGG TCT AGA ATC TCT 
AAT CAG CAG TGA AAC ATA CTG A -3' 
T1-S18 DL 16 
FEB 
2010 
Generation of 
the T1-S18 
CDR3 library 
β1 
FOR: 5'- GGA AGA TTC TGG TGT GTA TTT TTG CGC 
CTC TTC ANN SNN SNN SNN SNN SGT TG 
A ACA GTA TTT TGG TCC AGG TAC CCG TC -3' 
REV: 5'- TGA AGA GGC GCA AAA ATA CAC ACC 
AGA ATC TTC CAG TTC GGC CGG TTG AAT TTT 
CAG GG -3' 
T1-S18 DL 16 
FEB 
2010 
Generation of 
the T1-S18 
CDR3 library 
β2 
FOR: 5'- GGA AGA TTC TGG TGT GTA TTT TTG CGC 
CTC TTC ACA TGC GGG TCT GNN SNN SNN SNN 
SNN STT TGG TCC AGG TAC CCG TCT GAC C -3' 
REV: 5'- TGA AGA GGC GCA AAA ATA CAC ACC 
AGA ATC TTC CAG TTC GGC CGG TTG AAT TTT 
CAG GG -3' 
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T1-S8 SDM 04 
MAR 
2010 
Introduce 
S40Pα 
mutation to 
determine if 
stability is 
conferred 
FOR: 5'- CTT TTG GTA TCG CCA GTA TCC TGG TAA 
ATC ACC GGA A -3' 
REV: 5'- TTC CGG TGA TTT ACC AGG ATA CTG GCG 
ATA CCA AAA G -3' 
T1-S18 DL 26 
MAR 
2010 
Generation of 
the T1-S18 
CDR3 library 
α1 
FOR: 5'- CCA TCT GAT TCA GCC ACT TAT CTG TGC 
GCG GTG NNS NNS NNS NNS NNS CTG ATG TTT 
GGC GAT GGT ACC CAG CTG GTT GTG -3' 
REV: 5'- CAC CGC GCA CAG ATA AGT GGC TGA 
ATC AGA TGG TCG AGA ATC TCT AAT CAG CAG 
TGA AAC ATA CTG AGA -3' 
T1-S18 DL 26 
MAR 
2010 
Generation of 
the T1-S18 
CDR3 library 
α2 
FOR: 5'- CCA TCT GAT TCA GCC ACT TAT CTG TGC 
GCG GTG AAT GAT NNS NNS NNS NNS NNS TTT 
GGC GAT GGT ACC CAG CTG GTT GTG -3' 
REV: 5'- CAC CGC GCA CAG ATA AGT GGC TGA 
ATC AGA TGG TCG AGA ATC TCT AAT CAG CAG 
TGA AAC ATA CTG AGA -3' 
T1-wt 
T1-S18 
T1-S18.45 
SC 13 
JUL 
2010 
Sub-cloning 
into pET28 
FOR: 5'- TAT ACC ATG GGC AGC AGC CAT CAT CAT 
CAT CAT CAC AGC AGC GGC CTG GTG CCG CGC 
GGC AGC GAA GCT GGT GTT ACT CAA TTC -3' 
REV: 5'- TTT AGA ATT CTT AAA TAT TCG GTT TCA 
CAA CCA G -3' 
T1-S18.45 SDM 26 
JUL 
2011 
Generate T1-
S18.45 R28Aα 
FOR: 5'- GCG TCT CTG AAC TGT ACT TAT TCA GAT 
GCA GGT TCT CAA TCT TTC TT -3' 
REV: 5'- AAG AAA GAT TGA GAA CCT GCA TCT GAA 
TAA GTA CAG TTC AGA GAC GC -3' 
T1-S18.45 SDM 26 
JUL 
2011 
Generate T1-
S18.45 Q31Aα 
FOR: 5'- GTA CTT ATT CAG ATA GAG GTT CTG CAT 
CTT TCT TTT GGT ATC GCC AGT -3' 
REV: 5'- ACT GGC GAT ACC AAA AGA AAG ATG 
CAG AAC CTC TAT CTG AAT AAG TAC -3' 
T1-S18.45 SDM 26 
JUL 
2011 
Generate T1-
S18.45 Y51Aα 
FOR: 5'- CGG AAC TGA TCA TGT CTA TCG CTT CAA 
ACG GCG ATA AGG AAG -3' 
REV: 5'- CTT CCT TAT CGC CGT TTG AAG CGA TAG 
ACA TGA TCA GTT CCG -3' 
T1-S18.45 SDM 26 
JUL 
2011 
Generate T1-
S18.45 S52Aα 
FOR: 5'- CGG AAC TGA TCA TGT CTA TCT ATG CAA 
ACG GCG ATA AGG -3' 
REV: 5'- CCT TAT CGC CGT TTG CAT AGA TAG ACA 
TGA TCA GTT CCG -3' 
T1-S18 DL 10 
NOV 
2011 
Generation of 
the T1-S18.45 
position 
Q31α library  
FOR: 5'- CTG AAC TGT ACT TAT TCA GAT AGA GGT 
TCT NNS TCT TTC TTT TGG TAT CGC CAG TAT CCT 
GGT -3' 
REV: 5'- AGA ACC TCT ATC TGA ATA AGT ACA GTT 
CAG AGA CGC AAT GGC ACC TTC CGG CAC TGA 
CAG TGG -3' 
T1-S18 DL 10 
NOV 
2011 
Generation of 
the T1-S18.45 
position 
Y51α library 
FOR: 5'- CCT GGT AAA TCA CCG GAA CTG ATC ATG 
TCT ATC NNS TCA AAC GGC GAT AAG GAA GAT 
GGT CGT TTT ACC -3' 
REV: 5'- GAT AGA CAT GAT CAG TTC CGG TGA TTT 
ACC AGG ATA CTG GCG ATA CCA AAA GAA AGA 
TTG AGA ACC -3' 
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T1-S18.45 
Q31α  
library 
(Pre-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG ACG AGT GCG TGG TCC AGG TAC CCG TCT 
GAC CGT GAC TG -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG CGA CGA GGA CAC CGC GCA CAG ATA AGT 
GGC -3' 
T1-S18.45 
Q31α  
library 
(Post-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG ACG CTC GAC AGG TCC AGG TAC CCG TCT 
GAC CGT GAC TG -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG CGA CGA GGA CAC CGC GCA CAG ATA AGT 
GGC -3' 
T1-S18.45 
Y51α  
library 
(Pre-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG AGA CGC ACT CCC ACT GTC AGT GCC GGA 
AGG TGC CAT TGC G -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG CAG GAA GTC CGA CGA GGA CAC CGC GCA 
CAG -3' 
T1-S18.45 
Y51α  
library 
(Post-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG AGC ACT GTA GCC ACT GTC AGT GCC GGA 
AGG TGC CAT TGC G -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG CAG GAA GTC CGA CGA GGA CAC CGC GCA 
CAG -3' 
T1-S18.45 SDM 28 
JUN 
2012 
Generate T1-
S18.45 D27Aα 
FOR: 5'- GTC TCT GAA CTG TAC TTA TTC AGC TAG 
AGG TTC TCA ATC TTT CTT TT -3' 
REV: 5'- AAA AGA AAG ATT GAG AAC CTC TAG CTG 
AAT AAG TAC AGT TCA GAG AC -3' 
T1-S18.45 SDM 28 
JUN 
2012 
Generate T1-
S18.45 D27Yα 
FOR: 5'- CGT CTC TGA ACT GTA CTT ATT CAT ATA 
GAG GTT CTC AAT CTT TCT TT -3' 
REV: 5'- AAA GAA AGA TTG AGA ACC TCT ATA TGA 
ATA AGT ACA GTT CAG AGA CG -3' 
 
T1-S18.45 SDM 28 
JUN 
2012 
Generate T1-
S18.45 
D27Wα 
FOR: 5'- GGT GCC ATT GCG TCT CTG AAC TGT ACT 
TAT TCA TGG AGA GGT TCT CAA TCT TT -3' 
REV: 5'- AAA GAT TGA GAA CCT CTC CAT GAA TAA 
GTA CAG TTC AGA GAC GCA ATG GCA CC -3' 
T1-S18 SDM 22 
MAR 
2013 
Generate T1-
S18 Y51Aα in 
pET28 
FOR: 5'- CGG AAC TGA TCA TGT CTA TCG CTT CAA 
ACG GCG ATA AGG AAG -3' 
REV: 5'- CTT CCT TAT CGC CGT TTG AAG CGA TAG 
ACA TGA TCA GTT CCG -3' 
 
3.4 Templates based on the WT1-P22 scTv and variants 
 
Template 
Clone(s) 
Type Date Purpose Primer Sequences 
WT1-D13 
WT1-D15 
WT1-
D13.1 
DL 28 
JUL 
2010 
Generation of 
the WT1 
CDR3 library 
α1 
FOR: 5'- CAA CCG TCA GAT AGC GCC ACT TAC CTG 
TGC GCC NNS NNS NNS NNS NNS AAT ATG CTG 
ACC TTC GGT GGC GGT ACT CGC TTA ATG -3' 
REV: 5'- GGC GCA CAG GTA AGT GGC GCT ATC 
TGA CGG TTG GCT ATC ACG GAT TAA CAG AGA 
GAC ATA CTG GGA -3' 
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WT1-D13 
WT1-D15 
WT1-
D13.1 
DL 28 
JUL 
2010 
Generation of 
the WT1 
CDR3 library 
α2 
FOR: 5'- CAA CCG TCA GAT AGC GCC ACT TAC CTG 
TGC GCC GCG AAT AAC GCG NNS NNS NNS NNS 
NNS TTC GGT GGC GGT ACT CGC TTA ATG -3' 
REV: 5'- GGC GCA CAG GTA AGT GGC GCT ATC 
TGA CGG TTG GCT ATC ACG GAT TAA CAG AGA 
GAC ATA CTG GGA -3' 
WT1-D13 
WT1-D15 
WT1-
D13.1 
DL 28 
JUL 
2010 
Generation of 
the WT1 
CDR3 library 
β1 
FOR: 5'- AGT ACC AAT CAA ACT TCC ATG TAC CTG 
TGT GCA NNS NNS NNS NNS NNS GAA CAG TTT 
TTC GGC CCA GGT ACA AGA TTA ACG GTG -3' 
REV: 5'- TGC ACA CAG GTA CAT GGA AGT TTG ATT 
GGT ACT AGC GCT TTC CAG AAT CAA ACT GAA 
ACG TTC TTT -3' 
WT1-D13 
WT1-D15 
WT1-
D13.1 
DL 28 
JUL 
2010 
Generation of 
the WT1 
CDR3 library 
β2 
FOR: 5'- AGT ACC AAT CAA ACT TCC ATG TAC CTG 
TGT GCA AGC AGT TCC NNS NNS NNS NNS NNS 
TTC GGC CCA GGT ACA AGA TTA ACG GTG -3' 
REV: 5'- TGC ACA CAG GTA CAT GGA AGT TTG ATT 
GGT ACT AGC GCT TTC CAG AAT CAA ACT GAA 
ACG TTC TTT -3' 
WT1-P22 
WT1-D13 
WT1-D15 
DL 01 
DEC 
2010 
Generation of 
the WT1 
CDR1α library  
FOR: 5'- ATT GCA TCA TTG AAC TGC ACC TAT AGC 
GAT CGT NNS NNS NNS NNS TTC TTT TGG TAT 
AGA CAG TAC AGT GGC AAA TCC CCG -3' 
REV: 5'- ACG ATC GCT ATA GGT GCA GTT CAA TGA 
TGC AAT AGC ACC TTC CGG GAC ACT TAA TGG 
GCC GCT -3' 
WT1-
D13.1.1 
SDM 15 
JUN 
2011 
Generation of 
WT1-D13.0.1 
FOR: 5'- ATT GAA CTG CAC CTA TAG CGA TCG TGT 
CTC GCA GTC GTT CTT TTG GTA TAG ACA GTA 
CAG -3' 
REV: 5'- CTG TAC TGT CTA TAC CAA AAG AAC GAC 
TGC GAG ACA CGA TCG CTA TAG GTG CAG TTC 
AAT -3' 
WT1-
D13.1.1 
SC 15 
JUN 
2011 
Sub-cloning 
into pET28 
FOR: 5'- TAT ACC ATG GGC AGC AGC CAT CAT CAT 
CAT CAT CAC AGC AGC GGC CTG GTG CCG CGC 
GGC AGC GAT GTT AAA GTG ACA CAA TCT -3' 
REV: 5'- TTT AGA ATT CTT AGA TGT GAG GCT TAA 
CCA TTA A -3' 
WT1-
D13.1.1 
SDM 07 
SEP 
2011 
Generate 
WT1-D13.1.1 
Y51Aα 
FOR: 5'- CCC GGA ACT GAT TAT GTC TAT CGC CTC 
AAA TGG CGA TAA AGA AGA T -3' 
REV: 5'- ATC TTC TTT ATC GCC ATT TGA GGC GAT 
AGA CAT AAT CAG TTC CGG G -3' 
WT1-
D13.1.1 
DL 10 
NOV 
2011 
Generation of 
the WT1-
D13.1.1 
CDR1α 
position 29-31 
library 
 
FOR: 5'- GCA TCA TTG AAC TGC ACC TAT AGC GAT 
CGT NNS NNS NNS TCG TTC TTT TGG TAT AGA 
CAG TAC AGT GGC -3' 
REV: 5'- ACG ATC GCT ATA GGT GCA GTT CAA TGA 
TGC AAT AGC ACC TTC CGG GAC ACT TAA TGG 
GCC GCT -3' 
WT1-
D13.1.1 
DL 10 
NOV 
2011 
Generation of 
the WT1-
D13.1.1 
position 
Y51α library 
FOR: 5'- GGC AAA TCC CCG GAA CTG ATT ATG TCT 
ATC NNS TCA AAT GGC GAT AAA GAA GAT GGT 
CGC TTT ACC GCT -3' 
REV: 5'- GAT AGA CAT AAT CAG TTC CGG GGA TTT 
GCC ACT GTA CTG TCT ATA CCA AAA GAA CGA 
GCC C -3' 
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WT1-
D13.1.1 
CDR1α 
position 
29-31 
library 
(Pre-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG CGT GTC TCT AGG CTC TGC CGA TGA TGC 
TAA GAA AGA TGC TGC T -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG ACC CGC GTT ATT CGC GGC GCA CAG GTA 
AGT GGC -3' 
WT1-
D13.1.1 
CDR1α 
position 
29-31 
library 
(Post-20 
nM sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG CTC GCG TGT CGG CTC TGC CGA TGA TGC 
TAA GAA AGA TGC TGC T -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG ACC CGC GTT ATT CGC GGC GCA CAG GTA 
AGT GGC -3' 
WT1-
D13.1.1 
CDR1α 
position 
29-31 
library 
(Post-100 
nM sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG TAG TAT CAG CGG CTC TGC CGA TGA TGC 
TAA GAA AGA TGC TGC T -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG ACC CGC GTT ATT CGC GGC GCA CAG GTA 
AGT GGC -3' 
WT1-
D13.1.1 
Y51α  
library  
(Pre-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG ATC AGA CAC GAG CGG CCC ATT AAG TGT 
CCC GGA AGG TGC T -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG ACC CGC GTT ATT CGC GGC GCA CAG GTA 
AGT GGC -3' 
WT1-
D13.1.1 
Y51α  
library  
(Post-sort) 
454 25 
JAN 
2012 
Generate 
amplicon for 
454 
sequencing 
with unique 
barcode (MID) 
FOR: 5'- CCA TCT CAT CCC TGC GTG TCT CCG ACT 
CAG ATA TCG CGA GAG CGG CCC ATT AAG TGT 
CCC GGA AGG TGC T -3' 
REV: 5'- CCT ATC CCC TGT GTG CCT TGG CAG TCT 
CAG ACC CGC GTT ATT CGC GGC GCA CAG GTA 
AGT GGC -3' 
WT1-
D13.1.1 
SC 09 
OCT 
2012 
Sub-cloning 
into pET28 
with BirA tag 
FOR: (same as above from 15-JUN-2011) 
REV: 5'- TTT AGA ATT CTT ATT CGT GCC ATT CGA 
TTT TCT GAG CCT CGA AGA TGT CGT TCA GAC 
CGC CAC CGA TGT GAG GCT TAA CCA TTA A -3' 
 
3.5 Templates based on other constructs 
 
Template 
Clone(s) 
Type Date Purpose Primer Sequences 
HLA-A2 
α1α2 
module 
SC 13 
MAY 
2010 
To add 
overhangs for 
sub-cloning 
into pCT302 
FOR: 5'- GTA AAA CGA CGG CCA GTG -3' 
REV: 5'- GGA AAC AGC TAT GAC CAT G -3' 
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APPENDIX B 
 
 
 
REAGENTS AND SOLUTIONS 
 
 
 
B.1 Yeast display strain, plasmid, and primers 
 
1. Saccharomyces cerevisiae yeast display strain EBY100 (a GAL1-
AGA1::URA3 ura3-52 trp1 leu2Δ1 his3Ø200 pep4::HIS2 prb1Δ1.6R can1 
GAL) 
2. pCT302 yeast display vector 
3. pCT302 standard primers  
a. Splice 4L (forward): 5’ GGCAGCCCCATAAACACACAGTAT  
b. YRS (reverse): Rev 3’ CGAGCTAAAAGTACAGTGGG 
c. T7 (reverse): Rev 3’ TAATACGACTCACTATAG 
B.2 DNA purification 
1. Zymoprep kit II (Zymo Research) 
2. QIAprep spin miniprep kit (Qiagen) 
3. QIAquick gel extraction kit (Qiagen) 
4. Silica bead DNA gel extraction kit (Thermo Scientific) 
5. QIAquick PCR purification kit (Qiagen) 
6. DNA clean & concentrator-100 kit (Zymo Research) 
7. Pellet paint co-precipitant (Novagen) 
8. Agencourt AMPure XP PCR purification beads (Beckman Coulter) 
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B.3 Restriction enzymes and ligation  
1. BglII  
2. DpnI  
3. EcoRI 
4. NcoI 
5. NheI 
6. XhoI  
7. T4 DNA ligase 
8. Calf intestinal alkaline phosphatase (CIP)  
B.4 PCR  
1. FastStart high fidelity PCR system (Roche) 
2. dATP solution  
3. dCTP solution  
4. dGTP solution  
5. dTTP solution  
6. Deoxynucleotide (dNTP) solution mix (New England Biolabs) 
7. PfuTurbo DNA polymerase (Agilent) 
8. Taq DNA polymerase (Invitrogen) 
9. VentR DNA polymerase (New England Biolabs) 
B.5 LiOAc yeast heat shock transformation 
1. 50% PEG 3350: dissolve 5 g PEG 3350 to a final volume of 10 mL ddH2O, sterile 
filter and store at room temperature for up to 6 months. 
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2. 1 M LiOAc: dissolve 16.5 g LiOAc in 250 mL ddH2O, sterile filter and store at 
room temperature for up to 6 months. 
3. 10X TE: dissolve 121 mg Tris (10 mM) and 29 mg EDTA (1 mM) in 100 mL 
ddH2O, sterile filter, and store at room temperature for up to 6 months. 
4. Single-stranded carrier: Dissolve 200 mg salmon sperm DNA (Sigma) in 100 mL 
1X TE buffer, aliquot into 1 mL stocks, and store at -20°C. 
B.6 Electrocompetent E. coli strains 
1. For DNA amplification: Sub-cloning efficiency DH5α competent cells 
(Invitrogen) 
2. For DNA ligation: Turbo competent E. coli (New England Biolabs) 
3. For protein expression: BL21(DE3) competent E. coli (New England Biolabs) 
B.7 Yeast media 
 
1. YPD media: Dissolve 10 g yeast extract, 20 g bacto-peptone, and 20 g 
dextrose, bring volume to 1 L with ddH2O, autoclave, and store at room 
temperature for up to 1 month.  
2. YPD plates: Dissolve 10 g yeast extract, 20 g bacto-peptone, 15 g agar, and 
20 g dextrose, bring volume to 1 L dH2O, and autoclave.  Cool to ~55°C and 
pour ~25 mL into 100 mm X 15 mm plates. Cool and store at +4°C for up to 1 
month. 
3. SD-CAA media: Dissolve 14.8 g sodium citrate, 4.2 g citric acid monohydrate, 
5 g casamino acids, 6.7 g yeast nitrogen base (without amino acids), 20 g 
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dextrose, and 10 mL penicillin-streptomycin (10,000 U/mL), bring volume to 1 
L with ddH2O, sterile filter, and store at 4°C for up to 6 months. 
4. SD-CAA plates: Dissolve 91.1 g sorbitol, 7.5 g agar, 7.4 g sodium citrate, and 
2.1 g citric acid monohydrate in 400 mL of ddH2O, autoclave, and cool to 
~55°C. In a separate container combine 2.5 g casamino acids, 10 g dextrose 
and 3.35 g yeast nitrogen base (without amino acids) to 100 mL of ddH2O, 
sterile filter, and add to cooled autoclaved solution. Mix and pour ~25 mL into 
100 mm X 15 mm plates. Cool and store at +4°C for up to 6 months. 
5. SG-CAA media: Dissolve 14.8 g sodium citrate, 4.2 g citric acid monohydrate, 
5 g casamino acids, 6.7 g yeast nitrogen base (without amino acids), 20 g 
galactose, and 10 mL penicillin-streptomycin (10,000 U/mL), bring volume to 
1 L with ddH2O, sterile filter, and store at 4°C for up to 6 months. 
B.8 Yeast library  
1. 1 M sorbitol: dissolve 45.6 g sorbitol in 250 mL ddH2O, sterile filter, and store at 
4°C for up to 6 months. 
2. 1 M sorbitol/1 mM CaCl2: dissolve 45.5 g sorbitol and 27 mg of CaCl2 in 250 mL 
ddH2O, sterile filter, and store at 4°C for up to 6 months. 
3. 0.1 M LiAc/10 mM DTT: dissolve 1.65 g lithium acetate (LiAc) and 0.386 g 
dithiothreitol (DTT) in 250 mL ddH2O, sterile filter, and cool to 4°C for immediate 
use. 
4. 0.2 cm electroporation cuvettes 
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B.9 Yeast staining  
1. Phosphate-buffered saline (PBS): Dissolve 8 g NaCl, 0.2 g KCl, 1.15 g 
Na2HPO47H2O, and 0.2 g KH2PO4 (anhydrous); bring volume up to 1 L with 
ddH2O, adjust pH to 7.4, autoclave, and store at room temperature. 
2. PBS/1% BSA: Dissolve 10 g bovine serum albumin (BSA) in 1 L PBS, sterile 
filter, and chill to 4°C. 
3. Anti-c-myc, chicken IgY fraction (Invitrogen cat. no. A12181) 
4. HA.11 clone 16B12 monoclonal antibody (anti-HA) (Covance cat. no. MMS-
101P) 
5. AlexaFluor 647 goat anti-chicken IgG (H+L) (Molecular Probes cat. no. A-
21449) 
6. Streptavidin-phycoerythrin (BD Pharmingen cat. no. 554061) 
7. AlexaFluor 647 F(ab')2 fragment of goat anti-mouse IgG (H+L) (Molecular 
Probes cat. no. A-21237) 
8. Goat-anti-mouse IgM APC (Life Technologies cat. no M31505) 
9. BD DimerX HLA-A2:Ig recombinant fusion protein, human (BD Pharmingen) 
cat. no. 551263) 
10. Anti-Vα2 antibody (Generated in the Kranz lab) 
11. Antibodies against TCR Vβ 
a. Anti-hVβ3 FITC antibody (clone CH92; Beckman-Coulter) 
b. Anti-hVβ3.1 FITC antibody (clone 8F10; Thermo Scientific) 
c. Anti-Vβ14 antibody (clone CAS1.1.3; Beckman-Coulter) 
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d. Anti-Vβ16 antibody (clone TAMAYA1.2; Beckman-Coulter) 
e. Anti-hVβ20 antibody (clone ELL1.4; Beckman-Coulter) 
B.10 Expression plasmids 
1. HLA-A2 heavy chain (HLA-A2bsp in pHN1); obtained from the from University 
of Massachusetts Medical School Tetramer Facility 
2. HLA-A2 light chain (β2 microglobulin in pHN1); obtained from the NIH 
Tetramer Facility 
3. pET28b expression vector 
B.11 Bacterial expression media 
1. Luria broth (LB): Dissolve 5 g yeast extract, 10 g tryptone, and 10 g NaCl in 1 
L ddH2O, autoclave, and store at room temperature. 
2. Ampicillin (100 mg/mL): Stock solution can be made by dissolving 1 g into 10 
mL ddH2O, sterile filtering, and freezing individual aliquots at -20°C. 
3. Kanamycin (50 mg/mL): Stock solution can be made by dissolving 0.5 g into 
10 mL ddH2O, sterile filtering, and freezing individual aliquots at -20°C. 
4. LB + ampicillin (100 µg/mL) plates: Dissolve 5 g yeast extract, 10 g tryptone, 
10 g NaCl, and 15 g agar in 1 L dH2O and autoclave.  Cool to ~55°C, then 
add 1 mL ampicillin stock at 100 mg/mL, swirl, then pour ~25 mL into 100 mm 
X 15 mm plates.  Cool and store at +4°C. 
5. LB + kanamycin (50 µg/mL) plates: Dissolve 5 g yeast extract, 10 g tryptone, 
10 g NaCl, and 15 g agar in 1 L dH2O and autoclave.  Cool to ~55°C, then 
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add 1 mL kanamycin stock at 50 mg/mL, swirl, then pour ~25 mL into 100 mm 
X 15 mm plates.  Cool and store at +4°C. 
B.12 Inclusion body isolation  
1. Lysis buffer: 50 mM Tris base, 100 nM NaCl, 0.1% NaN3, 1% Triton X-100, 10 
mM dithiothreitol (DTT), and 1 mM phenylmethylsulfonyl fluoride (PMSF, 
dissolved in 1 mL isopropanol), bring volume to 1 L with ddH2O and adjust pH 
to 8.0 with hydrochloric acid. Buffer can be stored without DTT and PMSF for 
up to 6 months. 
2. Osmotic shock buffer: 20 mM Tris base and 2.5 mM 
ethylenediaminetetraacetic acid (EDTA); bring volume up to 1 L with ddH2O, 
adjust pH to 8.0, and chill to 4°C. 
3. Osmotic shock buffer with triton: Add 0.5% Triton X-100 to 1 L osmotic shock 
buffer and chill to 4°C. 
4. Urea extraction buffer: 8 M urea, 25 mM MES, 10 mM EDTA, and 0.1 mM 
dithiothreitol (DTT) in 10 mL at pH 6.0. 
5. Guanidine extraction buffer: 8 M guanidine-HCl, 50 mM Tris, 5 mM EDTA, 5 
mM dithiothreitol (DTT) in 10 mL at pH 8.0. 
B.13 scTCR refold 
1. scTCR refold buffer: 3 M urea, 50 mM Tris base; bring volume up to 400 mL 
with ddH2O, adjust pH to 8.0 with HCl, and chill to 4°C. 
2. scTCR dilution buffer: 200 mM NaCl, 50 mM Tris base; bring volume up to 3 L 
with ddH2O, adjust pH to 8.0 with HCl, and chill to 4°C. 
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3. Oxidized glutathione  
4. Reduced glutathione 
5. Phenylmethylsulfonyl fluoride (PMSF) 
6. Ni-NTA agarose (Qiagen) 
7. Elution buffer: 500 mM imidazole, 2.5 mM EDTA solution in 1 X PBS pH to 
8.0. 
B.14 MHC refold  
1. MHC refold buffer: 400 mM Tris, 400 mM L-Arg, 2 mM EDTA; bring volume 
up to 200 mL with ddH2O, adjust pH to 8.0, and chill to 4°C. 
2. Injection buffer: 3 M guanidine-HCl, 10 mM sodium acetate, and 10 mM 
EDTA; bring volume up to 250 mL with ddH2O and adjust pH to 4.2. Aliquots 
can be frozen and stored at -20°C. 
3. Dialysis buffer: 20 mM Tris in 3 L ddH2O, adjust pH to 8.0, and chill to 4°C. 
4. Regenerated cellulose 6-8 MWCO dialysis tubing 
5. Amicon Ultra-4 centrifugal filter units with Ultracel-10 membrane (Amicon) 
B.15  TCR and MHC biotinylation, purification, and quantification  
1. In vitro biotinylation kit (Avidity)  
2. TCR HPLC buffer: 1 X PBS, adjust to pH 8.0, and degas. 
3. MHC HPLC buffer: 20 mM tris and 50 mM NaCl in 1 L ddH2O, adjust pH to 
8.0, and degas. 
4. EDTA stock: 0.5 M EDTA in 50 mL ddH2O, adjust pH to 8.0, and sterile filter. 
5. BCA protein assay kit (Pierce) 
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B.16 MHC-restricted peptides 
1. UV-cleavable peptide, KILGFVFJV, where J is the photolabile amino acid 
residue, prepared by standard Fmoc-peptide solid phase synthesis using 
commercially available Fmoc-3-amino-3-(2-nitro)phenyl propionic acid as a 
building block; store in the dark at -20 °C. 
2. HLA-A2-restricted peptide(s) (20 mg/mL): Dissolve 20 mg of lyophilized 
peptide into 1 mL DMSO; store at -20°C. 
a. gp100209–217: ITDQVPFSV  
b. HBV-Env183–191: FLLTRILTI  
c. MART-127-35 (MART-1_9mer): AAGIGILTV  
d. MART-127-35 A28L: ALGIGILTV 
e. MART-126–35 A27L (MART-1_10mer): ELAGIGILTV  
f. MDM253-60: VLFYLGQY  
g. NYESO157 – 165: SLLMWITQC 
h. NYESO157 – 165 Q8NC9V (NYESO-Val): SLLMWITNV  
i. Preproinsulin15-24 (PPI): ALWGPDPAAA  
j. SL977-85 (HIV-gag): SLYNTVATL 
k. Survivin95–104: LTLGEFLKL  
l. Survivin95-104 T2M: LMLGEFLKL  
m. Tax11 – 19: LLFGYPVYV  
n. Tax11 – 19 F3A: LLAGYPVYV 
o. Tax11 – 19 F3G: LLGGYPVYV 
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p. Tax11 – 19 Y5A: LLFGAPVYV 
q. Tax11 – 19 Y8A: LLFGYPVAV 
r. Tax11 – 19 Y8T: LLFGYPVTV 
s. Tax11 – 19 F3AY8T: LLAGYPVTV 
t. Tax11 – 19 F3AY5AY8T: LLAGAPVTV 
u. Tel1p549–557: MLWGYLQYV  
v. WT1126-134: RMFPNAPYL 
3. HLA-A2-restricted peptide(s) (2 mg/mL): Perform a 1:10 dilution of 20 mg/mL 
peptide stock in DMSO in PBS; store at -20°C. 
B.17 Magnetic selection  
1. PBSM buffer: 8 g NaCl, 0.2 g KCl, 1.44 g Na2PO4, 0.24 g KH2PO4, 5 g bovine 
serum albumin, and 744 mg EDTA in 1 L dH2O, adjust to pH 7.4, sterile filter 
and store at 4°C. 
2. Microbeads conjugated to anti-mouse IgG (Miltenyi Biotec cat. no. 130-048-
401)  
3. Microbeads conjugated to strepavidin (Miltenyi Biotec cat. no. 130-048-101)  
4. Microbeads conjugated to anti-biotin (Miltenyi Biotec cat. no. 130-090-485) 
5. LS Columns (Miltenyi Biotec cat. no. 130-042-401) 
B.18 DNA quantification, analysis, site-directed Mutagenesis, and 454 
sequencing  
1. Qubit dsDNA HS assay kit (Life Technologies) 
2. Agilent DNA 7500 kit (Agilent Technologies) 
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3. QuikChange II or QuikChange lightening site-directed mutagenesis kit 
(Agilent)  
4. GS FLX titanium sequencing kit XL+ (Roche) 
5. GS FLX titanium PicoTiter plate kit 70x75 (Roche) 
B.19 Equipment 
1. Thermocycler 
2. Two temperature controlled incubator shakers 
3. Electroporator (BioRad Gene Pulser II electroporation system) 
4. Flow cytometer and FACS apparatus 
5. Amicon 8400 stirred ultrafiltration cell (Millipore) with regenerated cellulose 
ultrafiltration discs, YM-10, 10 kDa NMWL, 76mm (Millipore cat. no. 13642) 
6. Superdex 200 10/300 GL gel filtration column (GE Biosciences cat. no. 
17517501) 
7. CL-1000 ultraviolet crosslinker (UVP, LLC) 
8. MidiMACS separator (Miltenyi Biotec) 
9. MACS multiStand (Miltenyi Biotec) 
10. Qubit 2.0 fluorimeter (Life Technologies) 
11. Agilent 2100 bioanalyzer (Agilent Technologies) 
12. Roche/454 genome sequencer FLX+ (Roche) 
 
